<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004356.pub3" GROUP_ID="AIRWAYS" ID="389804010209465396" MERGED_FROM="" MODIFIED="2008-08-22 18:07:48 +0200" MODIFIED_BY="Toby Lasserson" NOTES="&lt;p&gt;Exported from Review Manager 4.2.7&lt;br&gt;CJC edit of update june 9 05&lt;br&gt;Authors' ContributionS - update added.&lt;/p&gt;&lt;p&gt;What's new - no change to conclusions added.&lt;/p&gt;&lt;p&gt;References;  fine&lt;/p&gt;&lt;p&gt;Table of included studies fine&lt;/p&gt;&lt;p&gt;Metaview Labels no change&lt;/p&gt;&lt;p&gt;&lt;br&gt;Discussion fine&lt;/p&gt;&lt;p&gt;&lt;br&gt;Spellchecked yes&lt;/p&gt;&lt;p&gt;Next action - this can go ahead for submission.&lt;/p&gt;&lt;p&gt;=======================================&lt;br&gt;16 FEb 2005&lt;br&gt;Peer Review Comments:&lt;br&gt;This competent review discloses a fairly murky area. The field is exposed as a muddle of patient selection (hypoxia) and methodologies. The identification of endurance outcomes as more sensitive is in line with other therapeutic interventions.&lt;br&gt;One major concern is the apparent acceptance that short term testing has any predictive ability with regard to uptake or compliance with ambulatory oxygen. What evidence there is suggests that the short-term response does not predict longer-term benefit. There are also very few data (if any) on the repeatability of short-term testing. The review could be set in this context. It is by no means certain that short term testing will have a role in prescription of ambulatory oxygen since a longer-term pragmatic individual trial may be more revealing. There is also some suggestion that people need time to learn how to adapt to ambulatory oxygen.&lt;/p&gt;&lt;p&gt;Specific points&lt;/p&gt;&lt;p&gt;The actual improvements in exercise capacity are rather modest (less than rehab for example)&lt;/p&gt;&lt;p&gt;The 10% figure for improvement in the RCP document was arbitrary (and seldom achieved in trials)&lt;/p&gt;&lt;p&gt;The value of short term testing may just turn out to be setting the correct flow rate&lt;/p&gt;&lt;p&gt;Should we look at more subtle outcomes? e.g daily activity or health status in the longer term.&lt;/p&gt;&lt;p&gt;I have added a rider to the discussion about individual variability and a reference to Senn 2004 (BMJ) to support this.&lt;br&gt;Toby please send back this final version to authors to check they are happy and then submit.&lt;/p&gt;&lt;p&gt;++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++&lt;br&gt;CJC edit 22 Jan&lt;br&gt;I am happy with this now. I have switched off the SMD pooling for the subgroup analyses as well and this can go out for peer review.&lt;br&gt;Thanks,&lt;br&gt;Chris.&lt;br&gt;=========================================================&lt;/p&gt;&lt;p&gt;Dear Toby &lt;br&gt;                  Just a few things to hightlight for u&lt;br&gt;&amp;gt;&lt;br&gt;&amp;gt;1. Reviewers comments on skewed data... we have not done anything with this comment... The SE were calulated using &amp;quot;Excell package&amp;quot; and so are estimated values but then others have been calculated in the same way. Do u think we need to do anything with this&lt;br&gt;&amp;gt;&lt;br&gt;TJL: Not really. This is OK. &lt;/p&gt;&lt;p&gt;&amp;gt;2. VO2 max... We put in original data for this (see results) but did not take out pooled SMD data from analysis....... ???? should this be removed?? &lt;br&gt;&amp;gt;&lt;br&gt;TJL: I have deselected the SMD analysis and left the narrative description of the trials intact. &lt;/p&gt;&lt;p&gt;&amp;gt;3. Blinding --we put in description studies re how many blinded... Do we need to put in that there was no differences in sensitivity analysis in those DB and SB?? or are we just happy to know that this has not impacted on the results...&lt;br&gt;&amp;gt;&lt;/p&gt;&lt;p&gt;TJL: Better to state this in the results.I have inserted a line to that effect (see red). &lt;/p&gt;&lt;p&gt;&amp;gt;4. We have added a stronger statement to the &amp;quot;implications for practice&amp;quot; re how these results should be used to develop O2 assessment procedure&lt;br&gt;&amp;gt;&lt;br&gt;&amp;gt;5. I have moved the three studies that move from meeting LTOT to not meeting LTOT criteria and have made the appropriate changes in both tables and in text&lt;br&gt;&amp;gt;&lt;br&gt;TJL: Fine. &lt;br&gt;&amp;gt;Judy&lt;/p&gt;&lt;p&gt;&lt;br&gt;-----------------------------------------&lt;/p&gt;&lt;p&gt;CJC Edit 6 Jan 2004&lt;br&gt;Reviewer's contributions; very succinct!&lt;/p&gt;&lt;p&gt;Objectives: Fine, but see comment. do you mean that you included trials only if they excluded non-COPD patients, or only used data from COPD patients if the triallists had a mixed population or what?&lt;/p&gt;&lt;p&gt;References: Fine&lt;/p&gt;&lt;p&gt;Table of included studies: good but there needs to be consistency in reporting SD or SEM for the patients. Sometimes an unspecified figure has been entered in brackets and sometimes an SEM is reported. Could you make these consistent please?&lt;/p&gt;&lt;p&gt;Synopsis: very clear&lt;/p&gt;&lt;p&gt;Abstract: fine - please explain ISOTIME.&lt;/p&gt;&lt;p&gt;Background: fine&lt;/p&gt;&lt;p&gt;Methods of the review: Although the Jadad scale is commonly used in Cochrane reviews I do not think that any composite scale is currently recommended as it is impossible to interpret the sum of individual scores. I would prefer that authors address the main threats to validity in the included studies and comment on them. If specified in advance this can then be used as the basis of a sensitivity analysis. I am happy to run with Jadad and PEDro in this review however.&lt;/p&gt;&lt;p&gt;Description of studies: I am not too happy with taking the SD off the mean PaO2 and then comparing this with the threshold of 7.3 The estimate of  SD is very impecise in small studies and may vary widely. Surely commonsense would indicate just using the mean? Did you discuss this with Mike? This will of course alter your cut point for the subgroups is it is changed. Can you explain further?&lt;/p&gt;&lt;p&gt;Results: The Davidson endurance walk seems to be out of keeping with all the other results? This seems to be due to skewed data and does not matter much as the weight is very low due to large SE (how did you derive this SE?). Raimondi and O'Donnell seem to carry very high weight - why are the SEs so low in comparison with other trials of a similar size. Were they derived in a different way?&lt;/p&gt;&lt;p&gt;VO2 max is a problem as it is not pooled using GIV. SMD is not reliable so if the scales are different I would not pool this outcome.&lt;/p&gt;&lt;p&gt;Discussion: How important do you think Blinding was in these studies and in how many was it adequate? Also see Red Text re MCID.&lt;/p&gt;&lt;p&gt;Next action: This is an elegant review and has been well thought out. Toby please send back to reviewers for response.&lt;br&gt;---------------------------------------------------------------------------------------------------------------------------------------------------------------------&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;br&gt;---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------&lt;br&gt;MG's edits 010804&lt;br&gt;This is a good effort and I congratulate the authors.The data tables etc aren't included and I'll have to take your word that they are all &lt;br&gt;correctly tabulated and comply with Cochrane conventions. Presumably Chris will be looking at the numbers so here's a few comments about the clinical aspects...&lt;br&gt;There seems to be an incosistency in their use of the terms Ve and VE -they're the same aren't they?The term should be explained for the less physiologically sophisticated. PaO2 was said to increase by a mean of 114mm Hg -that's 15 kpa :surely that can't be right in a population of patients with moderate COPD? It would be helpful to discuss the extent of the improvement in excercise capacity .Greenstein suggests that improvements in 6MW less that approximately 50 metres aren't clinically relevant to the patient- the&lt;br&gt;authors might wish to comment. How do these improvements with oxygen compare to those obtained by multidisciplinary pulmonary rehabilitation? Why does oxygen work in those who aren't very hypoxic or does the data not allow us tos ay that those that are virtually normoxic don't benefit? If we are so convinced that ambulatory O2 is a good thing why don't we use it more and should we be pushing for better reservoirs/conserving devices/liquid O2 on the NHS?&lt;br&gt;Best wishes,&lt;br&gt;Mike&lt;br&gt;-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------&lt;br&gt;Old title: *Short term ambulatory oxygen for chronic obstructive pulmonary disease (WITH TJL 131004)&lt;br&gt;Old title: Ambulatory Oxygen&lt;br&gt;Old title: *Short term ambulatory oxygen for chronic obstructive pulmonary disease (WITH JUDY AND BRENDA)&lt;br&gt;Old title: *Short term ambulatory oxygen for chronic obstructive pulmonary disease (COMMENTS WITH TJL PRE CHRIS 301104)&lt;br&gt;Old title: #Short term ambulatory oxygen for chronic obstructive pulmonary disease (WITH JUDY AND BRENDA 070105)&lt;br&gt;Old title: *Short term ambulatory oxygen for chronic obstructive pulmonary disease (WITH JUDY AND BRENDA)&lt;br&gt;Old title: #Short term ambulatory oxygen for chronic obstructive pulmonary disease (WITH CHRIS 180105)&lt;br&gt;Old title: #Short term ambulatory oxygen for chronic obstructive pulmonary disease (WITH JUDY FOR FINAL APPROVAL)&lt;br&gt;Old title: *Short term ambulatory oxygen for chronic obstructive pulmonary disease&lt;br&gt;Old title: #Short term ambulatory oxygen for chronic obstructive pulmonary disease UPDATE (WITH CHRIS 080605)&lt;/p&gt;" NOTES_MODIFIED="2008-08-22 17:02:27 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" REVIEW_NO="STO-COP" REVMAN_SUB_VERSION="5.0.15" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2008-08-22 18:07:48 +0200" MODIFIED_BY="Toby Lasserson">
<TITLE>Short-term ambulatory oxygen for chronic obstructive pulmonary disease</TITLE>
<CONTACT MODIFIED="2008-08-22 18:07:48 +0200" MODIFIED_BY="Toby Lasserson"><PERSON ID="11610" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Judy</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Bradley</LAST_NAME><POSITION>Reader in Physiotherapy</POSITION><EMAIL_1>jm.bradley@ulster.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Rehabilitation Sciences Research Institute School</DEPARTMENT><ORGANISATION>University of Ulster and Belfast City Hospital</ORGANISATION><ADDRESS_1>University of Ulster</ADDRESS_1><ADDRESS_2>Shore Road</ADDRESS_2><CITY>Newtownabbey</CITY><ZIP>BT37 0QB</ZIP><REGION>Northern Ireland</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 2890 368991</PHONE_1><PHONE_2>+44 2890 329241 ext. 2719</PHONE_2><FAX_1>+44 2890 368419</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-08-22 18:07:48 +0200" MODIFIED_BY="Toby Lasserson"><PERSON ID="11610" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Judy</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Bradley</LAST_NAME><POSITION>Reader in Physiotherapy</POSITION><EMAIL_1>jm.bradley@ulster.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Rehabilitation Sciences Research Institute School</DEPARTMENT><ORGANISATION>University of Ulster and Belfast City Hospital</ORGANISATION><ADDRESS_1>University of Ulster</ADDRESS_1><ADDRESS_2>Shore Road</ADDRESS_2><CITY>Newtownabbey</CITY><ZIP>BT37 0QB</ZIP><REGION>Northern Ireland</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 2890 368991</PHONE_1><PHONE_2>+44 2890 329241 ext. 2719</PHONE_2><FAX_1>+44 2890 368419</FAX_1></ADDRESS></PERSON><PERSON ID="12466" ROLE="AUTHOR"><PREFIX>Mrs</PREFIX><FIRST_NAME>Brenda</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>O'Neill</LAST_NAME><POSITION>Lecturer Practitioner</POSITION><EMAIL_1>b.oneill@ulster.ac.uk </EMAIL_1><ADDRESS><DEPARTMENT>Physiotherapy</DEPARTMENT><ORGANISATION>University of Ulster and Belfast City Hospital</ORGANISATION><CITY>Belfast </CITY><REGION>Northern Ireland </REGION><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-08-22 16:31:40 +0100" MODIFIED_BY="Toby Lasserson" NOTES="&lt;p&gt;Minor update: 2/17/05&lt;/p&gt;&lt;p&gt;New studies found and included or excluded: 3/1/04&lt;/p&gt;" NOTES_MODIFIED="2008-08-22 16:31:40 +0100" NOTES_MODIFIED_BY="Toby Lasserson">
<UP_TO_DATE>
<DATE DAY="8" MONTH="6" YEAR="2005"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="1" MONTH="3" YEAR="2004"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2005"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2005"/>
</DATES>
<WHATS_NEW NOTES="&lt;p&gt;Maltais 2001; Knebel 2000; Gosselin 2004; Palange 1995 were identified from update searches conducted in March 2005.  There were no changes to the conclusions of the review.&lt;/p&gt;">
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="24" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="8" MONTH="6" YEAR="2005"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>This review was supported by the Northern Ireland Reserach &amp; Development Office Fellowship Scheme</NAME>
<COUNTRY CODE="IE">Ireland</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-08-22 16:58:49 +0100" MODIFIED_BY="Toby J Lasserson">
<SUMMARY MODIFIED="2008-08-22 16:33:14 +0100" MODIFIED_BY="Toby J Lasserson">
<TITLE MODIFIED="2008-08-22 16:33:14 +0100" MODIFIED_BY="Toby J Lasserson">Short-term ambulatory oxygen for chronic obstructive pulmonary disease</TITLE>
<SUMMARY_BODY>
<P>Short-term studies indicate that people with chronic obstructive pulmonary disease respond to the administration of oxygen when they do exercise tests. Ambulatory oxygen is the use of supplemental oxygen during exercise and activities of daily living. One way to assess if ambulatory oxygen is beneficial for a patient with COPD is to compare the effects of breathing oxygen and breathing air on exercise capacity. Some people with COPD may benefit more than others, and trials should take account of whether people who do not already meet criteria for domiciliary oxygen also respond. This review shows that there is strong evidence that ambulatory oxygen (short-term) improves exercise capacity. Further research needs to focus on which COPD patients benefit from ambulatory oxygen, how much oxygen should be provided and the long-term effect of ambulatory oxygen. </P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Ambulatory oxygen is defined as the use of supplemental oxygen during exercise and activities of daily living. Ambulatory oxygen therapy is often used for patients on long term oxygen therapy during exercise, or for non long term oxygen therapy users who achieve some subjective and/or objective benefit from oxygen during exercise. The evidence for the use of ambulatory oxygen therapy is extrapolated from two sources: longer term studies and single assessment studies. Longer term studies assess the impact of ambulatory oxygen therapy used at home during activities of daily living. Single assessment studies compare performance during an exercise test using oxygen with performance during an exercise test using placebo air. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine the efficacy of ambulatory oxygen in patients with COPD using single assessment studies.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>The Cochrane Airways Group COPD register was searched with predefined search terms. Searches were current as of March 2005.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Only randomised controlled trials were included. Studies did not have to be blinded. Studies had to compare oxygen and placebo when administered to people with COPD who were undergoing an exercise test. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two reviewers (JB, B'ON) extracted and entered data in to RevMan 4.2. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Thirty one studies (contributing 33 data sets), randomising 534 participants met the inclusion criteria of the review. Oxygen improved all pooled outcomes relating to endurance exercise capacity (distance, time, number of steps) and maximal exercise capacity (exercise time and work rate). Data relating to VO<SUB>2 </SUB>max could not be pooled and results from the original studies were not consistent. For the secondary outcomes of breathlessness, SaO<SUB>2</SUB> and V<SUB>E</SUB>, comparisons were made at isotime. In all studies except two the isotime is defined as the time at which the placebo test ended. Oxygen improved breathlessness, SaO<SUB>2</SUB>/PaO<SUB>2</SUB> and V<SUB>E</SUB> at isotime with endurance exercise testing. There was no data on breathlessness at isotime with maximal exercise testing. Oxygen improved SaO<SUB>2</SUB>/PaO<SUB>2</SUB> and reduced V<SUB>E</SUB> at Isotime. </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>This review provides some evidence from small, single assessment studies that ambulatory oxygen improves exercise performance in people with moderate to severe COPD. The results of the review may be affected by publication bias, and the small sample sizes in the studies. Although positive, the findings of the review require replication in larger trials with more distinct subgroups of participants. Maximal or endurance tests can be used in ambulatory oxygen assessment. Consideration should be given to the measurement of SaO<SUB>2 </SUB>and breathlessness at isotime as these provide important additional information. We recommend that these outcomes are included in the assessment for ambulatory oxygen. Future research needs to establish the level of benefit of ambulatory oxygen in specific subgroups of people with COPD.<BR/>
</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-08-22 16:58:49 +0100" MODIFIED_BY="Toby J Lasserson">
<BACKGROUND>
<P>Chronic obstructive pulmonary disease (COPD) is a slowly progressive disorder characterised by airflow obstruction. The degree of airway narrowing is largely fixed but may be partially reversed with bronchodilator therapy (<LINK REF="REF-NICE-2004" TYPE="REFERENCE">NICE 2004</LINK>, <LINK REF="REF-GOLD-2001" TYPE="REFERENCE">GOLD 2001</LINK>; <LINK REF="REF-Romain-2001" TYPE="REFERENCE">Romain 2001</LINK>; <LINK REF="REF-BTS-1997" TYPE="REFERENCE">BTS 1997</LINK>; <LINK REF="REF-ATS-1995" TYPE="REFERENCE">ATS 1995</LINK>). Patients often present with breathlessness, a chronic cough and sputum production. As the disease progresses gas exchange becomes more abnormal and adequate oxygenation may no longer be maintained. Home oxygen may be prescribed as long term oxygen therapy (LTOT), short burst or as ambulatory oxygen therapy. Long term oxygen therapy has been used in hypoxaemic patients with COPD to increase life expectancy, quality of life, exercise tolerance and decrease shortness of breath. The efficacy of LTOT in patients with chronic hypoxaemia has been shown in a Cochrane review and its use and prescription are well established (<LINK REF="REF-Crockett-2000" TYPE="REFERENCE">Crockett 2000</LINK>). </P>
<P>Ambulatory oxygen is defined as the use of supplemental oxygen during exercise and activities of daily living (<LINK REF="REF-RCP-1999" TYPE="REFERENCE">RCP 1999</LINK>). Ambulatory oxygen therapy is often used by patients on LTOT during exercise, or for non LTOT users with or without resting hypoxaemia if they show evidence of exercise desaturation and demonstrate improvement in exercise capacity with supplemental oxygen. There are criteria for assessment and use of ambulatory oxygen therapy (<LINK REF="REF-ATS-1995" TYPE="REFERENCE">ATS 1995</LINK>; <LINK REF="REF-RCP-1999" TYPE="REFERENCE">RCP 1999</LINK>; <LINK REF="REF-Young-1998" TYPE="REFERENCE">Young 1998</LINK>). The RCP guidelines provide the most objective criteria which can be used to ascertain if ambulatory oxygen is required (<LINK REF="REF-RCP-1999" TYPE="REFERENCE">RCP 1999</LINK>). These criteria include (i) a fall in SaO<SUB>2</SUB> of at least 4% to reach a reading below 90% during a baseline walking test whilst breathing air; (ii) an improvement of at least 10% in walking distance and/or breathlessness score when walking with supplemental oxygen compared with an air cylinder; and (iii) the level of oxygen prescribed should be adequate to maintain SaO<SUB>2</SUB> above 90%.</P>
<P>Ambulatory oxygen therapy is usually provided in small oxygen cylinders lasting up to 4 hours at 2 L/min or liquid oxygen systems which have a higher oxygen carrying capacity lasting up to 6-10 hours at 2 L/min. The evidence for the use of ambulatory oxygen therapy is extrapolated from two sources: longer term studies and single assessment studies. Longer term studies assess the impact of ambulatory therapy used at home during activities of daily living. Single assessment studies compare performance during an exercise test using oxygen with performance during an exercise test using placebo air. </P>
<P>A Cochrane review investigating the long term efficacy of ambulatory therapy showed that there was little evidence of its effectiveness (<LINK REF="REF-Ram-2003" TYPE="REFERENCE">Ram 2003</LINK>) however this review did not include the single assessment studies which are recommended for assessment of ambulatory oxygen in clinical practice. </P>
</BACKGROUND>
<OBJECTIVES>
<P>To determine the efficacy of ambulatory oxygen in patients with COPD using single assessment studies.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-08-22 16:49:11 +0100" MODIFIED_BY="Toby J Lasserson">
<SELECTION_CRITERIA MODIFIED="2008-08-22 16:34:36 +0100" MODIFIED_BY="Toby J Lasserson">
<CRIT_STUDIES>
<P>Randomised controlled trials comparing ambulatory oxygen therapy versus placebo air. Only assessment studies comparing performance during a single exercise test using ambulatory oxygen compared to performance during a single exercise test with placebo air were considered. Longer term studies assessing the efficacy of ambulatory oxygen therapy or studies assessing the efficacy of LTOT were not included.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Studies were included only when adult patients with stable COPD were randomised to either ambulatory oxygen or placebo. COPD should have been diagnosed according to criteria included in internationally accepted guidelines e.g. <LINK REF="REF-GOLD-2001" TYPE="REFERENCE">GOLD 2001</LINK>; <LINK REF="REF-Romain-2001" TYPE="REFERENCE">Romain 2001</LINK>; <LINK REF="REF-BTS-1997" TYPE="REFERENCE">BTS 1997</LINK>; <LINK REF="REF-ATS-1995" TYPE="REFERENCE">ATS 1995</LINK>. Studies published prior to 1995 were included if patients had a diagnosis equivalent to COPD. Patients who did not have a diagnosis of COPD were excluded. Studies with mixed populations where excluded if data from patients with COPD were not analysed separately. </P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>The intervention in the actively treated group was ambulatory oxygen therapy, provided either via oxygen cylinders or a reservoir system. In the control group, the intervention should have been delivered via air cylinders or a reservoir system.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-08-22 16:34:36 +0100" MODIFIED_BY="Toby J Lasserson">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-08-22 16:33:41 +0100" MODIFIED_BY="Toby J Lasserson">
<OL>
<LI>Exercise capacity (e.g. distance, time or steps during maximal tests or endurance tests)</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-08-22 16:34:28 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Secondary outcomes measured at isotime:</P>
<OL>
<LI>Dyspnoea scores (e.g. Borg scores or visual analogue scale)</LI>
<LI>Arterial oxygen saturation (pulse oximetry or arterial blood gases) during or post exercise</LI>
<LI>Physiological measurements (e.g. V<SUB>E</SUB> during exercise)</LI>
<LI>Patient preference</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-08-22 16:36:58 +0100" MODIFIED_BY="Toby J Lasserson">
<ELECTRONIC_SEARCHES MODIFIED="2008-08-22 16:36:52 +0100" MODIFIED_BY="Toby J Lasserson">
<P>The Cochrane Airways Group Specialised Register of RCTs was searched using the search terms:</P>
<P>(portable* or ambulat* or oxygen* or O2 or hypoxaemia* or hypoxemia*) and (therap*)</P>
<P>The Register contains records downloaded from CENTRAL, MEDLINE, EMBASE and CINAHL, as well as records identified through hand-searching journals and meeting abstracts, including the American Thoracic Society, British Thoracic Society and European Respiratory Society meetings.</P>
<P>In order to minimise the chance of missing potential studies separate searches were also completed on the Cochrane Central Register of Controlled Trials (CENTRAL). In addition, other electronically available databases and search engines were searched for trials (CINAHL, Science Citation Index, EMBASE, MEDLINE, Scirus, UK National Research Register, PEDro, ClinicalTrials.gov, Google.com). Electronic web sites of the following journals were searched: American Journal of Respiratory and Critical Care Medicine, Annals of Internal Medicine, British Medical Journal, Chest, European Respiratory Journal, Lancet, Respiratory Care, Respiratory Medicine, Thorax). All databases were searched from their inception up until February 2004.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-08-22 16:36:57 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Following this the bibliographies of each included RCT as well as any review articles found were searched for additional papers that may contain further RCTs. All authors of identified RCTs were contacted and asked to confirm that the data extracted and the assessment of quality was correct. Where relevant they were also requested to provide further information. Eight authors responded (<LINK REF="STD-Bye-1985" TYPE="STUDY">Bye 1985</LINK>; <LINK REF="STD-Garrod-1999" TYPE="STUDY">Garrod 1999</LINK>; <LINK REF="STD-Dean-1992" TYPE="STUDY">Dean 1992</LINK>; <LINK REF="STD-O_x0027_Donnell-1997" TYPE="STUDY">O'Donnell 1997</LINK>; <LINK REF="STD-O_x0027_Donnell-2001" TYPE="STUDY">O'Donnell 2001</LINK>; <LINK REF="STD-Light-1989" TYPE="STUDY">Light 1989</LINK>; <LINK REF="STD-Swinburn-1984" TYPE="STUDY">Swinburn 1984</LINK>; <LINK REF="STD-Fujimoto-2002a" TYPE="STUDY">Fujimoto 2002a</LINK>) and confirmed that the data extracted and assessment of quality was correct. Four studies (<LINK REF="STD-Garrod-1999" TYPE="STUDY">Garrod 1999</LINK>; <LINK REF="STD-Dean-1992" TYPE="STUDY">Dean 1992</LINK>; <LINK REF="STD-O_x0027_Donnell-1997" TYPE="STUDY">O'Donnell 1997</LINK>; <LINK REF="STD-O_x0027_Donnell-2001" TYPE="STUDY">O'Donnell 2001</LINK>) provided further information (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> Included Studies).</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-08-22 16:49:11 +0100" MODIFIED_BY="Toby J Lasserson">
<STUDY_SELECTION MODIFIED="2008-08-22 16:37:30 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Two reviewers independently selected trials for inclusion in the review. Disagreement did not arise on the suitability of a trial for inclusion in the review or in its quality however if this occurs for future updates of this review a consensus will be reached by the two reviewers.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2008-08-22 16:48:08 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Data from the trials was independently extracted by two reviewers (JB, BON) using standard data extraction forms.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2008-08-22 16:49:11 +0100" MODIFIED_BY="Toby J Lasserson">
<P>The methodological quality of each trial was assessed by each reviewer using two scales: the Jadad scale (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>) and the PEDro scale. The PEDro is an 11 item scale based on the previously validated Delphi list (<LINK REF="REF-Verhagen-1998" TYPE="REFERENCE">Verhagen 1998</LINK>). The Pedro scale examines issues of randomisation, allocation, whether patients were similar at baseline, extent of blinding in the study, proportion of patients for which data was available and the method in which this data was reported.</P>
<P>The PEDro scale has been shown to be reliable measure of study quality (<LINK REF="REF-Moseley-1999" TYPE="REFERENCE">Moseley 1999</LINK>). The PEDro scale is available at http://ptwww.cchs.usyd.edu.au/pedro. The PEDro scale scores studies out of 10.</P>
<P>The quality of included studies was also assessed using the Cochrane allocation concealment scale.</P>
</QUALITY_ASSESSMENT>
<UNIT_OF_ANALYSIS MODIFIED="2008-08-22 16:46:55 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Due to the crossover design of the studies, we opted to enter data based as generic inverse variance (GIV) data. This takes the mean difference between treatment and control, with a standard error (SEM) for the difference. Where possible, we have taken the published SEM, but where this was not available, we have used the published P value to estimate a standard error. Where data were reported as non-significant, and no other means of obtaining the variance was possible, we have entered the published means and SDs as a weighted mean difference (WMD - see below) as reported in the published paper and used that as a basis of calculating the SEM for between treatment group differences. This would tend to underestimate the treatment effect as it would overlook the sensitivity of paired data for within patient differences.</P>
</UNIT_OF_ANALYSIS>
<DATA_SYNTHESIS MODIFIED="2008-08-22 16:47:37 +0100" MODIFIED_BY="Toby J Lasserson">
<P>For continuous outcomes (exercise capacity, breathlessness scores), a WMD was used when combining data. Data from the same variable (for example the FEV<SUB>1</SUB>), but expressed differently in different trials (for example as change in litres and change expressed as percentage of baseline) were combined using a standardised mean difference (SMD). If dichotomous outcomes had been identified they would have been analysed using the relative risk or odds ratio. Random and/or fixed effects model were used depending upon the level of statistical heterogeneity observed. Where I<SUP>2 </SUP>exceeded 0% we applied Random Effects modelling, and compared this with a Fixed Effects model in order to determine whether taking account of within and between study variation impacts upon the overall pooled effect estimate.</P>
<P>Note: For many of the outcomes, the focus is on a favourable outcome. Here the aim of the treatment is to increase the outcome, rather than decrease it. This requires the graph labels to be reversed from the standard format of "favours treatment" on the left of the graph and "favours control" on the right.</P>
<P>All trial data was combined using Review Manager. Funnel plots were carried out to test for the presence of publication bias where possible.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2008-08-22 16:47:54 +0100" MODIFIED_BY="Toby J Lasserson">
<P>If enough studies had been available we would have carried out the following sub group analyses: disease severity; and method of oxygen delivery.</P>
<P>Due to the way in which studies were conducted and reported, we opted to perform a <I>post-hoc</I> subgroup analysis based upon the level of hypoxaemia and the dose of oxygen delivered. A sensitivity analysis was performed to examine the impact of blinding on the study results (single versus double blind studies).</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2008-08-22 16:48:20 +0100" MODIFIED_BY="Toby J Lasserson">
<P>If significant heterogeneity was found a sensitivity analyses would have been conducted on study quality (Cochrane scores and or Pedro scale).</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-08-22 16:58:49 +0100" MODIFIED_BY="Toby J Lasserson">
<STUDY_DESCRIPTION MODIFIED="2008-08-22 16:48:55 +0100" MODIFIED_BY="Toby J Lasserson">
<P>A total of 60 studies were retrieved literature search results. Of these, 29 studies failed to meet the inclusion criteria (see Table 'Characteristics of Excluded Studies'). Four new studies have been included in this update of the review (see 'What's New'). Thirty-one studies (contributing 33 randomised data sets) met the inclusion criteria.</P>
<SUBSECTION>
<HEADING LEVEL="6">Study design</HEADING>
<P>Thirty one studies (contributing 33 data sets) with a total of 534 participants met the inclusion criteria for this review. All the trials included in this review were cross-over in design.</P>
<P>Freeman et al (1989) suggest that only on the grounds of biological reasoning can it can be assumed that there is no carry-over in cross over studies. They argue against using statistical tests to assess if there is a crossover effect. No studies in this review tested for a carry-over effect although the duration between successive tests is variable. There is no consensus in the literature regarding the minimum time required to eliminate the carry-over effect of exercise testing.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Participants</HEADING>
<P>Sample size varied from 5 to 41. The mean age reported in the included studies ranged from 47 to 73 years. With the exception of one study which included a group of mild patients (<LINK REF="STD-Fujimoto-2002a" TYPE="STUDY">Fujimoto 2002a</LINK>) all studies included patients with moderate to severe airflow obstruction.</P>
<P>The mean PaO<SUB>2</SUB> ranged from 6.9 KPa to 11.3 KPa (52 mmHg to 85 mmHg). Judging by the baseline mean PaO<SUB>2 </SUB>, the following loose categorisations can be made: seven studies included patients who <I>likely</I> met the criteria for LTOT on the grounds that baseline mean kPa was lower than 7.3 (see Table characteristics of included studies): (<LINK REF="STD-O_x0027_Donnell-2001" TYPE="STUDY">O'Donnell 2001</LINK>; <LINK REF="STD-Garrod-2000" TYPE="STUDY">Garrod 2000</LINK>; <LINK REF="STD-Bye-1985" TYPE="STUDY">Bye 1985</LINK>; <LINK REF="STD-King-1973" TYPE="STUDY">King 1973</LINK>; <LINK REF="STD-Leach-1992" TYPE="STUDY">Leach 1992</LINK>; <LINK REF="STD-Leggett-1977" TYPE="STUDY">Leggett 1977</LINK>; <LINK REF="STD-Mannix-1992" TYPE="STUDY">Mannix 1992</LINK>). Twenty three studies included patients who did not or <I>likely </I>did not meet the criteria for LTOT on the grounds that mean baseline kPa exceeded 7.3 (see Table characteristics of included studies):<LINK REF="STD-Eaton-2002" TYPE="STUDY">Eaton 2002</LINK>; <LINK REF="STD-O_x0027_Donnell-1997" TYPE="STUDY">O'Donnell 1997</LINK>, <LINK REF="STD-Dean-1992" TYPE="STUDY">Dean 1992</LINK>; <LINK REF="STD-Garrod-1999" TYPE="STUDY">Garrod 1999</LINK>; <LINK REF="STD-Wadell-2001" TYPE="STUDY">Wadell 2001</LINK>; <LINK REF="STD-Bradley-1978" TYPE="STUDY">Bradley 1978</LINK>; <LINK REF="STD-Criner-1987" TYPE="STUDY">Criner 1987</LINK>; <LINK REF="STD-Davidson-1988" TYPE="STUDY">Davidson 1988</LINK>; <LINK REF="STD-Fujimoto-2002a" TYPE="STUDY">Fujimoto 2002a</LINK>; <LINK REF="STD-Fujimoto-2002b" TYPE="STUDY">Fujimoto 2002b</LINK>; <LINK REF="STD-Fujimoto-2002c" TYPE="STUDY">Fujimoto 2002c</LINK>; <LINK REF="STD-Light-1989" TYPE="STUDY">Light 1989</LINK>; <LINK REF="STD-McKeon-1988" TYPE="STUDY">McKeon 1988</LINK>; <LINK REF="STD-McDonald-1995" TYPE="STUDY">McDonald 1995</LINK>; <LINK REF="STD-Somfay-2001" TYPE="STUDY">Somfay 2001</LINK>; <LINK REF="STD-Stein-1982" TYPE="STUDY">Stein 1982</LINK>; <LINK REF="STD-Ishimine-1995" TYPE="STUDY">Ishimine 1995</LINK>; <LINK REF="STD-Kurihara-1989" TYPE="STUDY">Kurihara 1989</LINK>; <LINK REF="STD-Swinburn-1984" TYPE="STUDY">Swinburn 1984</LINK>; <LINK REF="STD-Vyas-1971" TYPE="STUDY">Vyas 1971</LINK>; <LINK REF="STD-Woodcock-1981" TYPE="STUDY">Woodcock 1981</LINK>; <LINK REF="STD-Knebel-2000" TYPE="STUDY">Knebel 2000</LINK>; <LINK REF="STD-Maltais-2001" TYPE="STUDY">Maltais 2001</LINK>; <LINK REF="STD-Palange-1995" TYPE="STUDY">Palange 1995</LINK>; <LINK REF="STD-Gosselin-2004" TYPE="STUDY">Gosselin 2004</LINK>). In one study there was no information relating to baseline oxygen status (<LINK REF="STD-Raimondi-1970" TYPE="STUDY">Raimondi 1970</LINK>). <LINK REF="STD-Knebel-2000" TYPE="STUDY">Knebel 2000</LINK> cited current oxygen usage as an exclusion criterion.</P>
<P>These categorisations form the basis of the subgroup analyses which are based upon baseline oxygen status (mean baseline PaO2 &lt;7.3 kPa/55 mmHg; mean baseline PaO2 &gt;=7.3 kPa/55 mmHg or status unclear). This value (PaO2 &lt;7.3 kPa) is based on the recommendation from NICE for LTOT (<LINK REF="REF-NICE-2004" TYPE="REFERENCE">NICE 2004</LINK>).<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Intervention and setting</HEADING>
<P>In thirteen studies the oxygen was delivered via nasal specs, in one study the oxygen was delivered via a face mask, in one study the oxygen was delivered via a face mask or nasal specs and in sixteen studies oxygen was delivered via a mouthpiece with a reservoir system (*see Table characteristics of included studies). It was decided that oxygen delivery of less than or equal to 4 L/min or 35% would be termed "low dose oxygen" and oxygen delivery of greater than this would be termed "high dose oxygen". Twenty studies used low dose oxygen (<LINK REF="STD-Criner-1987" TYPE="STUDY">Criner 1987</LINK>; <LINK REF="STD-Eaton-2002" TYPE="STUDY">Eaton 2002</LINK>; <LINK REF="STD-Fujimoto-2002a" TYPE="STUDY">Fujimoto 2002a</LINK>; <LINK REF="STD-Fujimoto-2002b" TYPE="STUDY">Fujimoto 2002b</LINK>; <LINK REF="STD-Fujimoto-2002c" TYPE="STUDY">Fujimoto 2002c</LINK>; <LINK REF="STD-Garrod-1999" TYPE="STUDY">Garrod 1999</LINK>; <LINK REF="STD-Garrod-2000" TYPE="STUDY">Garrod 2000</LINK>; <LINK REF="STD-Ishimine-1995" TYPE="STUDY">Ishimine 1995</LINK>; <LINK REF="STD-King-1973" TYPE="STUDY">King 1973</LINK>; <LINK REF="STD-Kurihara-1989" TYPE="STUDY">Kurihara 1989</LINK>; <LINK REF="STD-Leach-1992" TYPE="STUDY">Leach 1992</LINK>; <LINK REF="STD-Leggett-1977" TYPE="STUDY">Leggett 1977</LINK>; <LINK REF="STD-Light-1989" TYPE="STUDY">Light 1989</LINK>; <LINK REF="STD-Mannix-1992" TYPE="STUDY">Mannix 1992</LINK>; <LINK REF="STD-McDonald-1995" TYPE="STUDY">McDonald 1995</LINK>; <LINK REF="STD-McKeon-1988" TYPE="STUDY">McKeon 1988</LINK>; <LINK REF="STD-Raimondi-1970" TYPE="STUDY">Raimondi 1970</LINK>; <LINK REF="STD-Stein-1982" TYPE="STUDY">Stein 1982</LINK>; <LINK REF="STD-Woodcock-1981" TYPE="STUDY">Woodcock 1981</LINK>; <LINK REF="STD-Gosselin-2004" TYPE="STUDY">Gosselin 2004</LINK>; <LINK REF="STD-Palange-1995" TYPE="STUDY">Palange 1995</LINK>; <LINK REF="STD-Knebel-2000" TYPE="STUDY">Knebel 2000</LINK>), nine studies used high dose oxygen (<LINK REF="STD-Bradley-1978" TYPE="STUDY">Bradley 1978</LINK>; <LINK REF="STD-Bye-1985" TYPE="STUDY">Bye 1985</LINK>; <LINK REF="STD-Dean-1992" TYPE="STUDY">Dean 1992</LINK>; <LINK REF="STD-O_x0027_Donnell-1997" TYPE="STUDY">O'Donnell 1997</LINK>; <LINK REF="STD-O_x0027_Donnell-2001" TYPE="STUDY">O'Donnell 2001</LINK>; <LINK REF="STD-Swinburn-1984" TYPE="STUDY">Swinburn 1984</LINK>; <LINK REF="STD-Vyas-1971" TYPE="STUDY">Vyas 1971</LINK>; <LINK REF="STD-Wadell-2001" TYPE="STUDY">Wadell 2001</LINK>; <LINK REF="STD-Maltais-2001" TYPE="STUDY">Maltais 2001</LINK>) and 2 studies used both (<LINK REF="STD-Davidson-1988" TYPE="STUDY">Davidson 1988</LINK>; <LINK REF="STD-Somfay-2001" TYPE="STUDY">Somfay 2001</LINK>).</P>
<P>Twenty-nine studies compared one oxygen intervention with a placebo intervention. Two studies compared more than one oxygen intervention with a placebo intervention (<LINK REF="STD-Davidson-1988" TYPE="STUDY">Davidson 1988</LINK>; <LINK REF="STD-Somfay-2001" TYPE="STUDY">Somfay 2001</LINK>); in these two studies only one low dose and only one high dose oxygen intervention was selected. The <LINK REF="STD-Davidson-1988" TYPE="STUDY">Davidson 1988</LINK> study had more than one low dose intervention and the <LINK REF="STD-Somfay-2001" TYPE="STUDY">Somfay 2001</LINK> study had more than one high dose intervention. The oxygen intervention closest to the critical level (4 L/min or 35%) was chosen.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Exercise Tests</HEADING>
<P>Twelve studies used maximal exercise tests only and 17 used endurance exercise tests and two studies used two tests. For details of each study please see Table characteristics of included studies. Various types of exercise tests were used: treadmill (6 studies); cycle ergometry (12 studies); incremental shuttle walk test (2 studies); 6MW test (10 studies); step test (one study); other walk tests (three studies). A number of studies assessed response to more than one type of exercise test.</P>
<P>A variety of exercise test protocols were used and details of these are provided in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>. In 10 studies there was no familiarization or practice test; six studies used familiarization only<B> </B>and 14 studies used practice tests +/- familiarisation (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>) and one study used practice tests +/- familiarisation in two out of three exercise tests (<LINK REF="STD-Davidson-1988" TYPE="STUDY">Davidson 1988</LINK>).</P>
<P>Up to four submaximal tests were performed on the same day and the rest period between tests ranged from 10 mins to one day. In one study 16 tests where performed over three days (<LINK REF="STD-Woodcock-1981" TYPE="STUDY">Woodcock 1981</LINK>).<BR/>
<BR/>17/31 of the studies controlled for factors which can affect performance on exercise test such as time of day, food intake and medication such as bronchodilators.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Outcome</HEADING>
<P>There was a wide range of outcome measures reported in the studies. Exercise capacity was measured using five methods: distance (14 studies); time (12 studies); VO<SUB>2</SUB> (7 studies); number steps (1 study); watts (3 studies). The following measurements were made at isotime: breathlessness, 4 studies;. SaO<SUB>2</SUB>/PaO<SUB>2</SUB>, 6 studies (1 mmHg = 0.133 kPa); V<SUB>E</SUB>, 9 studies: (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK> Outcome measures used).</P>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>Overall, the methodological quality of the included studies as rated by the Jadad score was low (16 studies had score of 1; nine studies had a score of 2; 4 studies had a score of 3; and two studies had a score of 5). These low scores can be attributed to lack of double blinding (14 studies single blind; 15 double blind; two studies no blinding) or lack of detail in the reporting of the blinding or randomisation (Table characteristics of included studies).</P>
<P>The Pedro scale includes a wider variety of quality criteria relating to both internal and external validity. Overall, the methodological quality of the included studies as rated by the Pedro score was good (2 studies has score of 6; 14 studies had a score of 7; 2 studies had a score of 8; 12 studies had a score of 9; 1 study had a score of 10) (Table characteristics of included studies). </P>
<P>One study reported dropouts (<LINK REF="STD-Knebel-2000" TYPE="STUDY">Knebel 2000</LINK>). </P>
<P>One study reported the use of a concealed randomisation procedure (<LINK REF="STD-Garrod-1999" TYPE="STUDY">Garrod 1999</LINK>). </P>
<P>In general the sample size of many individual studies was small (range 5 to 41 participants) and no studies reported that the sample size was based on a power calculation. </P>
<P>29/31 studies included in the review reported on at least 1 of the primary outcome measures. <LINK REF="STD-King-1973" TYPE="STUDY">King 1973</LINK> and <LINK REF="STD-Light-1989" TYPE="STUDY">Light 1989</LINK> did not report on a primary outcome measure.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-08-22 16:58:49 +0100" MODIFIED_BY="Toby J Lasserson">
<SUBSECTION>
<HEADING LEVEL="4">ENDURANCE TEST STUDIES</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Primary outcome measure: Exercise capacity</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Distance</HEADING>
<P>(<LINK REF="STD-Eaton-2002" TYPE="STUDY">Eaton 2002</LINK>; <LINK REF="STD-Fujimoto-2002a" TYPE="STUDY">Fujimoto 2002a</LINK>; <LINK REF="STD-Fujimoto-2002b" TYPE="STUDY">Fujimoto 2002b</LINK>; <LINK REF="STD-Fujimoto-2002c" TYPE="STUDY">Fujimoto 2002c</LINK>; <LINK REF="STD-Ishimine-1995" TYPE="STUDY">Ishimine 1995</LINK>; <LINK REF="STD-Kurihara-1989" TYPE="STUDY">Kurihara 1989</LINK>; <LINK REF="STD-McDonald-1995" TYPE="STUDY">McDonald 1995</LINK>; <LINK REF="STD-Davidson-1988" TYPE="STUDY">Davidson 1988</LINK>;<LINK REF="STD-Woodcock-1981" TYPE="STUDY">Woodcock 1981</LINK>; <LINK REF="STD-Knebel-2000" TYPE="STUDY">Knebel 2000</LINK>)</P>
<P>All studies assessed the effects of low dose oxygen. <LINK REF="STD-Davidson-1988" TYPE="STUDY">Davidson 1988</LINK> reported results from two exercise tests (6MWT and endurance walk test). In order to avoid double-counting participants, we calculated two pooled estimates. There was significant heterogeneity between the studies with either data-set used. With fixed effects modelling oxygen significantly improved exercise distance by 18.86 metres (95% CI 13.11 to 24.61, N=238 <LINK REF="STD-Davidson-1988" TYPE="STUDY">Davidson 1988</LINK> 6 MWT; <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>), and 18.61 metres [95% CI 12.83 to 24.39], N = 238 <LINK REF="STD-Davidson-1988" TYPE="STUDY">Davidson 1988</LINK> endurance walk test; <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). Random Effects modelling did not alter the significance of these effects.</P>
<P>Three studies did not report data in a usable format for meta-analysis. All assessed the effects of low dose oxygen. <LINK REF="STD-Leach-1992" TYPE="STUDY">Leach 1992</LINK>
<B> </B>reported no significant increase in distance walked (mean % increase 28.6 [95% CI - 21.5 to 111, N = 20]. <LINK REF="STD-Leggett-1977" TYPE="STUDY">Leggett 1977</LINK>
<B> </B>reported censored data (N=8) from a study of 26 participants, which showed a significant increase in distance walked 12MWT (mean SEM increase 53 m +/- 12.7. <LINK REF="STD-Wadell-2001" TYPE="STUDY">Wadell 2001</LINK>
<B> </B>reported that oxygen significantly improved the median distance walked on a 6MWT [median (min-max) improvement 30 (-30 to 60) metres, N = 20].</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Exercise time</HEADING>
<P>(<LINK REF="STD-Davidson-1988" TYPE="STUDY">Davidson 1988</LINK>; <LINK REF="STD-Raimondi-1970" TYPE="STUDY">Raimondi 1970</LINK>; <LINK REF="STD-Somfay-2001" TYPE="STUDY">Somfay 2001</LINK>; <LINK REF="STD-Bye-1985" TYPE="STUDY">Bye 1985</LINK>; <LINK REF="STD-Dean-1992" TYPE="STUDY">Dean 1992</LINK>; <LINK REF="STD-O_x0027_Donnell-1997" TYPE="STUDY">O'Donnell 1997</LINK>; <LINK REF="STD-O_x0027_Donnell-2001" TYPE="STUDY">O'Donnell 2001</LINK>).</P>
<P>One study assessed the effects of treatment with low dose oxygen (<LINK REF="STD-Raimondi-1970" TYPE="STUDY">Raimondi 1970</LINK>). Two studies reported data on the effects of treatment with both low dose and high dose oxygen (<LINK REF="STD-Somfay-2001" TYPE="STUDY">Somfay 2001</LINK>; <LINK REF="STD-Davidson-1988" TYPE="STUDY">Davidson 1988</LINK>) and four studies assessed the effects of treatment with high dose oxygen (<LINK REF="STD-Bye-1985" TYPE="STUDY">Bye 1985</LINK>; <LINK REF="STD-Dean-1992" TYPE="STUDY">Dean 1992</LINK>; <LINK REF="STD-O_x0027_Donnell-1997" TYPE="STUDY">O'Donnell 1997</LINK>; <LINK REF="STD-O_x0027_Donnell-2001" TYPE="STUDY">O'Donnell 2001</LINK>). In one study the effect of low dose oxygen was assessed using two different endurance tests (cycle test and an endurance walk test, <LINK REF="STD-Davidson-1988" TYPE="STUDY">Davidson 1988</LINK>). To avoid over-estimating the effects of treatment in the placebo arms of the studies, three pooled estimates have been calculated. There was no significant heterogeneity between the subgroups in any instance. With low dose data from <LINK REF="STD-Somfay-2001" TYPE="STUDY">Somfay 2001</LINK> and <LINK REF="STD-Davidson-1988" TYPE="STUDY">Davidson 1988</LINK>, oxygen significantly improved exercise time irrespective of whether data related to the cycle test (Low dose: WMD 2.70 minutes [95% CI 1.95 to 3.44], N = 77) or endurance walk test (Low dose: WMD 2.63 minutes [95% CI 1.91 to 3.44], N = 77). With high dose data from both studies entered oxygen significantly increased exercise time (High dose: WMD 2.71 minutes [95% CI 1.96 to 3.46], N = 77).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Step</HEADING>
<P>(<LINK REF="STD-McDonald-1995" TYPE="STUDY">McDonald 1995</LINK>)</P>
<P>Data from the original study showed that low dose oxygen significantly improved the mean (SD) number of steps climbed oxygen 35 (21) versus placebo 30 (18), N = 26.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">VO<SUB>2</SUB>
</HEADING>
<P>(<LINK REF="STD-Palange-1995" TYPE="STUDY">Palange 1995</LINK>)</P>
<P>Data from the original study showed that low dose oxygen significantly improved VO2 oxygen 2280 (426) versus placebo 1120 (204), N = 9.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Patient Preference</HEADING>
<P>No studies reported on patient preference.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">MAXIMAL TEST STUDIES</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Primary outcome: Exercise capacity</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Distance</HEADING>
<P>(<LINK REF="STD-Garrod-1999" TYPE="STUDY">Garrod 1999</LINK>; <LINK REF="STD-Garrod-2000" TYPE="STUDY">Garrod 2000</LINK>; <LINK REF="STD-McKeon-1988" TYPE="STUDY">McKeon 1988</LINK>; <LINK REF="STD-Woodcock-1981" TYPE="STUDY">Woodcock 1981</LINK>).</P>
<P>All studies assessed the effects of low dose oxygen. There was a significant improvement in distance walked during oxygen versus placebo of 32 metres [95% 20.61 to 43.38], N = 70. There was a moderate level of heterogeneity between the studies. Random Effects modelling widened the confidence interval but the result remained significant (39.57 metres [95% CI 17.03 to 62.11]).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Time</HEADING>
<P>(<LINK REF="STD-Criner-1987" TYPE="STUDY">Criner 1987</LINK>; <LINK REF="STD-Mannix-1992" TYPE="STUDY">Mannix 1992</LINK>; <LINK REF="STD-Raimondi-1970" TYPE="STUDY">Raimondi 1970</LINK>; <LINK REF="STD-Stein-1982" TYPE="STUDY">Stein 1982</LINK>; <LINK REF="STD-Swinburn-1984" TYPE="STUDY">Swinburn 1984</LINK>; <LINK REF="STD-Vyas-1971" TYPE="STUDY">Vyas 1971</LINK>).</P>
<P>Fixed effect modelling gave a significant difference of 1.06 minutes in favour of oxygen [95% CI: 0.67, 1.46], N = 50. Although there was a moderate level of heterogeneity (I<SUP>2</SUP> 51.7%), Random Effects modelling did not alter the significance of this finding (1.19 minutes [0.53, 1.86]).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">VO<SUB>2</SUB>max</HEADING>
<P>(<LINK REF="STD-Bradley-1978" TYPE="STUDY">Bradley 1978</LINK>; <LINK REF="STD-Criner-1987" TYPE="STUDY">Criner 1987</LINK>; <LINK REF="STD-Mannix-1992" TYPE="STUDY">Mannix 1992</LINK>; <LINK REF="STD-Vyas-1971" TYPE="STUDY">Vyas 1971</LINK>; <LINK REF="STD-Gosselin-2004" TYPE="STUDY">Gosselin 2004</LINK>).</P>
<P>Three studies assessed the effects of low dose oxygen (<LINK REF="STD-Criner-1987" TYPE="STUDY">Criner 1987</LINK>; <LINK REF="STD-Gosselin-2004" TYPE="STUDY">Gosselin 2004</LINK>; <LINK REF="STD-Mannix-1992" TYPE="STUDY">Mannix 1992</LINK>) and two studies assessed the effects of high dose oxygen (<LINK REF="STD-Bradley-1978" TYPE="STUDY">Bradley 1978</LINK>; <LINK REF="STD-Vyas-1971" TYPE="STUDY">Vyas 1971</LINK>). As each study used different units of measurement these studies could not be pooled. Data from the original studies showed that oxygen significantly (P&lt;0.05) improved VO<SUB>2</SUB> max in three studies [<LINK REF="STD-Criner-1987" TYPE="STUDY">Criner 1987</LINK>; N=6, oxygen 13.4 (0.9) versus placebo 9.6 (1.4)ml kg<SUP>-1 min-1</SUP>; <LINK REF="STD-Gosselin-2004" TYPE="STUDY">Gosselin 2004</LINK>; N=9, oxygen 22.03 (4.2) versus placebo 20.2 (5.7) ml kg-1 min-1; <LINK REF="STD-Vyas-1971" TYPE="STUDY">Vyas 1971</LINK>; N=12, oxygen 4.14 (1.21) versus placebo 2.74 (0.86) L 0.5 min<SUP>-1</SUP>]. Oxygen did not improve VO<SUB>2</SUB> max in the other two studies [<LINK REF="STD-Mannix-1992" TYPE="STUDY">Mannix 1992</LINK>; N=10, oxygen 740 (335.20) versus placebo 609 (220.39)ml min<SUP>-1</SUP>; <LINK REF="STD-Bradley-1978" TYPE="STUDY">Bradley 1978</LINK>; N=26, oxygen 8.7 (3.0) versus placebo 8.20 (2.60)ml min<SUP>-1</SUP>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Work rate</HEADING>
<P>(<LINK REF="STD-Light-1989" TYPE="STUDY">Light 1989</LINK>; <LINK REF="STD-Gosselin-2004" TYPE="STUDY">Gosselin 2004</LINK>; <LINK REF="STD-Maltais-2001" TYPE="STUDY">Maltais 2001</LINK>)</P>
<P>Two studies assessed the effects of low dose oxygen (<LINK REF="STD-Light-1989" TYPE="STUDY">Light 1989</LINK>; <LINK REF="STD-Gosselin-2004" TYPE="STUDY">Gosselin 2004</LINK>) and one study assessed the effects of high dose oxygen (<LINK REF="STD-Maltais-2001" TYPE="STUDY">Maltais 2001</LINK>). There was no significant heterogeneity between the studies and oxygen significantly increased work rate compared to placebo by 8.88 watts [95% CI 5.71 to 12.06] N=40.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Patient Preference</HEADING>
<P>No studies reported on patient preference.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4"/>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcome measure at Isotime</HEADING>
<P>Secondary outcomes e.g. breathlessness, SaO<SUB>2</SUB>, V<SUB>E</SUB> at end exercise are not directly comparable as they are dependant on exercise performance (time/distance/VO2/work rate). Therefore it was decided to compare the effect of oxygen treatment on these secondary outcomes at isotime. In all studies except two the isotime is defined as the time at which the placebo test ended. One study used the point of comparison as the time at which the lesser test ended (<LINK REF="STD-Vyas-1971" TYPE="STUDY">Vyas 1971</LINK>). One study used the point of comparison as the time at which stage 1 (no resistance or zero watts) ended (<LINK REF="STD-Mannix-1992" TYPE="STUDY">Mannix 1992</LINK>). One study reported data on isotimes with both high and low dose oxygen treatment so to avoid double-counting the effects of treatment two pooled estimates have been calculated (<LINK REF="STD-Somfay-2001" TYPE="STUDY">Somfay 2001</LINK>).</P>
<P>
<B>ENDURANCE TEST ISOTIMES STUDIES</B>
</P>
<SUBSECTION>
<HEADING LEVEL="6">Breathlessness</HEADING>
<P>(<LINK REF="STD-Dean-1992" TYPE="STUDY">Dean 1992</LINK>; <LINK REF="STD-O_x0027_Donnell-1997" TYPE="STUDY">O'Donnell 1997</LINK>; <LINK REF="STD-O_x0027_Donnell-2001" TYPE="STUDY">O'Donnell 2001</LINK>; <LINK REF="STD-Somfay-2001" TYPE="STUDY">Somfay 2001</LINK>).</P>
<P>Three studies assessed the effects of treatment with high dose oxygen (<LINK REF="STD-Dean-1992" TYPE="STUDY">Dean 1992</LINK>; <LINK REF="STD-O_x0027_Donnell-1997" TYPE="STUDY">O'Donnell 1997</LINK>; <LINK REF="STD-O_x0027_Donnell-2001" TYPE="STUDY">O'Donnell 2001</LINK>) and one study assessed the effects of both high and low dose oxygen (<LINK REF="STD-Somfay-2001" TYPE="STUDY">Somfay 2001</LINK>). There was a moderate level of heterogeneity between the studies (I<SUP>2</SUP> 40-44%). With low and high dose oxygen data from <LINK REF="STD-Somfay-2001" TYPE="STUDY">Somfay 2001</LINK> entered separately oxygen significantly decreased breathlessness (Low dose data from <LINK REF="STD-Somfay-2001" TYPE="STUDY">Somfay 2001</LINK>: WMD -1.15 [95% CI -1.65 to -0.66] and high dose data from <LINK REF="STD-Somfay-2001" TYPE="STUDY">Somfay 2001</LINK>: WMD -1.15 [95% CI -1.66 to -0.65]). Random Effects modelling gave a significant result in favour of oxygen (<LINK REF="STD-Somfay-2001" TYPE="STUDY">Somfay 2001</LINK> low dose: -1.46 [95% CI -2.30 to -0.62]; <LINK REF="STD-Somfay-2001" TYPE="STUDY">Somfay 2001</LINK> high dose: -1.51 [95% CI -2.41 to -0.61] N=44).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">SaO<SUB>2</SUB>/PaO<SUB>2</SUB>
</HEADING>
<P>(<LINK REF="STD-Bye-1985" TYPE="STUDY">Bye 1985</LINK>; <LINK REF="STD-O_x0027_Donnell-1997" TYPE="STUDY">O'Donnell 1997</LINK>; <LINK REF="STD-Somfay-2001" TYPE="STUDY">Somfay 2001</LINK>)</P>
<P>Two studies assessed the effects of treatment with high dose oxygen (<LINK REF="STD-Bye-1985" TYPE="STUDY">Bye 1985</LINK>; <LINK REF="STD-O_x0027_Donnell-1997" TYPE="STUDY">O'Donnell 1997</LINK>) and one study assessed the effects of both high and low dose oxygen (<LINK REF="STD-Somfay-2001" TYPE="STUDY">Somfay 2001</LINK>). There was no significant heterogeneity between the studies. Oxygen significantly improved SaO<SUB>2</SUB> with low and high dose data from <LINK REF="STD-Somfay-2001" TYPE="STUDY">Somfay 2001</LINK> (<LINK REF="STD-Somfay-2001" TYPE="STUDY">Somfay 2001</LINK> low dose: 8.36% [95% CI 5.08 to 11.64]; <LINK REF="STD-Somfay-2001" TYPE="STUDY">Somfay 2001</LINK> high dose: 8.80% [95% CI 5.36 to 12.24] N=29).</P>
<P>Data for PaO<SUB>2</SUB> was reported in two high dose studies (<LINK REF="STD-Dean-1992" TYPE="STUDY">Dean 1992</LINK>; <LINK REF="STD-O_x0027_Donnell-2001" TYPE="STUDY">O'Donnell 2001</LINK>). PaO<SUB>2</SUB> was significantly greater with oxygen versus placebo by 15.15 kPa [95% CI 6.42 to 23.89] N=23.</P>
<P>V<SUB>E </SUB>(<LINK REF="STD-Dean-1992" TYPE="STUDY">Dean 1992</LINK>; <LINK REF="STD-Bye-1985" TYPE="STUDY">Bye 1985</LINK>; <LINK REF="STD-O_x0027_Donnell-1997" TYPE="STUDY">O'Donnell 1997</LINK>; <LINK REF="STD-O_x0027_Donnell-2001" TYPE="STUDY">O'Donnell 2001</LINK>; <LINK REF="STD-Somfay-2001" TYPE="STUDY">Somfay 2001</LINK>)<BR/>V<SUB>E </SUB>is the volume of air inhaled per minute. Four studies assessed the effects of treatment with high dose oxygen (<LINK REF="STD-Dean-1992" TYPE="STUDY">Dean 1992</LINK>; <LINK REF="STD-Bye-1985" TYPE="STUDY">Bye 1985</LINK>; <LINK REF="STD-O_x0027_Donnell-1997" TYPE="STUDY">O'Donnell 1997</LINK>; <LINK REF="STD-O_x0027_Donnell-2001" TYPE="STUDY">O'Donnell 2001</LINK>) and one study assessed the effects of both high and low dose oxygen (<LINK REF="STD-Somfay-2001" TYPE="STUDY">Somfay 2001</LINK>). Pooled estimates with both high and low dose data from <LINK REF="STD-Somfay-2001" TYPE="STUDY">Somfay 2001</LINK> indicated that oxygen significantly decreased V<SUB>E</SUB> (<LINK REF="STD-Somfay-2001" TYPE="STUDY">Somfay 2001</LINK> high dose: -3.58 [95% CI -4.85 to -2.31]; <LINK REF="STD-Somfay-2001" TYPE="STUDY">Somfay 2001</LINK> low dose: -3.60 L/min [95% CI -4.88 to -2.33] N=52).</P>
<P>
<B>MAXIMAL TEST ISOTIMES</B>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Breathlessness</HEADING>
<P>Data from 14 patients showed high dose oxygen significantly reduced breathlessness compared to placebo but no data was provided (<LINK REF="STD-Maltais-2001" TYPE="STUDY">Maltais 2001</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">SaO<SUB>2</SUB> and PaO<SUB>2 </SUB>
</HEADING>
<P>(<LINK REF="STD-Light-1989" TYPE="STUDY">Light 1989</LINK>; <LINK REF="STD-Maltais-2001" TYPE="STUDY">Maltais 2001</LINK>)</P>
<P>One study assessed the effects of low dose oxygen (<LINK REF="STD-Light-1989" TYPE="STUDY">Light 1989</LINK>) and one study assessed effects of high dose oxygen (<LINK REF="STD-Maltais-2001" TYPE="STUDY">Maltais 2001</LINK>). There was no significant heterogeneity between the studies and oxygen significantly increased SaO2 versus placebo by 7.82% [95% CI 4.89 to 10.74] N=31.</P>
<P>
<I>V<SUB>E</SUB>
</I>
<SUB> </SUB>(<LINK REF="STD-Light-1989" TYPE="STUDY">Light 1989</LINK>; <LINK REF="STD-Mannix-1992" TYPE="STUDY">Mannix 1992</LINK>; <LINK REF="STD-Vyas-1971" TYPE="STUDY">Vyas 1971</LINK>; <LINK REF="STD-Gosselin-2004" TYPE="STUDY">Gosselin 2004</LINK>)</P>
<P>Three studies assessed the effects of treatment with low dose oxygen (<LINK REF="STD-Light-1989" TYPE="STUDY">Light 1989</LINK>; <LINK REF="STD-Mannix-1992" TYPE="STUDY">Mannix 1992</LINK>; <LINK REF="STD-Gosselin-2004" TYPE="STUDY">Gosselin 2004</LINK>) and one study assessed the effects of treatment high oxygen (<LINK REF="STD-Vyas-1971" TYPE="STUDY">Vyas 1971</LINK>).<B> </B>There was a significant difference in V<SUB>E</SUB> in favour of oxygen, of -3.26 L/min [95% CI -4.33 to -2.19] N=48.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Sensitivity &amp; Subgroup Analyses</HEADING>
<P>It was not possible to conduct a sub group analysis according to disease severity or method of oxygen delivery.</P>
<P>Subgroup analyses according to baseline oxygen status did not provide evidence of different response to treatment between those studies which included patients that did/likely did meet the criteria for LTOT and those studies that did not/ likely did not. This may be explained in part by the nature of the distinctions made. These have been made at the 'trial level', and as such may have been too arbitrary to differentiate between different patient populations. However, such distinctions are based upon internationally approved guidelines (<LINK REF="REF-NICE-2004" TYPE="REFERENCE">NICE 2004</LINK>).<BR/>
<B>
<BR/>
</B>Two trials evaluated the effects of low dose and high dose oxygen (<LINK REF="STD-Somfay-2001" TYPE="STUDY">Somfay 2001</LINK>; <LINK REF="STD-Davidson-1988" TYPE="STUDY">Davidson 1988</LINK>). Both trials reported data on endurance exercise time. Head to head comparison showed no significant improvement in endurance time WMD 1.85 [95% CI -0.16 to 3.86] during high dose versus low dose oxygen. A number of factors undermine the validity of this estimate: i) the original studies compared a number of categories (<LINK REF="STD-Somfay-2001" TYPE="STUDY">Somfay 2001</LINK>, 30;50;75;100%: <LINK REF="STD-Davidson-1988" TYPE="STUDY">Davidson 1988</LINK>, 2;4;6 L) of oxygen and did report benefit from higher dose compared to lower dose. In this review data relating to the oxygen intervention closest to the critical level was extracted; ii) the SEM for the <LINK REF="STD-Davidson-1988" TYPE="STUDY">Davidson 1988</LINK> was imputed, based upon the variance from a P value given for a comparison with placebo; iii) the data for the two studies extracted from different exercise tests (<LINK REF="STD-Davidson-1988" TYPE="STUDY">Davidson 1988</LINK>: endurance cycle; <LINK REF="STD-Somfay-2001" TYPE="STUDY">Somfay 2001</LINK>: endurance walk test). Further studies comparing high with low dose oxygen are required before the dose effect can be more fully explored.</P>
<P>
<LINK REF="STD-Somfay-2001" TYPE="STUDY">Somfay 2001</LINK> reported on endurance isotime. No significant difference was reported in breathlessness or V<SUB>E</SUB> at isotime between high and low dose oxygen. SaO2 was significantly greater at isotime during high dose versus low dose oxygen (high dose: 99.7% (SEM 0.2), low dose: 98% (SEM 0.8), (P &lt; 0.05).</P>
<SUBSECTION>
<HEADING LEVEL="6">Other Results</HEADING>
<P>There is no documented criteria on the minimal clinically important difference for ambulatory oxygen, however the RCP guidelines state that ambulatory oxygen therapy should be prescribed when there is an improvement of at least 10% in walking distance and/or breathlessness score when walking with supplemental oxygen compared to air. 28/31 studies provided data on mean exercise performance (distance, time. work rate) and/or mean breathlessness score. Of these 23/28 studies (in <LINK REF="STD-Fujimoto-2002c" TYPE="STUDY">Fujimoto 2002c</LINK> patients with severe disease only) demonstrated an improvement of at least 10% in mean exercise performance and/or mean breathlessness score when walking with supplemental oxygen compared with an air cylinder.</P>
<P>Lack of adequate blinding procedures may exert some bias on the effect estimates, if the study investigators are aware as to which intervention participants are receiving during an exercise test. The majority of the studies assembled in the primary outcomes were double-blind and a <I>post-hoc</I> sensitivity analysis suggested that the removal of single-blind studies did not reduce the significance of the summary estimate (Exercise distance: double-blind studies: 20.68 metres (14.11, 27.25; seven studies); exercise time: 3.22 (2.15, 4.29; four studies).</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-08-22 16:58:49 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Thirty-one studies (contributing 33 data sets), comparing performance during a single exercise test using ambulatory oxygen with performance during a single exercise test with placebo have been included in this review. The overall effect of oxygen was estimated (low dose plus high dose). Oxygen improved all outcomes relating to endurance exercise capacity (distance, time, number of steps) when the studies were pooled. Oxygen improved exercise distance, time, and work rate during maximal exercise testing in a mixed population of patients. Data for VO<SUB>2</SUB> max during maximal exercise testing could not be pooled and data from original studies was not consistent.</P>
<P>The secondary outcomes of breathlessness, SaO<SUB>2 </SUB>and V<SUB>E </SUB>are not directly comparable at end exercise, so comparisons were made at isotime. Oxygen improved breathlessness, SaO<SUB>2</SUB>/PaO<SUB>2</SUB> and V<SUB>E</SUB> at isotime with endurance exercise testing. Data from studies comparing high dose versus low dose oxygen were analysed but they may have been inadequately powered to explore the dose response in terms of breathlessness or V<SUB>E</SUB> at isotime. No data from maximal exercise test data were reported on breathlessness at isotime; oxygen improved V<SUB>E </SUB>and<SUB> </SUB>SaO<SUB>2</SUB>/PaO<SUB>2</SUB> at isotime.</P>
<SUBSECTION>
<HEADING LEVEL="6">Methodological issues</HEADING>
<P>The results of this review are noteworthy because of the lack of statistical heterogeneity in many of the meta-analyses. The studies differed in several ways, notably in the type of exercise test deployed (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>), the method and amount of oxygen, whether participants were known to be able to exercise up to a certain capacity, whether studies were single or double-blind, and the severity of the participants recruited to the studies. Due to the way in which participant characteristics were described we could not answer important questions surrounding the fulfilment of LTOT criteria as a predictor of short-term response. We could not determine whether the assessments derived from the different exercise tests used differed sufficiently to avoid combining them. Comparisons of the different exercise tests could elucidate this issue further. The studies assembled did not provide evidence that high and low doses of oxygen are too dissimilar to keep apart in a meta-analysis. However, the entry criteria did not allow us to explore the effects of oxygen in this setting in different patient populations. Rather than interpret this review as indicative of a consistent effect across several subgroups of patients with COPD, we feel that further studies are required in more distinct patient populations before this can be stated with authority.</P>
<P>Publication bias was suggested by funnel plots of primary outcomes (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). In spite of extensive literature searches, contact with trialists and the incorporation of data from two studies published in Japanese, there remains the possibility that there are several small negative studies that have not been published, or identified by the search strategy employed in this review. The recent identification of <LINK REF="STD-Knebel-2000" TYPE="STUDY">Knebel 2000</LINK> provides an opportunity to revisit the question of publication bias on the primary outcome. This is the only non-significant study in this subset of trials, and takes up the third largest weighting for this outcome (16%). The level of heterogeneity has increased to only a modest level (33%) and the fixed effect summary estimate has moved a small amount towards the null compared with the previous version of this review. The addition of this study goes part way to correcting for some of the publication bias suggested by the initial funnel plot published in this review in issue 2, 2005, but additional large studies in future versions of this review will help further to provide a more reliable estimate.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">External validity</HEADING>
<P>Three characteristics of the studies affect the generalisability of the review: inclusion and exclusion criteria of individual studies, method of delivery of oxygen, and outcome assessment.<BR/>
<BR/>Few of the trials categorised patients at baseline according to level of hypoxaemia. Due to the lack of variation between effect estimates, subgroup analyses did not provide useful insights in to whether baseline oxygen status affected response to ambulatory oxygen in the studies. This may be because the studies recruited mixed populations, rendering trial-level distinctions on this basis somewhat arbitrary. A baseline 'mean' can be a crude measurement of population health, especially in this review where threshold values indicate treatment with LTOT oxygen on an individual patient level. The subgroup analysis from available data relating to level of hypoxaemia provides some evidence that there is benefit of ambulatory oxygen in patients who meet/likely meet as well as those who do not meet/likely do not meet the criteria for LTOT. The absence of a significant difference between treatment responses could well indicate that these studies have recruited mixed populations, with some variation between them in the percentage of participants who would qualify for LTOT.</P>
<P>Current UK guidelines state that non-LTOT patients who desaturate by 4% to a point below 90% on a baseline walk should be assessed for ambulatory oxygen (<LINK REF="REF-RCP-1999" TYPE="REFERENCE">RCP 1999</LINK>). The majority of studies in this review do not provide information on the level homogeneity of the patients with regard to exercise induced desaturation and do not provide sufficient information to enable us to ascertain whether trials (and/or all the patients in each trial) meet the current UK criteria for ambulatory oxygen assessment. Therefore it was not possible to conduct a sub-group analysis on the following categories: (a) patients who did not meet criteria for LTOT but have evidence of resting hypoxaemia (desaturation &lt;90%); (b) patients who did not meet criteria for LTOT and did not have evidence of resting hypoxaemia, but who demonstrated a fall in SaO2 of at least to reach a reading below 90% during a baseline walking test whilst breathing air (c) patients who do not meet any of these criteria. Therefore we are unable to determine how accurately the results of this review can be inferred to the population which the UK guidelines recommend that ambulatory oxygen should be considered.</P>
<P>UK guidelines state that assessment should include titrating oxygen to a level in which SaO2 is kept above 90% (<LINK REF="REF-RCP-1999" TYPE="REFERENCE">RCP 1999</LINK>). It is unclear whether the flow rate/percentage of oxygen used in these studies was adequate to achieve this. If the oxygen level was inadequate it may underestimate the effect of ambulatory oxygen.</P>
<P>The studies in this review used a variety of methods to deliver oxygen which could affect the outcome and nasal speculae were the most frequently used method of delivery of ambulatory oxygen.</P>
<P>Subgroup analysis of high versus low dose oxygen did not indicate that this distinction explains any heterogeneity between the studies on any outcome. In studies where these two treatment regimens have been compared directly, there is insufficient evidence to conclude that a dose response effect exists. More studies are required in this area.</P>
<P>The results of our review demonstrate that maximal or endurance tests can be used in ambulatory oxygen assessments. The choice of exercise test should be determined by a number of factors: e.g. the psychometric properties of the test is important and it has been suggested that endurance exercise testing may be more sensitive and more related to functional exercise capacity and activities of daily living than maximal exercise testing (<LINK REF="REF-Revill-1999" TYPE="REFERENCE">Revill 1999</LINK>; <LINK REF="REF-ATS-2002" TYPE="REFERENCE">ATS 2002</LINK>). Other important factors include the resources available; and the patient activity levels. For example a maximal test may be appropriate for patients who intend to use ambulatory oxygen during intense activities and endurance tests may be more appropriate during functional activities of daily living.<BR/>
<BR/>It has been shown that the use of familiarisation and/or a practice periods prior to exercise testing will improve the quality of the data obtained (<LINK REF="REF-ATS-2002" TYPE="REFERENCE">ATS 2002</LINK>; <LINK REF="REF-Singh-1992" TYPE="REFERENCE">Singh 1992</LINK>). Some exercise tests have standardised protocols which include information on how many practice tests are required (e.g. 6MWT 2 practice tests, incremental shuttle walk test - 1 practice test) (<LINK REF="REF-ATS-2002" TYPE="REFERENCE">ATS 2002</LINK>; <LINK REF="REF-Singh-1992" TYPE="REFERENCE">Singh 1992</LINK>). The majority of studies in this review included a familiarisation period and approximately half the studies included a practice period.</P>
<P>There is no specific guidance on length of time between repeated exercise tests and how many tests can be performed on a single day. For maximal exercise testing it has been suggested that 24-48 hours should be left between tests, and it is unclear how long should be left between endurance tests although there is some evidence to suggest that at least 30 minutes should be left between repeat endurance tests (<LINK REF="REF-Marques-1998" TYPE="REFERENCE">Marques 1998</LINK>; <LINK REF="REF-ATS-2002" TYPE="REFERENCE">ATS 2002</LINK>). Repeated exercise testing could result in an order effect with patients performing less well on repeated testing (<LINK REF="REF-Marques-1998" TYPE="REFERENCE">Marques 1998</LINK>). It is unclear how much impact the order and frequency of testing could have influenced the results.</P>
<P>While the effects of short episodes of hypoxaemia are still unclear (especially in patients adapted to chronic hypoxaemia) single assessment studies are useful in determining the efficacy of ambulatory oxygen in patients with COPD, although it is not known how variable the results of single assessments are in any given individual (<LINK REF="REF-Senn-2004" TYPE="REFERENCE">Senn 2004</LINK>), nor how far the response to short term testing predicts uptake or compliance with therapy in the longer term.</P>
<P>Estimates for the Minimal Clinically Important Difference (MCID) are available for the 6MWT and the shuttle walk test. <LINK REF="REF-Redelmeier-1997" TYPE="REFERENCE">Redelmeier 1997</LINK> estimates the MCID for the 6MWT to be 50 metres [95% CI 37 to 71], and <LINK REF="REF-Singh-2002" TYPE="REFERENCE">Singh 2002</LINK> estimates the MCID for the SWT to be 48 metres [95% CI 33.6 to 63.6]. Although effect sizes from the outcomes measuring exercise capacity in this review were statistically significant, the clinical significance of this result remains open to interpretation, especially as the lower confidence interval for our summary estimates are lower than those estimated by the above studies. No estimates on MCID for the other outcome measures have been identified. A mean difference less than the MCID does not exclude the fact that some patients in the study may actually have achieved the MCID and it would be useful for future studies to state how many individual patients achieve the MCID for primary outcome measure.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Internal validity</HEADING>
<P>The methodological quality of the trials in this review were assessed using two different scales -the Jadad and PEDro scales. Both scales were used because different quality scales have been shown to generate discrepant results. Both of these scales mostly assess different aspects of internal validity- Jadad: randomisation (2 questions, 40%), blinding (2 questions, 40%) and withdrawal (1 question, 20%); PEDro: randomisation (2 questions, 20%), blinding (3 questions, 30%), withdrawal (2 questions, 20%). In addition PEDro includes aspects relating to baseline characteristics (1 question, 10%) and statistics (2 questions, 20%). Jadad gives more weighting to quality of reporting than actual methodological quality, for example Jadad focuses on reporting of randomisation and the reporting of the randomisation procedure where as PEDro focuses on whether there is randomised and concealed allocation. In Jadad a statement on withdrawals will earn a point independently of how many patients were excluded or whether "intention to treat" was used whereas the PEDro scale examines the impact of patient withdrawals in detail. These differences explain any discrepancies in the rank order of quality rating between the Jadad and Pedro scales. A score of 3 on the Jadad scale represents "high quality" (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>). Six studies scored 3 or above on the Jadad scale. All studies which scored 3 on the Jadad scale scored 9 or 10 on the PEDro. There is no reference criteria regarding high quality on the PEDro scale- all studies in this review scored 6 or more. We would propose that the PEDro scale may be more sensitive than the Jadad scale to aspects of internal validity relevant to the ambulatory oxygen studies included in this review and that a score of 6 or more demonstrates that all the trials in this review have at least reasonable internal validity.</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>This review provides evidence from single assessment studies that ambulatory oxygen improves exercise performance. It is our opinion that it is no longer necessary to compare performance during an exercise test using oxygen versus placebo air but rather an ambulatory assessment should determine whether patients demonstrate objective benefit during an exercise test using oxygen versus room air. The system used in the ambulatory oxygen assessment should be the system that would be potentially made available to the patient and should be used in the same way that the patient would be advised to use it (for example, if the patient will be required to carry/wheel the ambulatory system during activities of daily living then they should carry/wheel it during the ambulatory oxygen assessment). </P>
<P>Maximal or endurance tests could be used in ambulatory oxygen assessment. Consideration should be given to the measurement of signs and symptoms such as SaO<SUB>2</SUB>/SpO<SUB>2</SUB> and breathlessness at isotime as these provide important information. We recommend that these outcomes are included in the assessment for ambulatory oxygen. Consideration should also be given to the amount of oxygen required to maintain SaO<SUB>2</SUB>/SpO<SUB>2</SUB> at an acceptable level. The technology for the delivery of ambulatory oxygen is developing rapidly and in the future such systems should be accessible to those who demonstrate objective benefit during an ambulatory oxygen assessment (<LINK REF="REF-Law-2004" TYPE="REFERENCE">Law 2004</LINK>; <LINK REF="REF-DOH" TYPE="REFERENCE">DOH</LINK> <LINK REF="REF-BTS-2004" TYPE="REFERENCE">BTS 2004</LINK>). Detailed and standardised assessment procedures for ambulatory oxygen therapy should be developed and these should include assessment of potential utilisation by the patient as well as objective benefit. <BR/> </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>This review has established the short-term efficacy of ambulatory oxygen, although additional studies may help to reduce suspected bias in reporting of the primary outcome. In our opinion research should focus on establishing the long-term efficacy, and on developing a method for determining the optimal dose and delivery system for ambulatory oxygen. Further trials are also required to establish whether improvements in primary and secondary outcomes which reach statistical significance are clinically important. We remain uncertain of the level of benefit of ambulatory oxygen in specific subgroups of COPD: patients who already meet the criteria for LTOT; (b) patients who do not meet criteria for LTOT but have evidence of resting hypoxaemia (desaturation &lt;90%); (c) patients who do not meet criteria for LTOT and do not have evidence of resting hypoxaemia but who demonstrate a fall in SpO<SUB>2</SUB> of at least 4% to reach a reading below 90% during a baseline walking test whilst breathing air.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2008-08-22 16:56:27 +0100" MODIFIED_BY="Toby J Lasserson">
<P>We would like to thank Toby Lasserson for his support. We would like to thank Makiko Meguro for translating studies from Japanese. Mike Greenstone was the assigned editor for this review. We would like to thank Prof JS Elborn and Dr J MacMahon Deaprtment of Respiratory Medicine Belfast City Hospital, for reviewing papers and offering clinical and medical viewpoints.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>There are no known conflicts of interest. </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>The title for the protocol was conceived by J. Bradley and B. O'Neill in collaboration with the Cochrane Airways Group. </P>
<P>J. Bradley, B. O'Neill and Felix Ram designed and assisted in writing the protocol. </P>
<P>J. Bradley and B. O'Neill designed and wrote the review, and updated it in June 2005</P>
<P>T Lasserson acted as supervisor for the review. </P>
<P>J. Bradley acts as guarantor of the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-08-22 16:58:51 +0100" MODIFIED_BY="Toby J Lasserson">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Bradley-1978" NAME="Bradley 1978" YEAR="1978">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bradley BL, Garner AE, Billiu D, Mestas JM, Forman J.</AU>
<TI>Oxygen assisted exercise in chronic obstructive lung disease</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1978</YR>
<VL>118</VL>
<PG>239-243</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bye-1985" NAME="Bye 1985" YEAR="1985">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bye PT, Esau SA, Levy RD, Shiner RJ, Macklem PT, Martin JG, Pardy RL</AU>
<TI>Ventilatory muscle function during exercise in air and oxygen in patients with chronic air-flow limitation</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1985</YR>
<VL>132</VL>
<PG>236-240</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Criner-1987" NAME="Criner 1987" YEAR="1987">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Criner GJ, Celli BR</AU>
<TI>Ventilatory muscle recruitment in exercise with O2 in obstructed patients with mild hypoxemia</TI>
<SO>Journal of Applied Physiology</SO>
<YR>1987</YR>
<VL>63</VL>
<NO>1</NO>
<PG>195-200</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davidson-1988" NAME="Davidson 1988" YEAR="1988">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Davidson AC, Leach R, George RJ, Geddes DM.</AU>
<TI>Supplemental oxygen and exercise ability in chronic obstructive airways disease</TI>
<SO>Thorax</SO>
<YR>1988</YR>
<VL>43</VL>
<PG>965-971</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dean-1992" NAME="Dean 1992" YEAR="1992">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dean NC, Brown JK, Himelman RB, Docherty JJ, Gold WM, Stulbarg MS</AU>
<TI>Oxygen may improve dyspnea and endurance in patients with chronic obstructive pulmonary disease and only mild hypoxemia</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1992</YR>
<VL>146</VL>
<PG>941-945</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eaton-2002" NAME="Eaton 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eaton T, Garrett JE, Young W, Fergusson W, Kolbe J, Rudkin S, Whyte KL</AU>
<TI>Ambulatory oxygen improves quality of life of COPD patients: a randomised controlled study</TI>
<SO>European Respiratory Journal</SO>
<YR>2002</YR>
<VL>20</VL>
<PG>306-312</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fujimoto-2002a" NAME="Fujimoto 2002a" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fujimoto K, Matsuzawa Y, Yamaguchi S, Koizumi T and Kubo K</AU>
<TI>Benefits of oxygen on exercise performance and pulmonary hemodynamics in patients with COPD with mild hypoxemia</TI>
<SO>Chest</SO>
<YR>2002</YR>
<VL>122</VL>
<PG>457-463</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fujimoto-2002b" NAME="Fujimoto 2002b" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fujimoto K, Matsuzawa Y, Yamaguchi S, Koizumi T and Kubo K.</AU>
<TI>Benefits of oxygen on exercise performance and pulmonary hemodynamics in patients with COPD with mild hypoxemia. Chest 2002;122:457-463..</TI>
<SO>Chest</SO>
<YR>2002</YR>
<VL>122</VL>
<PG>457-463</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fujimoto-2002c" NAME="Fujimoto 2002c" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fujimoto K, Matsuzawa Y, Yamaguchi S, Koizumi T and Kubo K.</AU>
<TI>Benefits of oxygen on exercise performance and pulmonary hemodynamics in patients with COPD with mild hypoxemia. Chest 2002;122:457-463... Chets 2002;122:457-463.</TI>
<SO>Chest</SO>
<YR>2002</YR>
<VL>122</VL>
<PG>457-463</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garrod-1999" NAME="Garrod 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garrod R, Bestall JC, Paul E and Wedzicha JA</AU>
<TI>Evaluation of pulsed dose oxygen delivery during exercise in patients with severe chronic obstructive pulmonary disease</TI>
<SO>Thorax</SO>
<YR>1999</YR>
<VL>54</VL>
<PG>242-244</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garrod-2000" NAME="Garrod 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garrod R, Paul EA, Wedzicha JA</AU>
<TI>Supplemental oxygen therapy during pulmonary rehabilitation in patients with COPD and exercise hypoxaemia</TI>
<SO>Thorax</SO>
<YR>2000</YR>
<VL>55</VL>
<PG>539-543</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gosselin-2004" NAME="Gosselin 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gosselin N, Durand F, Poulain M, Lambert K, Ceugniet F, Prefaut C et al</AU>
<TI>Effect of acute hyperoxia during exercise on quadriceps electrical activity in active COPD patients</TI>
<SO>Acta Physiologica Scandinavica</SO>
<YR>2004</YR>
<VL>181</VL>
<NO>3</NO>
<PG>333-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ishimine-1995" NAME="Ishimine 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ishimine A, Saito T, Nishimura S, Nakano G, Miyamoto, Kawakami</AU>
<TI>The effect of oxygen supplementation during exercise in COPD patients with PaO2 over 60 Torr</TI>
<SO>Japanese Journal of Chest Disease</SO>
<YR>1995</YR>
<VL>33</VL>
<PG>510-518</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-King-1973" NAME="King 1973" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>King AJ, Cooke NJ, Leitch AG, Flenley DC</AU>
<TI>The effects of 30% oxygen on the respiratory response to treadmill exercise in chronic respiratory failure</TI>
<SO>Clinical Science</SO>
<YR>1973</YR>
<VL>44</VL>
<PG>151-162</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Knebel-2000" NAME="Knebel 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Knebel AR, Bentz E, Barnes P</AU>
<TI>Dyspnea management in alpha-1 antitrypsin deficinency: effect of oxygen administration</TI>
<SO>Nursing Research</SO>
<YR>2000</YR>
<VL>49</VL>
<NO>6</NO>
<PG>333-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kurihara-1989" NAME="Kurihara 1989" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kurihara N, Fujimoto S, Kouno, Futoda K, Hirata K, Takeda C</AU>
<TI>Exercise induced hypoxemia and exercise tolerance in patients with COPD and the benefits of oxygen supplementation</TI>
<SO>Japanese Journal of Chest Disease</SO>
<YR>1989</YR>
<VL>26</VL>
<PG>155-162</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leach-1992" NAME="Leach 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leach RM, Davidson AC, Chinn S, Twort CHC, Cameron IR, Bateman NT</AU>
<TI>Portable liquid oxygen and exericse ability in severe respiratory disability</TI>
<SO>Thorax</SO>
<YR>1992</YR>
<VL>47</VL>
<PG>781-789</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leggett-1977" NAME="Leggett 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leggett RJE, Flenley DC</AU>
<TI>Portable oxygen and exercise tolerance in patients with chronic hypoxic cor pulmonale</TI>
<SO>British Medical Journal</SO>
<YR>1977</YR>
<VL>2</VL>
<PG>84-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Light-1989" NAME="Light 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Light RW, Mahutte CK, Stansbury DW, Fischer CE, Brown SE</AU>
<TI>Relationship between improvement in exercise performance with supplemental oxygen and hypoxic ventilatory drive in patients with chronic airflow obstruction</TI>
<SO>Chest</SO>
<YR>1989</YR>
<VL>95</VL>
<PG>751-756</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maltais-2001" NAME="Maltais 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maltais F, Simon M, Jobin J, Desmeules M, Sullivan MJ, Belanger M, Leblanc P</AU>
<TI>Effects of oxygen on lower limb blood flow and O2 uptake during exercise in COPD</TI>
<SO>Medicine &amp; Science in Sports &amp; Exercise</SO>
<YR>2001</YR>
<VL>33</VL>
<NO>6</NO>
<PG>916-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mannix-1992" NAME="Mannix 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mannix ET, Manfredi F, Palange P, Dowdeswell IR, Farber MO.</AU>
<TI>Oxygen may lower the O2 cost of ventilation in chronic obstructive lung disease</TI>
<SO>Chest</SO>
<YR>1992</YR>
<VL>101</VL>
<PG>910-915</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McDonald-1995" NAME="McDonald 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mc Donald CF, Blyth CM, Lazarus MD, Marschner I, Barter CE</AU>
<TI>Exertional oxygen of limited benefit in patients with chronic obstructive pulmonary disease and mild hypoxemia</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1995</YR>
<VL>152</VL>
<PG>1616-1619</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McKeon-1988" NAME="McKeon 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McKeon JL, Tarrant EP, Tomlinson JC, Mitchell CA</AU>
<TI>Poratble oxygen in patients with severe chronic obstructive pulmonary disease</TI>
<SO>Australian New Zealand Journal of Medicine</SO>
<YR>1988</YR>
<VL>18</VL>
<PG>125-129</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Donnell-1997" NAME="O'Donnell 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Donnell DE, Bain DJ, Webb KA</AU>
<TI>Factors contributing to relief of exertional breathlessness during hyperoxia in chronic airflow limitation</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1997</YR>
<VL>155</VL>
<PG>530-535</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Donnell-2001" NAME="O'Donnell 2001" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>O'Donnell DE, D'Arsigny C, Webb KA</AU>
<TI>Effects of hyperoxia on ventilatory limitation during exercise in advanced chronic obstructive pulmonary disease</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2001</YR>
<VL>163</VL>
<PG>892-898</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Palange-1995" NAME="Palange 1995" YEAR="1995">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Palange P, Galassetti P, Mannix ET, Farber MO, Manfredi F, Serra P, Caarlone S</AU>
<TI>Oxygen effect on O2 deficit and VO2 kinetics during exercise in obstructive pulmonary disease</TI>
<SO>Journal of Applied Physiology</SO>
<YR>1995</YR>
<VL>78</VL>
<PG>2228-2234</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raimondi-1970" NAME="Raimondi 1970" YEAR="1970">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Raimondi AC, Edwards RHT, Denison DM, Leaver DG, Spencer RG, Siddorn JA</AU>
<TI>Exercise tolerance breathing a low density gas mixture, 35% oxygen and air in patients with chronic obstructive bronchitis</TI>
<SO>Clinical Science</SO>
<YR>1970</YR>
<VL>39</VL>
<PG>675-685</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Somfay-2001" NAME="Somfay 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Somfay A, Porszasz J, Lee SM, Casaburi R</AU>
<TI>Dose-response effect of oxygen on hyperinflation and exercise endurance in nonhypoxaemic COPD patients</TI>
<SO>European Respiratory Journal</SO>
<YR>2001</YR>
<VL>18</VL>
<PG>77-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stein-1982" NAME="Stein 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stein DA, Bradley BL, Miller WC</AU>
<TI>Mechanisms of oxygen effects on exercise in patients with chronic obstructive pulmonary disease</TI>
<SO>Chest</SO>
<YR>1982</YR>
<VL>81</VL>
<PG>6-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Swinburn-1984" NAME="Swinburn 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Swinburn CR, Wakefield JM and Jones PW</AU>
<TI>Relationship between ventilation and breathlessness during exercise in chronic obstructive airways disease is not altered by prevention of hypoxaemia.</TI>
<SO>Clinical Science</SO>
<YR>1984</YR>
<VL>67</VL>
<PG>515-519</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vyas-1971" NAME="Vyas 1971" YEAR="1971">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vyas MN, Banister EW, Morton JW and Grzybowski S</AU>
<TI>Response to exercise in patients with chronic airway obstruction</TI>
<SO>American review of Respiratory Disease</SO>
<YR>1971</YR>
<VL>103</VL>
<PG>401 - 412</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wadell-2001" NAME="Wadell 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wadell K, Henriksson-Larsen K, Lundgren R</AU>
<TI>Physical training with and without oxygen in patients with Chronic Obstructive Pulmonary Disease and exercise induced hypoxaemia</TI>
<SO>Journal of Rehabilitation and Medicine</SO>
<YR>2001</YR>
<VL>33</VL>
<PG>200-205</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Woodcock-1981" NAME="Woodcock 1981" YEAR="1981">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Woodcock AA, Gross ER, Geddes DM</AU>
<TI>Oxygen relieves breathlessness in "pink puffers"</TI>
<SO>The Lancet</SO>
<YR>1981</YR>
<PG>907-909</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Arlati-1988" NAME="Arlati 1988" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arlati S, Rolo J, Micallef E, Sacerdoti C, Brambilla I</AU>
<TI>A reservoir nasal cannula improves protection given by oxygen during muscular exercise in COPD</TI>
<SO>Chest</SO>
<YR>1988</YR>
<VL>93</VL>
<PG>1165-1169</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barach-1966" NAME="Barach 1966" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barach AL</AU>
<TI>Oxygen supported exercise and rehabilitation of patients with chronic obstructive lung disease</TI>
<SO>Annals of Allergy</SO>
<YR>1966</YR>
<VL>24</VL>
<PG>51-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bower-1988" NAME="Bower 1988" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bower JS, Brook CJ, Zimmer K, Davies D</AU>
<TO>Performance of a demand oxygen saver system during rest, exercise and sleep in hyoxemic patients</TO>
<SO>Chest</SO>
<YR>1988</YR>
<VL>94</VL>
<PG>77-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brambilla-1985" NAME="Brambilla 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brambilla I, Arlati S, Micallef E, Sacerdoti C, Rolo J.</AU>
<TO>A portable oxygen system corrects hypoxemia without significantly increasing metabolic demands</TO>
<SO>American Reviews of Respiratory Disease</SO>
<YR>1985</YR>
<VL>131</VL>
<NO>1</NO>
<PG>51-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Braun-1992" NAME="Braun 1992" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Braun SR, Spratt G, Scott GC, Ellersieck M</AU>
<TO>Comparison of six oxygen delivery systems for COPD patients at rest and during exercise</TO>
<SO>Chest</SO>
<YR>1992</YR>
<VL>102</VL>
<PG>694-698</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Corriveau-1989" NAME="Corriveau 1989" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Corriveau ML, Rosen BJ, Dolan GF</AU>
<TI>Oxygen transport and oxygen consumption during supplemental oxygen administration in patients with chronic obstructive pulmonary disease</TI>
<SO>The American Journal of Medicine</SO>
<YR>1989</YR>
<VL>87</VL>
<PG>633-637</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cotes-1956" NAME="Cotes 1956" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cotes JE, Gilson JC</AU>
<TO>Effect of oxygen on exercise ability in chronic respiratory insufficiency</TO>
<SO>The Lancet</SO>
<YR>1956</YR>
<VL>June</VL>
<PG>872-876</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cotes-1963" NAME="Cotes 1963" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cotes JE, Pisa Z, Thomas AJ</AU>
<TI>Effect of breathing oxygen upon cardiac output, heart rate, ventilation, systemic and pulmonary blood pressure in patients with chronic lung disease</TI>
<SO>Clinical Science</SO>
<YR>1963</YR>
<VL>25</VL>
<PG>305-321</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cuvelier-2002" NAME="Cuvelier 2002" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cuvelier A, Nuir JF, Chakroun N, Aboab J, Onea G, Benhamou D</AU>
<TO>Refillable oxygen cylinders may be an alternative for ambulatory oxygen therapy in COPD</TO>
<SO>Chest</SO>
<YR>2002</YR>
<VL>122</VL>
<PG>451-456</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eaton-2001" NAME="Eaton 2001" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eaton TE, Grey C, Garrett JE</AU>
<TI>An evaluation of short-term oxygen therapy: the prescription of oxygen to patients with chronic lung disease hypoxic at discharge</TI>
<SO>Respiratory Medicine</SO>
<YR>2001</YR>
<VL>95</VL>
<PG>582-587</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Emtner-2002" NAME="Emtner 2002" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Emtner M, Porszasz J, Burns M, Somfay A, Casaburi R</AU>
<TI>Benefits of supplemental oxygen in exercise training in nonhypoxemic chronic obstructive pulmonary disease</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2003</YR>
<VL>168</VL>
<PG>1034-1042</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guyatt-2001" NAME="Guyatt 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt G, McKim D, Weaver B, Austin P, Bryan R, Walter S et al</AU>
<TO>Development and testing of formal protocols for oxygen prescribing</TO>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2001</YR>
<VL>163</VL>
<NO>4</NO>
<PG>942-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hargarty-1997" NAME="Hargarty 1997" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hagarty EM, Skorodin MS, Langein WE, Hultman CI, Jessen JA, Maki KC</AU>
<TO>Comparison of three oxygen delivery systems during exercise in hypoxemic patients with chronic obstrucitve pulomonary disease</TO>
<SO>Amercian Journal of Respiratory and Critical Care Medicine</SO>
<YR>1997</YR>
<VL>155</VL>
<PG>893-898</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jolly-2001" NAME="Jolly 2001" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jolly EC, Di Boscio V, Aguirre L, Lun CM, Berensztein S, Gene RJ</AU>
<TO>Effects of supplemental oxygen during activity in patients with advanced COPD without severe resting hypoxemia</TO>
<SO>Chest</SO>
<YR>2001</YR>
<VL>120</VL>
<PG>437-443</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lacasse-2003" NAME="Lacasse 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lacasse Y, Lecours R, Pelletier C, Begin R, Maltais F</AU>
<TO>Oxygene de deambulation chez les MPOC oxygeno-dependants: essai clinique randomise.</TO>
<SO>Abreges de communication. Reunion annuelle conjointe: APPQ et Reseau en sante respiratoire du FRSQ, november 14-15, 2003. Quebec : Centre des congres de Quebec; 2003.</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lane-1987" NAME="Lane 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lane R, Cockcroft A, Adams L, Guz A</AU>
<TO>Arterial oxygen saturation and breathlessness in patients with chronic obstructive airways disease</TO>
<SO>Clinical Science</SO>
<YR>1987</YR>
<VL>72</VL>
<PG>693-698</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lilker-1975" NAME="Lilker 1975" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lilker ES, Karnick A, Lerner L</AU>
<TO>Portable oxygen in chronic obstructive lund disease with hypoxemia and cor pulmonale</TO>
<SO>Chest</SO>
<YR>1975</YR>
<VL>68</VL>
<PG>236-241</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lock-1991" NAME="Lock 1991" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lock SH, Paul EA, Rudd RM, Wedzicha JA</AU>
<TI>Portable oxygen therapy: assessment and usage</TI>
<SO>Respiratory Medicine</SO>
<YR>1991</YR>
<VL>85</VL>
<PG>407-412</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lock-1992" NAME="Lock 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lock SH, Blower G, Prynne J, Wedzicha JA</AU>
<TO>Comparison of liquid and gaseous oxygen for domicilary portable use</TO>
<SO>Thorax</SO>
<YR>1992</YR>
<VL>47</VL>
<PG>98-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Patessio-1996" NAME="Patessio 1996" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Patessio A, Casaburi R, Carone M, Appendini L, Purro A, Gudjonsdottir M, Donner CF, Wasserman K</AU>
<TI>Exercise capacity in COPD patients</TI>
<SO>European Respiratory Journal</SO>
<YR>1996</YR>
<VL>23</VL>
<PG>379s</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pierce-1965" NAME="Pierce 1965" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pierce AK, Paez PN, Miller WF</AU>
<TI>Exercise training with the aid of a portable oxygen supply in patients with emphysema</TI>
<SO>The American Review of Respiratory Diseases</SO>
<YR>1965</YR>
<VL>91</VL>
<PG>653-659</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Revill-2000" NAME="Revill 2000" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Revill SM, Singh SJ, Morgan DL</AU>
<TO>Randomized controlled trial of ambulatory oxygen and an ambulatory ventilator on endurance exercise in COPD</TO>
<SO>Respiratory Medicine</SO>
<YR>2000</YR>
<VL>94</VL>
<PG>778-783</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roberts-1996" NAME="Roberts 1996" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roberts CM, Bell J, Wedzicha JA</AU>
<TO>Comparison of the efficacy of a demand oxygen delivery system with continuous low flow oxygen in subjects with stable COPD and severe oxygen desaturation on walking</TO>
<SO>Thorax</SO>
<YR>1996</YR>
<VL>51</VL>
<PG>831-834</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rooyackers-1997" NAME="Rooyackers 1997" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rooyackers JM, Dekhuijzen PNR, Van Herwaarden CLA, Folgering HTM</AU>
<TO>Training with supplemental oxygen in patients with COPD and hypoxaemia at peak exercise</TO>
<SO>European Respiratory Journal</SO>
<YR>1997</YR>
<VL>10</VL>
<PG>1278-1284</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Scano-1982" NAME="Scano 1982" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scano G, Meerhaeghe V, Willeput R, Vachaudez JP, Sergysels R</AU>
<TI>Effect of oxygen on breathing during exercise in patients with chronic obstructive pulmonary disease</TI>
<SO>European Journal of Respiratory Disease</SO>
<YR>1982</YR>
<VL>63</VL>
<PG>23-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tiep-2002" NAME="Tiep 2002" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tiep BL, Barnett J, Schiffman G, Sanchez O, Carter R</AU>
<TO>Maintaining oxygenation via demand oxygen delivery during rest and exercise</TO>
<SO>Respiratory Care</SO>
<YR>2002</YR>
<VL>47</VL>
<PG>887-892</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vergeret-1989" NAME="Vergeret 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vergeret J, Brambilla C, Mounier L.</AU>
<TO>Portable oxygen therapy: use and benefit in hypoxaemic COPD patients on long-term oxygen therapy.</TO>
<SO>European Respiratory Journal</SO>
<YR>1989</YR>
<VL>2</VL>
<NO>1</NO>
<PG>20-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Waterhouse-1983" NAME="Waterhouse 1983" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Waterhouse JC, Howard P</AU>
<TO>Breathlessness and portable oxygen in chronic obstructive airways and disease</TO>
<SO>Thorax</SO>
<YR>1983</YR>
<VL>38</VL>
<PG>302-306</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wedzicha-1996" NAME="Wedzicha 1996" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wedzicha JA</AU>
<TO>Ambulatory oxygen in chronic obstructive pulmonary disease</TO>
<SO>Monaldi Archives of Chest Disease</SO>
<YR>1996</YR>
<VL>51</VL>
<PG>243-245</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-08-22 16:58:51 +0100" MODIFIED_BY="Toby J Lasserson">
<ADDITIONAL_REFERENCES MODIFIED="2008-08-22 16:58:51 +0100" MODIFIED_BY="Toby J Lasserson">
<REFERENCE ID="REF-ATS-1995" MODIFIED="2008-08-22 16:58:51 +0100" MODIFIED_BY="Toby J Lasserson" NAME="ATS 1995" TYPE="JOURNAL_ARTICLE">
<AU>ATS</AU>
<TI>Standards for the Diagnosis and Care of Patients with Chronic Obstructive Pulmonary Disease</TI>
<SO>Am J Respir Crit care Med</SO>
<YR>1995</YR>
<VL>152</VL>
<PG>S77-S120</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ATS-2002" MODIFIED="2008-08-22 16:58:51 +0100" MODIFIED_BY="Toby J Lasserson" NAME="ATS 2002" TYPE="JOURNAL_ARTICLE">
<AU>ATS 2002</AU>
<TI>ATS statement guidelines for the six minute walk test</TI>
<SO>Am J Resp Crit Care Med</SO>
<YR>2002</YR>
<VL>166</VL>
<PG>111-117</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-BTS-1997" MODIFIED="2008-08-22 16:58:51 +0100" MODIFIED_BY="Toby J Lasserson" NAME="BTS 1997" TYPE="JOURNAL_ARTICLE">
<AU>British Thoracic Society</AU>
<TI>COPD Guidelines Summary</TI>
<SO>Thorax</SO>
<YR>1997</YR>
<VL>52</VL>
<PG>S1-S32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-BTS-2004" MODIFIED="2008-08-22 16:58:51 +0100" MODIFIED_BY="Toby J Lasserson" NAME="BTS 2004" TYPE="JOURNAL_ARTICLE">
<AU>British Thoracic Working Group on Home Oxygen services</AU>
<TI>Clinical component for the home oxygen servive in England and Wales</TI>
<SO>www.brit-thoracic.org.uk/public_content.asp?pageid=10</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Crockett-2000" MODIFIED="2008-08-22 16:58:51 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Crockett 2000" TYPE="COCHRANE_REVIEW">
<AU>Crockett AJ, Cranston JM, Moss JR, Alpers JH</AU>
<TI>Domiciliary oxygen for chronic obstructive pulmonary disease [Cochrane Review]</TI>
<SO>Cochrane Library</SO>
<YR>2000</YR>
<NO>1</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Curtin-2002" NAME="Curtin 2002" TYPE="JOURNAL_ARTICLE">
<AU>Curtin F, Altman DG, Elbourne D.</AU>
<TI>Meta-analysis combining parallel and cross over trials.</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>2131-44.</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DOH" MODIFIED="2008-08-22 16:58:51 +0100" MODIFIED_BY="Toby J Lasserson" NAME="DOH" TYPE="OTHER">
<SO>www.dh.gov.uk/policyAndGuidance/medicinesPharmacyAndIndustry/Prescriptions</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A.</AU>
<TI>Meta-analyses involving cross-over trials: methodological issues.</TI>
<SO>International Epidemiological Association</SO>
<YR>2002</YR>
<VL>31</VL>
<PG>140-9.</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GOLD-2001" MODIFIED="2008-08-22 16:58:51 +0100" MODIFIED_BY="Toby J Lasserson" NAME="GOLD 2001" TYPE="JOURNAL_ARTICLE">
<AU>GOLD</AU>
<TI>Global iniative for chronic obstructive lung diseases (GOLD): time to act</TI>
<SO>Eur Resp Journal</SO>
<YR>2001</YR>
<VL>81</VL>
<PG>901-902</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" MODIFIED="2008-08-22 16:58:51 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AK, Moore A, Carroll D et al</AU>
<TI>Assessing quality of reports of randomised controlled trials: is blinding necessary</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Law-2004" MODIFIED="2008-08-22 16:58:51 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Law 2004" TYPE="JOURNAL_ARTICLE">
<AU>Law S, Lehoux P</AU>
<TO>Hospital Technology at Home: Portable Oxygen Therapy in COPD. Report prepared by Susan Law and Pascale Lehoux</TO>
<SO>Agence d'evaluation des technologies et des modes d'intervention en sante (AETMIS)</SO>
<YR>2004</YR>
<CY>Montreal</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marques-1998" MODIFIED="2008-08-22 16:58:51 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Marques 1998" TYPE="JOURNAL_ARTICLE">
<AU>Marques-Magallanes JA, Storer TW and Cooper CB</AU>
<TI>Treadmill exercise duration and dyspnea recovery time in chronic pulmonary disease: effects of oxygen breathing and repeated testing.</TI>
<SO>Respiratory Medicine</SO>
<YR>1998</YR>
<VL>92</VL>
<PG>735-738</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moseley-1999" MODIFIED="2008-08-22 16:58:51 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Moseley 1999" TYPE="JOURNAL_ARTICLE">
<AU>Moseley A, Sherrington C, Herbet R, Maher C</AU>
<TI>Reliability of a scale for measuring the methodological quality of clinical trials</TI>
<SO>Proceedings of the Cochrane Colloquium</SO>
<YR>October 1999</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NICE-2004" MODIFIED="2008-08-22 16:58:51 +0100" MODIFIED_BY="Toby J Lasserson" NAME="NICE 2004" TYPE="JOURNAL_ARTICLE">
<AU>National Institute of Clinical Excellence</AU>
<TI>COPD: National clinical guideline on managment of chronic obstructive pulmonary disease in adults in primary and secondary care</TI>
<SO>Thorax</SO>
<YR>2004</YR>
<VL>59</VL>
<PG>181-272 Supplement 1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ram-2003" MODIFIED="2008-08-22 16:58:51 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Ram 2003" TYPE="COCHRANE_REVIEW">
<AU>Ram FSF, Wedzicha JA</AU>
<TI>Ambulatory oxygen for chronic obstructive pulmonary disease [Cochrane Review]</TI>
<SO>Cochrane Library</SO>
<YR>2003</YR>
<NO>1</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RCP-1999" MODIFIED="2008-08-22 16:58:51 +0100" MODIFIED_BY="Toby J Lasserson" NAME="RCP 1999" TYPE="JOURNAL_ARTICLE">
<AU>Royal College of Physicians</AU>
<TI>Domicilary oxygen therapy services- Clinical Guidelines and Advice for Prescribers</TI>
<YR>1999</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Redelmeier-1997" MODIFIED="2008-08-22 16:58:51 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Redelmeier 1997" TYPE="JOURNAL_ARTICLE">
<AU>Redelmeier DA, Bayoumi AM, Goldstein RS, Guyatt GH</AU>
<TI>Interpreting small differences in functional status: the Six Minute Walk test in chronic lung disease patients</TI>
<SO>Am J Respir Crit care Med</SO>
<YR>1997</YR>
<VL>155</VL>
<NO>4</NO>
<PG>1278-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Revill-1999" MODIFIED="2008-08-22 16:58:51 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Revill 1999" TYPE="JOURNAL_ARTICLE">
<AU>Revill SM, Morgan MDL, Singh SJ, Williams J, Hardman AE. The endurance walk: a new field test for the assessment of endurance capacity in COPD. Thorax 1999;54:213-222.</AU>
<TI>The endurance walk: a new field test for the assessment of endurance capacity in COPD</TI>
<SO>Thorax</SO>
<YR>1999</YR>
<VL>54</VL>
<PG>213-222</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Romain-2001" MODIFIED="2008-08-22 16:58:51 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Romain 2001" TYPE="JOURNAL_ARTICLE">
<AU>Romain A, Pauwels RA, Buist S, Calverley PMA, Jenkins CR, Hurd SS (on behalf of the GOLD Committee)</AU>
<TI>Global Strategy for the Diagnosis, Managment, and Prevention of Chronic Obstructive Pulmonary Disease</TI>
<SO>Am J Respir Crit Care Med</SO>
<YR>2001</YR>
<VL>163</VL>
<PG>1256-1276</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Senn-2004" MODIFIED="2008-08-22 16:58:51 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Senn 2004" TYPE="JOURNAL_ARTICLE">
<AU>Senn S</AU>
<TI>Individual response to treatment: is it a valid assumption</TI>
<SO>BMJ</SO>
<YR>2004</YR>
<VL>329</VL>
<PG>966-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Singh-1992" MODIFIED="2008-08-22 16:58:51 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Singh 1992" TYPE="JOURNAL_ARTICLE">
<AU>Singh SJ, Morgan MDL, Scott S et al</AU>
<TI>Developemnt of a shuttle walking test of disability in patients with chronic airway obstruction</TI>
<SO>Thorax</SO>
<YR>1992</YR>
<VL>47</VL>
<PG>1019-1025</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Singh-2002" MODIFIED="2008-08-22 16:58:51 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Singh 2002" TYPE="JOURNAL_ARTICLE">
<AU>Singh SJ</AU>
<TI>What is the minimal clinically important difference in the SWT observed in pulmonary rehabilitation</TI>
<SO>European Respir J</SO>
<YR>2002</YR>
<VL>20 suppl 38</VL>
<PG>520</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Verhagen-1998" MODIFIED="2008-08-22 16:58:51 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Verhagen 1998" TYPE="JOURNAL_ARTICLE">
<AU>Verhagen A, de Vet H, de Brie R, Kessels A, Boers M, Bouter L, Knipschild P</AU>
<TI>The Delphi List: A criteria for quality assessment of randomised clinical trials for conducting systematic reviews developed by the Depli Consensus.</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>1998</YR>
<VL>51</VL>
<PG>1235-1241</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Young-1998" MODIFIED="2008-08-22 16:58:51 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Young 1998" TYPE="JOURNAL_ARTICLE">
<AU>Young IH, Crockett AJ, McDonald CF</AU>
<TI>Adult Domicilary Oxygen therapy- Position Statement of the Thoracic Society of Australia and New Zealand</TI>
<SO>MJA</SO>
<YR>1998</YR>
<VL>168</VL>
<PG>21-25</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-08-22 17:02:07 +0100" MODIFIED_BY="Toby J Lasserson">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-08-22 17:02:07 +0100" MODIFIED_BY="Toby J Lasserson" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Bradley-1978">
<CHAR_METHODS>
<P>Blinding: single; Randomisation: no description;<BR/>Withdrawals: none;<BR/>Baseline characteristics:<BR/>comparable; Point/ variability estimates for between group analysis: yes<BR/>Power calculation: none</P>
<P>Jadad=1/5<BR/>Pedro=7/10</P>
<P>Statistical analysis: Student's paired t test</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country USA;<BR/>N=26; 11M; 64.7 (8.7) years; FEV1 22.2 (7.8)%; FVC 47.9 (14)%; SaO2 92 (4.1)%; **PaO2 69 (14.3)mmHg; PaCO2 41.8 (8.1) mmHg;</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>5 L/min O2 or air via cylinder and nasal specs</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>see table- outcome measures used</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No contact address</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-22 16:59:05 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Bye-1985">
<CHAR_METHODS MODIFIED="2008-08-22 16:59:05 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Blinding: double; Randomisation: no description;<BR/>Withdrawals: None;<BR/>Baseline characteristics:<BR/>Comparable; Point/ variability estimates for between group analysis: Yes<BR/>Power calculation: None<BR/>Jadad=2/5<BR/>Pedro=9/10</P>
<P>Statistical analysis: Paired t test</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country Canada; N=8; 8M; 61 SEM 3 years ; FEV1 32 SEM 4 %, FVC 59 SEM 5 % *PaO2 63 SEM6 mmHg, PaCO2 43 SEM 3mmHg;</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>40% O2 or humidified air via reservoir and mouth piece</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES/>
<CHAR_NOTES>
<P>Author contacted: data confirmed</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-22 16:59:37 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Criner-1987">
<CHAR_METHODS>
<P>Blinding: single; Randomisation: no description;<BR/>Withdrawals: none;<BR/>Baseline characteristics:<BR/>comparable; Point/ variability estimates for between group analysis: yes<BR/>Power calculation: <BR/>none<BR/>Jadad=1/5<BR/>Pedro=7/10</P>
<P>Statistical analysis: Paired t test</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country USA; N=6; 5M; 64 (7) years; FEV1 0.66 (0.13)L; PaO2 67 (6.2) mmHg**, PaCO2 41 (3) mmHg</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-22 16:59:37 +0100" MODIFIED_BY="Toby J Lasserson">
<P>30% O2 or air via reservoir and mouth piece</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES/>
<CHAR_NOTES>
<P>Author contacted: no response</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Davidson-1988">
<CHAR_METHODS>
<P>Blinding: single; Randomisation: no description;<BR/>Withdrawals:none;<BR/>Baseline characteristics:<BR/>comparable; Point/ variability estimates for between group analysis: yes<BR/>Power calculation: none<BR/>Jadad=1/5<BR/>Pedro=7/10</P>
<P>Statistical test: Wilcoxon's signed rank test</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country UK; N=17; 64.4 SEM 2.1 years; FEV1 0.79 SEM 0.03 L, FVC 2.14 SEM 0.11L; **PaO2 8.8 SEM 0.3 kPa, PaCO2 6 SEM 0.4 kPa;</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>6L/min O2 or air via mouthpiece <BR/>4L/min O2 or air via nasal specs or mask for walking tests</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES/>
<CHAR_NOTES>
<P>Author contacted: no response;</P>
<P>Data not extracted relating to 2LO2</P>
<P>
<BR/>Quality scores relate to cycle test. Walking tests were double blinded <BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-22 16:59:43 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Dean-1992">
<CHAR_METHODS>
<P>Blinding: double; Randomisation: flip coin;<BR/>Withdrawals:none;<BR/>Baseline characteristics:<BR/>comparable; Point/ variability estimates for between group analysis: yes<BR/>Power calculation: none<BR/>Jadad= 5/5<BR/>Pedro = 9/10</P>
<P>Statistical test: Paired t test</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country USA; N=12; 12M; &gt;50years; FEV1 0.89 SEM 0.09 L; FVC 2.37 SEM 0.2 L; **PaO2 71 SEM 2.6 mmHg</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-22 16:59:43 +0100" MODIFIED_BY="Toby J Lasserson">
<P>40% oxygen or air via reservoir and mouthpiece</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES/>
<CHAR_NOTES>
<P>Author contacted: data confirmed further details provided on details of exercise test </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-22 16:59:48 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Eaton-2002">
<CHAR_METHODS MODIFIED="2008-08-22 16:59:48 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Blinding: double; Randomisation: no details;<BR/>Withdrawals: N = 11;<BR/>Baseline characteristics:<BR/>comparable; Point/ variability estimates for between group analysis: yes<BR/>Power calculation: none</P>
<P>Statistical test: Mixed model approach which used information from all participants. 41 participants reported, but 39 participants completed both arms.<BR/>Jadad= 3/5<BR/>Pedro = 9/10</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country New Zealand; 29M; N=41; 67.1 (9.3) years; FEV1 25.9% SaO2 94 (1.9)%; **PaO2 9.2kPa; PaCO2 5.8 (0.7)kPa;</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>4 L/min O2 or air via cylinder and nasal specs. </P>
<P>Study duration: 12 weeks. Participants prescribed O2 for 2 x 6 week periods. This was used as ambulatory O2.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES/>
<CHAR_NOTES>
<P>Author contacted: no response;</P>
<P>This was a 12 week study of ambulatory O2. Data was extracted for the acute responses at baseline of 41/50 patients who completed 12 week study<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-22 16:59:54 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Fujimoto-2002a">
<CHAR_METHODS>
<P>Blinding: double; Randomisation: no description;<BR/>Withdrawals: none;<BR/>Baseline characteristics:<BR/>comparable; Point/ variability estimates for between group analysis: yes<BR/>Power calculation: none<BR/>Jadad=2/5<BR/>Pedro=9/10</P>
<P>Statistical analysis: Paired t test</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country Japan; N=16; 16M; 71 (2) years; FEV1 62.7SEM 2.9%; PaO2 10.07** SEM 0.25, PaCO2 5.27</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 L/min O2 or air via cylinder and nasal specs</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2008-08-22 16:59:54 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Author contacted: data confirmed</P>
<P>This study stratifies patients according to disease severity and reports results for each group separately</P>
<P>Data not extracted for haemodynamic study as measurements taken 3 mins into exercise only</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-22 17:00:02 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Fujimoto-2002b">
<CHAR_METHODS MODIFIED="2008-08-22 16:59:59 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Blinding: double; Randomisation: no description;<BR/>Withdrawals:None;<BR/>Baseline characteristics:<BR/>Comparable; Point/ variability estimates for between group analysis: Yes<BR/>Power calculation: None<BR/>Jadad=2/5<BR/>Pedro=9/10</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country Japan; N=25; 25M; 69 (1) years; FEV1 40.9 SEM 1%; PaO2 9.1** SEM 0.1, PaCO2 5.5 SEM 0.1</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 L/min O2 or air via cylinder and nasal specs</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2008-08-22 17:00:02 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Author contacted: ?5/5/04</P>
<P>This study stratifies patients according to disease severity and reports results for each group separately</P>
<P>Data not extracted for haemodynamic study as measurements taken 3 mins into exercise only</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-22 17:00:10 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Fujimoto-2002c">
<CHAR_METHODS>
<P>Blinding: double; Randomisation: no description;<BR/>Withdrawals:none;<BR/>Baseline characteristics:<BR/>comparable; Point/ variability estimates for between group analysis: yes<BR/>Power calculation: none<BR/>Jadad=2/5<BR/>Pedro=9/10</P>
<P>Statistical analysis: Paired t test</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country Japan; N=34; 34M; 66 (1) years; FEV1 25 SEM 1.1%; PaO2 9.4** SEM 0.1, PaCO2 5.7 SEM 0.1</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 L/min O2 or air via cylinder and nasal specs</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2008-08-22 17:00:10 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Author contacted: data confirmed</P>
<P>This study stratifies patients according to disease severity and reports results for each group separately</P>
<P>Data not extracted for haemodynamic study as measurements taken 3 mins into exercise only</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-22 17:00:16 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Garrod-1999">
<CHAR_METHODS>
<P>Blinding: single; Randomisation: no description;<BR/>Withdrawals:none;<BR/>Baseline characteristics:<BR/>comparable; Point/ variability estimates for between group analysis: yes<BR/>Power calculation: none<BR/>Jadad=1/5<BR/>Pedro=8/10</P>
<P>Statistical test: paired t test</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country UK; N=15; mean age 66 range (50-75) years; FEV1 32 (9.4)%; PaO2 8.38 (1.24) kPa,** PaCO2 5.95 (0.86) kPa</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-22 17:00:16 +0100" MODIFIED_BY="Toby J Lasserson">
<P>2 L/min O2 or air via cylinder and nasal specs</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES/>
<CHAR_NOTES>
<P>Author contacted: data confirmed</P>
<P>This study also evaluated pulsed dose oxygen delivery</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Garrod-2000">
<CHAR_METHODS>
<P>Blinding: single; Randomisation: no description;<BR/>Withdrawals: none;<BR/>Baseline characteristics:<BR/>comparable; Point/ variability estimates for between group analysis: yes<BR/>Power calculation: none<BR/>Jadad=1/5<BR/>Pedro=7/10</P>
<P>Statistical test: paired t test</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country UK; N=25; 19M; median age 70 range 52-84years; FEV1 30 (9.89)%; fall in SaO2 by 4% from baseline to 90% or below on exercise testing; *11/25 on LTOT</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>4 L/min O2 or air via cylinder and nasal specs</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES/>
<CHAR_NOTES>
<P>Author contacted:<BR/>data confirmed further details provided on point/ variability estimates for between group <BR/>analysis</P>
<P>This was a 6 week study of supplemental oxygen in pulmonary rehabilitation. Data was extracted for the acute responses at baseline of 25 patients recruited<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Gosselin-2004">
<CHAR_METHODS>
<P>Blinding: single <BR/>Randomisation: no description;<BR/>Withdrawals: none<BR/>Baseline characteristics: comparable <BR/>Point/ variability estimates for between group analysis: yes<BR/>Power calculation: none<BR/>Jadad= 1/5<BR/>Pedro = 7/10<BR/>Statistical test: two-way analysis of variance<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country France; N=9; 7M; 62 SEM 2.2 years; FEV1 1.5 SEM 0.1 L; FVC 2.9 SEM 0.1 L; PaO2 **9.1 (0.4) kPa; PaCO2 4.2 SEM 0.08 kPa</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>30% O2 or air via mouthpiece</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES/>
<CHAR_NOTES>
<P>Authors not contacted</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Ishimine-1995">
<CHAR_METHODS>
<P>Blinding: double; Randomisation: no description;<BR/>Withdrawals: none;<BR/>Baseline characteristics:<BR/>comparable; Point/ variability estimates for between group analysis: yes<BR/>Power calculation: none<BR/>Jadad= 2/5<BR/>Pedro = 9/10</P>
<P>Statistical test: unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country Japan: N=22; 22M; 69 (7) years; FEV1 44.9 (22.7)%; FVC 2.26 (0.57)L; PaO2 75.9 (8.6)mmHg; PaCO2 43.6 (4.8)mmHg ** no LTOT</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>3 L/min O2 or air via cylinder and nasal specs</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES/>
<CHAR_NOTES>
<P>Authors not contacted</P>
<P>Japanese article study translated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-22 17:00:59 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-King-1973">
<CHAR_METHODS>
<P>Blinding: single; Randomisation: no description;<BR/>Withdrawals: none;<BR/>Baseline characteristics:<BR/>comparable; Point/ variability estimates for between group analysis: yes<BR/>Power calculation: none<BR/>Jadad= 1/5<BR/>Pedro = 7/10</P>
<P>Statistical test: paired t test</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country UK: N=10; 7M; 60.2 (7.1) years; FEV1 0.76 (0.32)L; *PO2 48.8 (5.8)mmHg; PaCO2 52.1 (8.8)mmHg;</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-22 17:00:59 +0100" MODIFIED_BY="Toby J Lasserson">
<P>30% O2 or air via reservoir and mouthpiece</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES/>
<CHAR_NOTES>
<P>Author contacted: no response;</P>
<P>No data available for primary or secondary outcomes</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Knebel-2000">
<CHAR_METHODS>
<P>Blinding: double<BR/>Randomisation: yes, random numbers table<BR/>Withdrawals: none<BR/>Baseline characteristics: comparable<BR/>Point/ variability estimates for between group analysis: yes<BR/>Power calculation: none<BR/>Jadad= 5/5<BR/>Pedro = 10/10<BR/>Statistical test: Paired t tests<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country USA: N=33; 22M; 47 (7) years; FEV1 48 (13) %; **SpO2 97.1 (1.7) %. Participants excluded for current use of O2.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>4 L/min O2 or air via cylinder and nasal specs</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES/>
<CHAR_NOTES>
<P>Author not contacted<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kurihara-1989">
<CHAR_METHODS>
<P>Blinding: single; Randomisation: no description;<BR/>Withdrawals: none;</P>
<P>
<BR/>Baseline characteristics:<BR/>comparable; Point/ variability estimates for between group analysis: yes<BR/>Power calculation: none<BR/>Jadad= 1/5<BR/>Pedro = 7/10</P>
<P>Statistical test: Wilcoxon t test</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country Japan: N=14; 11M; 68.8 (8.9) years; FEV1% 30.8 (6.4)%; FVC 58.3 (6.2)%; PaO2 68.8 (8.9)mmHg ** no LTOT</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>3 L/min O2 or air via cylinder and nasal specs</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES/>
<CHAR_NOTES>
<P>Authors not contacted</P>
<P>Japanese article study translated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Leach-1992">
<CHAR_METHODS>
<P>Blinding: double; Randomisation: no description;<BR/>Withdrawals:none;<BR/>Baseline characteristics:<BR/>comparable; Point/ variability estimates for between group analysis: yes<BR/>Power calculation: none<BR/>Jadad= 2/5<BR/>Pedro = 9/10</P>
<P>Statistical test: paired t test<BR/>Stats test: paired t test</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country UK: N=20; 12M; 63.4 (7.2) years; FEV1 0.74 (0.25)L, FVC 1.94 (0.51)L; *PaO2 8.74 (2.38)kPa; PaCO2 5.55 (1.26)kPa</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>4 L/min O2 or air via facemask</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES/>
<CHAR_NOTES>
<P>Author contacted: no response;</P>
<P>Mixed population, data extracted for COPD only</P>
<P>
<BR/>Data not extracted relating to 2 or 6LO2 as no comparable placebo</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-22 17:01:18 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Leggett-1977">
<CHAR_METHODS MODIFIED="2008-08-22 17:01:18 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Blinding: single; Randomisation: no description;<BR/>Withdrawals:none;<BR/>Baseline characteristics: comparable; Point/ variability estimates for between group analysis: yes<BR/>Power calculation: none<BR/>Jadad= 1/5<BR/>Pedro = 7/10</P>
<P>Statistical test: paired t test<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country UK: N=8; assessed for LTOT*</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>4 L/min O2 or air via cylinder and nasal specs</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Distance walked in 12 minutes</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Data not extracted relating to 2 L/min O2 or 4L/min O2 when carrying walker. </P>
<P>No data available for primary or secondary outcomes on the treadmill/bicycle study</P>
<P>as no comparable placebo</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Light-1989">
<CHAR_METHODS>
<P>Blinding: single; Randomisation: no description; <BR/>Withdrawals: none;<BR/>Baseline characteristics: comparable;<BR/>Point/ variability estimates for between group analysis: yes<BR/>Power calculation: none; </P>
<P>Jadad= 1/5<BR/>Pedro = 7/10</P>
<P>Statistical test: Student's paired t test</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country USA: N=17; 16M; 62 (5.3) years; FEV1 0.99 (0.45)L; FVC 2.65 (1)L; **PaO2 68.7 (12.1)mmHg, PaCO2 40.3 (6.6)mmHg SaO2 91.2 (4)%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>30% O2 or air via mouth piece</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES/>
<CHAR_NOTES>
<P>Author contacted:<BR/>data confirmed</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Maltais-2001">
<CHAR_METHODS>
<P>Blinding: double<BR/>Randomisation: no description<BR/>Withdrawals: none<BR/>Baseline characteristics:comparable<BR/>Point/ variability estimates for between group analysis: yes<BR/>Power calculation: none <BR/>Jadad=2<BR/>Pedro=9<BR/>Statistical test: ANOVA<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country Canada: N=14; FEV1 1.04 SEM (0.07), FVC 2.64 SEM 0.15; **PaO2 85 SEM 4 mmHg; <BR/>PaCO2 37 SEM 2 mmHg<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>75% O2 or air via a mouthpiece</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES/>
<CHAR_NOTES>
<P>Author nor contacted<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Mannix-1992">
<CHAR_METHODS>
<P>Blinding: none; Randomisation: no description;<BR/>Withdrawals: none;<BR/>Baseline characteristics:<BR/>comparable; Point/ variability estimates for between group analysis: yes<BR/>Power calculation: none<BR/>Jadad=1/5<BR/>Pedro=6/10</P>
<P>Statistical test: ANOVA; significant tests followed by paired t test</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country USA: N=10; 10M; FEV1 0.96 SEM 0.25, FVC 2.27 SEM 0.35; *PaO2 54 SEM 3 mmHg; PaCO2 47 SEM 3 mmHg</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>30% O2 or air via mouth piece</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES/>
<CHAR_NOTES>
<P>Author contacted:<BR/>no response</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-McDonald-1995">
<CHAR_METHODS>
<P>Blinding: double; Randomisation: no description;<BR/>Withdrawals: none;<BR/>Baseline characteristics:<BR/>comparable; Point/ variability estimates for between group analysis: yes<BR/>Power calculation: none<BR/>Jadad= 3/5<BR/>Pedro = 9/10</P>
<P>Statistical tests: paired t test</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country Australia: N=26; 24M; 73 (6) years; FEV1 0.9 (0.4)L; **PaO2.69 (8.5)mmHg;</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>4 L/min O2 or air via cylinder and nasal specs</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>
<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Author contacted: no response;</P>
<P>This was a 12 week study of supplemental oxygen. Data was extracted for the acute responses at baseline of 26/36 patients recruited</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-McKeon-1988">
<CHAR_METHODS>
<P>Blinding: double; Randomisation: no description;<BR/>Withdrawals: none;<BR/>Baseline characteristics:<BR/>Comparable; Point/ variability estimates for between group analysis: yes<BR/>Power calculation: none<BR/>Jadad= 3/5<BR/>Pedro=9/10</P>
<P>Statistical test: ANOVA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country Australia: N=21; 10M; 62 (9) years; FEV1, 29(13)%; FVC 58(20)%; **PaO266.4 (11)mmHg; PaCO2 43.9 (8.8)mmHg; 6 on home O2 15 hours per day</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>4 L/min O2 or air via light weight cylinder and nasal specs</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES/>
<CHAR_NOTES>
<P>Author contacted: no response;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-O_x0027_Donnell-1997">
<CHAR_METHODS>
<P>Blinding: double; Randomisation: no description;<BR/>Withdrawals: none;<BR/>Baseline characteristics:<BR/>comparable; Point/ variability estimates for between group analysis: yes<BR/>Power calculation: none<BR/>Jadad= 2/5<BR/>Pedro=9/10</P>
<P>Statistical test: Paired t test<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country Canada: N=11; 7M; 68 (2) years; FEV1 0.97 (0.13)L, FVC 2.27 (0.25)L; **non LTOT and mildly hypoxemic and did not meet criteria for ambulatory O2</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>60% O2 or air via mouthpiece</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES/>
<CHAR_NOTES>
<P>Author contacted: data confirmed and further details provided on exercise test and on point/ variability estimates for between group <BR/>analysis<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-22 17:01:45 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-O_x0027_Donnell-2001">
<CHAR_METHODS MODIFIED="2008-08-22 17:01:45 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Blinding: double; Randomisation: no description;<BR/>Withdrawals: none;<BR/>Baseline characteristics:<BR/>comparable; Point/ variability estimates for between group analysis: yes<BR/>Power calculation: none<BR/>Jadad= 2/5<BR/>Pedro=9/10</P>
<P>Statistical analysis: Paired t test</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country Canada: N=11; 4M; 68 (2) years; FEV1 0.65 (0.06)L, FVC 1.59 (0.11)L; *PaO2 52.4 (2.2)mmHg; PaCO2 48.5 (2.1)mmHg; met the criteria for ambulatory O2 in Canada</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>60% O2 or air via mouthpiece</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES/>
<CHAR_NOTES>
<P>Author contacted: data confirmed and further details provided on exercise test</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Palange-1995">
<CHAR_METHODS>
<P>Blinding: none<BR/>Randomisation: no description<BR/>Withdrawals: none<BR/>Baseline characteristics :comparable; <BR/>Point/ variability estimates for between group analysis: yes<BR/>Power calculation: none<BR/>Jadad= 1/5<BR/>Pedro=6/10<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country Italy: N =9; 67 SEM 1 years; FEV11.0 SEM 0.1L; FVC 2.6 SEM 0.2L; **PaO2 64 SEM 2 mmHg; PaCO2 43 SEM 1 mmHg</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>30% O2 in via mouthpiece</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES/>
<CHAR_NOTES>
<P>Author nor contacted</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Raimondi-1970">
<CHAR_METHODS>
<P>Blinding: single; Randomisation: no description;<BR/>Withdrawals: none;<BR/>Baseline characteristics:<BR/>comparable; Point/ variability estimates for between group analysis: yes<BR/>Power calculation: none<BR/>Jadad= 1/5<BR/>Pedro=7/10</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country UK: N =8; 51-70 years; FEV1 0.74 range 0.55-0.95L; ***no information re O2 status</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>35% O2 in nitrogen and 21% O2 in helium via mouthpiece</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES/>
<CHAR_NOTES>
<P>No contact address</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Somfay-2001">
<CHAR_METHODS>
<P>Blinding: single; Randomisation: no description;<BR/>Withdrawals: none;<BR/>Baseline characteristics:<BR/>comparable; Point/ variability estimates for between group analysis: yes<BR/>Power calculation: none<BR/>Jadad= 1/5 Pedro=7/10</P>
<P>Statistical test: ANOVA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country USA: N=10; 6M; 65 (7) years; FEV1 31 (10)%, FVC 76 (15)%; **mild hypoxaemia SaO2&gt;92% and during exercise &gt;88%, none qualified for ambulatory O2</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>30% and 50% O2 or air via mouth piece</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES/>
<CHAR_NOTES>
<P>Author contacted: no response</P>
<P>No data extracted for 75% or100% O2</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Stein-1982">
<CHAR_METHODS>
<P>Blinding: single; Randomisation: no details;<BR/>Withdrawals: none;<BR/>Baseline characteristics:<BR/>comparable; Point/ variability estimates for between group analysis: yes<BR/>Power calculation: none<BR/>Jadad=1 /5 Pedro=7/10</P>
<P>Statistical test: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country USA: N=9; 8M; FEV1 29 (3)% **PaO2 63 (10)PaCO2 39 (6)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>30% O2 in 70% nitrogen or air via mouthpiece</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES/>
<CHAR_NOTES>
<P>Author contacted: no response</P>
<P>Data for exercise time estimated from graph</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-22 17:02:02 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Swinburn-1984">
<CHAR_METHODS>
<P>Blinding: double; Randomisation: no description;<BR/>Withdrawals: none;<BR/>Baseline characteristics:<BR/>comparable; Point/ variability estimates for between group analysis: yes<BR/>Power calculation: none<BR/>Jadad=2/5<BR/>Pedro=9/10</P>
<P>Statistical analysis: Student's paired t test</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country UK: N=5; 2M; 65 (53-72) years; FEV1 0.8 (0.2) L; FVC 1.8 (0.4)L; SaO2 93.2 (82-94)%**</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-22 17:02:02 +0100" MODIFIED_BY="Toby J Lasserson">
<P>60% O2 or air via reservoir and mouth piece</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES/>
<CHAR_NOTES>
<P>Author contacted: data confirmed</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-22 17:02:07 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Vyas-1971">
<CHAR_METHODS>
<P>Blinding: double; Randomisation: no description;<BR/>Withdrawals: yes n=2?;<BR/>Baseline characteristics:<BR/>comparable; Point/ variability estimates for between group analysis: none<BR/>Power calculation: none<BR/>Jadad=2/5<BR/>Pedro=8/10</P>
<P>Statistical test: t test</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N=14; 12M; FEV1 29.5 (10.2)% **PaO2 71.4 (8.78) PaCO2 38.4 (4.6) Country Canada:</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-22 17:02:07 +0100" MODIFIED_BY="Toby J Lasserson">
<P>40% O2 or air via reservoir mouth piece</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES/>
<CHAR_NOTES>
<P>Author contacted: Primary author deceased ?sent to second author</P>
<P>Demographic data documented in previous article</P>
<P>Point/variability estimates for between group <BR/>analysis calculated from raw data<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wadell-2001">
<CHAR_METHODS>
<P>Blinding: single; Randomisation: yes blocks of men and women;<BR/>Withdrawals: none;<BR/>Baseline characteristics:<BR/>comparable; Point/ variability estimates for between group analysis: yes<BR/>Power calculation: none<BR/>Jadad= 2/5<BR/>Pedro=7/10</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country Sweden: N=20; &lt;75 years; FEV1&lt;70%; **PaO2&gt;= 8kPa; SaO2,90% during corridor 6 minute walk test;</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>5 L/min O2 or air via cylinder and nasal specs</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES/>
<CHAR_NOTES>
<P>Author contacted: no response</P>
<P>This was a 8 week study of physical training with and without oxygen. Data for acute responses at baseline is presented as medians (range) for oxygen training group and air training group extracted separately</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Woodcock-1981">
<CHAR_METHODS>
<P>Blinding: double; Randomisation: no details;<BR/>Withdrawals: none;<BR/>Baseline characteristics:<BR/>comparable; Point/ variability estimates for between group analysis: yes<BR/>Power calculation: none<BR/>Jadad= 3/5<BR/>Pedro=9/10</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country England: N=10; 9M; FEV1 0.71 (0.29)Lmin **PaO2 9.65 (1.51) PaCO2 4.55 (0.6)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>4 L/min O2 or air via cylinder and nasal specs</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES/>
<CHAR_NOTES>
<P>Author not contacted 16/12/04</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>*Studies in which some patients likely met the criteria for LTOT (mean PaO2 &lt; 7.3kPa or 55mmHg)<BR/>**Studies in which patients did not/likely did not meet the criteria for LTOT<BR/>*** no information given re baseline oxygen status</P>
<P>
<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Arlati-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Room air not true placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Barach-1966">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bower-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Brambilla-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Braun-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Corriveau-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Order of gas not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cotes-1956">
<CHAR_REASON_FOR_EXCLUSION>
<P>Room air not true placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cotes-1963">
<CHAR_REASON_FOR_EXCLUSION>
<P>Mixed population</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cuvelier-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Order of gas not randomised<BR/>Room air not true placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Eaton-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Emtner-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Order of gas not randomised<BR/>(in assessment acute responses to exercise)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Guyatt-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hargarty-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jolly-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>No specific oxygen flow rate</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lacasse-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lane-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lilker-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not short term ambulatory assessment study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lock-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Mixed population</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lock-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Mixed population<BR/>No placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Patessio-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Exercise training study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pierce-1965">
<CHAR_REASON_FOR_EXCLUSION>
<P>Order of gas not randomised<BR/>Room air not true placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Revill-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Room air not true placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Roberts-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Room air is not true placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rooyackers-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Order of gas not randomised <BR/>(in assessment of acute responses to exercise)<BR/>Room air not true placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Scano-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tiep-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>No true placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vergeret-1989">
<CHAR_REASON_FOR_EXCLUSION/>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Waterhouse-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>No equivalent control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wedzicha-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2008-08-22 17:02:27 +0100" MODIFIED_BY="Toby J Lasserson">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2008-08-22 17:02:27 +0100" MODIFIED_BY="Toby J Lasserson" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-22 16:59:21 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Bradley-1978">
<DESCRIPTION>
<P>Information not available (Cochrane Grade B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-22 16:59:32 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Bye-1985">
<DESCRIPTION>
<P>Information not available (Cochrane Grade B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-22 16:59:35 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Criner-1987">
<DESCRIPTION>
<P>Information not available (Cochrane Grade B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-22 16:59:41 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Davidson-1988">
<DESCRIPTION>
<P>Information not available (Cochrane Grade B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-22 16:59:45 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Dean-1992">
<DESCRIPTION>
<P>Information not available (Cochrane Grade B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-22 16:59:50 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Eaton-2002">
<DESCRIPTION>
<P>Information not available (Cochrane Grade B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-22 16:59:57 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Fujimoto-2002a">
<DESCRIPTION>
<P>Information not available (Cochrane Grade B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-22 17:00:05 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Fujimoto-2002b">
<DESCRIPTION>
<P>Information not available (Cochrane Grade B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-22 17:00:12 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Fujimoto-2002c">
<DESCRIPTION>
<P>Information not available (Cochrane Grade B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-22 17:00:43 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Garrod-1999">
<DESCRIPTION>
<P>Inestigators unaware as to order of treatment group assignment (Cochrane Grade A)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-22 17:00:47 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Garrod-2000">
<DESCRIPTION>
<P>Information not available (Cochrane Grade B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-22 17:00:50 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Gosselin-2004">
<DESCRIPTION>
<P>Information not available (Cochrane Grade B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-22 17:00:56 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Ishimine-1995">
<DESCRIPTION>
<P>Information not available (Cochrane Grade B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-22 17:01:00 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-King-1973">
<DESCRIPTION>
<P>Information not available (Cochrane Grade B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-22 17:01:03 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Knebel-2000">
<DESCRIPTION>
<P>Information not available (Cochrane Grade B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-22 17:01:06 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Kurihara-1989">
<DESCRIPTION>
<P>Information not available (Cochrane Grade B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-22 17:01:09 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Leach-1992">
<DESCRIPTION>
<P>Information not available (Cochrane Grade B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-22 17:01:12 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Leggett-1977">
<DESCRIPTION>
<P>Information not available (Cochrane Grade B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-22 17:01:25 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Light-1989">
<DESCRIPTION>
<P>Information not available (Cochrane Grade B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-22 17:01:28 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Maltais-2001">
<DESCRIPTION>
<P>Information not available (Cochrane Grade B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-22 17:01:31 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Mannix-1992">
<DESCRIPTION>
<P>Information not available (Cochrane Grade B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-22 17:01:34 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-McDonald-1995">
<DESCRIPTION>
<P>Information not available (Cochrane Grade B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-22 17:01:39 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-McKeon-1988">
<DESCRIPTION>
<P>Information not available (Cochrane Grade B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-22 17:01:43 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-O_x0027_Donnell-1997">
<DESCRIPTION>
<P>Information not available (Cochrane Grade B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-22 17:01:47 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-O_x0027_Donnell-2001">
<DESCRIPTION>
<P>Information not available (Cochrane Grade B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-22 17:01:51 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Palange-1995">
<DESCRIPTION>
<P>Information not available (Cochrane Grade B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-22 17:01:54 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Raimondi-1970">
<DESCRIPTION>
<P>Information not available (Cochrane Grade B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-22 17:01:57 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Somfay-2001">
<DESCRIPTION>
<P>Information not available (Cochrane Grade B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-22 17:02:00 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Stein-1982">
<DESCRIPTION>
<P>Information not available (Cochrane Grade B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-22 17:02:04 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Swinburn-1984">
<DESCRIPTION>
<P>Information not available (Cochrane Grade B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-22 17:02:13 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Vyas-1971">
<DESCRIPTION>
<P>Information not available (Cochrane Grade B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-22 17:02:24 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Wadell-2001">
<DESCRIPTION>
<P>Information not available (Cochrane Grade B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-22 17:02:27 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Woodcock-1981">
<DESCRIPTION>
<P>Information not available (Cochrane Grade B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-08-22 16:58:51 +0100" MODIFIED_BY="Toby J Lasserson">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2008-08-22 16:58:51 +0100" MODIFIED_BY="Toby J Lasserson" NO="1">
<TITLE>Details of Exercise Tests Used</TITLE>
<TABLE COLS="6" ROWS="32">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Test</P>
</TH>
<TH>
<P>Practice Tests</P>
</TH>
<TH>
<P>Time Between Tests</P>
</TH>
<TH>
<P>Predosing</P>
</TH>
<TH>
<P>Pretest checks</P>
</TH>
</TR>
<TR>
<TD>
<P>Leggett (1977)</P>
</TD>
<TD>
<P>Distance walked in 12 mins on the level and at own pace (including stops if desired): not carrying cylinder</P>
</TD>
<TD>
<P>Not documented</P>
</TD>
<TD>
<P>30mins (up to 4 tests per day)</P>
</TD>
<TD>
<P>Not documented</P>
</TD>
<TD>
<P>Not documented</P>
</TD>
</TR>
<TR>
<TD>
<P>McKeon (1988)</P>
</TD>
<TD>
<P>Treadmill test level grade at 1.5km/h and increasing 0.5km/h each min; ?not carrying cylinder</P>
</TD>
<TD>
<P>Initial practice walk</P>
</TD>
<TD>
<P>30 mins (4 tests on the same day)</P>
</TD>
<TD>
<P>Not documented</P>
</TD>
<TD>
<P>Bronchodilators withheld during study</P>
</TD>
</TR>
<TR>
<TD>
<P>Dean (1992)</P>
</TD>
<TD>
<P>Endurance cycle ergometer test based on 80% of incremental cycle test; Incremental test 10W incraesing 10-20 W every 2 mins to symptom limited max; not carrying oxygen</P>
</TD>
<TD>
<P>Not documented</P>
</TD>
<TD>
<P>At least 30mins and up to 60 mins</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Light breakfast; usual medications including bronchodilators</P>
</TD>
</TR>
<TR>
<TD>
<P>Garrod (2000)</P>
</TD>
<TD>
<P>Shuttle walk test carrying small portable tank</P>
</TD>
<TD>
<P>Practice walk</P>
</TD>
<TD>
<P>20 mins</P>
</TD>
<TD>
<P>Not documented</P>
</TD>
<TD>
<P>Not documented</P>
</TD>
</TR>
<TR>
<TD>
<P>ODonnell (1997)</P>
</TD>
<TD>
<P>Endurance cycle ergometer at 50% work of maximum work rate. Maximum work rate established on cycle test at 50-70rpm. (Not carrying oxygen)</P>
</TD>
<TD>
<P>Thorough familiarisation</P>
</TD>
<TD>
<P>60-90mins</P>
</TD>
<TD>
<P>At least 10mins resting breathing air/oxygen</P>
</TD>
<TD>
<P>Avoid caffeine alcohol heavy exertion and heavy meal 4 hours pre testing</P>
</TD>
</TR>
<TR>
<TD>
<P>McDonald (1995)</P>
</TD>
<TD>
<P>6 Minute Walk Step Test Test (Not carrying cylinder)</P>
</TD>
<TD>
<P>2 practice tests 6 minute walk test and step test</P>
</TD>
<TD>
<P>20 mins (for 6 minute walk test -repeated at least three times on each gas until within 5 % agreement between 2 tests)</P>
</TD>
<TD>
<P>Not documented</P>
</TD>
<TD>
<P>Not documented</P>
</TD>
</TR>
<TR>
<TD>
<P>Wadell (2001)</P>
</TD>
<TD>
<P>Treadmill 6 minute walk using non motorised treadmill and speed driven by patients own walking speed (Not carrying cylinder)</P>
</TD>
<TD>
<P>Demonstration given and 1-2 minute practice before test</P>
</TD>
<TD>
<P>1 hour</P>
</TD>
<TD>
<P>Not documented</P>
</TD>
<TD>
<P>Not documented</P>
</TD>
</TR>
<TR>
<TD>
<P>Raimondi (1970)</P>
</TD>
<TD>
<P>Cycle ergometer test start at 100kpm/min and increased by 100kpm/min each minute Single load cycle test at 70% of maximum achieved on air test</P>
</TD>
<TD>
<P>Not documented</P>
</TD>
<TD>
<P>30 mins (3 tests on two day)</P>
</TD>
<TD>
<P>Not documented</P>
</TD>
<TD>
<P>Isoprenaline 10 mins pre exercise</P>
</TD>
</TR>
<TR>
<TD>
<P>Somfay (2001)</P>
</TD>
<TD>
<P>Cycle ergometer at a constant work rate equal to 75% of highest work rate achieved during a symptom limited test breathing room air</P>
</TD>
<TD>
<P>Not documented but were familiaris with exercise tests</P>
</TD>
<TD>
<P>1 hour (2 tests per visit with 3 visits 3-5 days apart)</P>
</TD>
<TD>
<P>Not documented</P>
</TD>
<TD>
<P>No caffeine alcohol meals pre testing</P>
</TD>
</TR>
<TR>
<TD>
<P>ODonnell (2001)</P>
</TD>
<TD>
<P>Endurance cycle ergometer at 50% work of maximum work rate. Maximum work rate established on cycle test at 50-70rpm. (Not carrying oxygen)</P>
</TD>
<TD>
<P>Thorough familiarisation</P>
</TD>
<TD>
<P>60-90mins</P>
</TD>
<TD>
<P>At least 10mins resting breathing air/oxygen</P>
</TD>
<TD>
<P>Avoid caffeine alcohol heavy exertion and heavy meal 4 hours pre testing</P>
</TD>
</TR>
<TR>
<TD>
<P>Davidson (1988)</P>
</TD>
<TD>
<P>Endurance cycle test at 50-70% max work rate. Maximum work rtae assessed during a proressive cyscle test at 25W increments at 1 minut intervals 6 minute walk test Endurance walk- walk as far as possible at a pace as though late for appointment" and stop when unable to go further (Cyclinder carried by patients during 4Lmin 6 minute walk and endurance tests</P>
</TD>
<TD>
<P>3 practice walks for 6 minute walk test. No practice for endurance or cycle test</P>
</TD>
<TD>
<P>3 hours (no more than 2 cycling and 2 walk tests on each day with testing on 3 consecutive days)</P>
</TD>
<TD>
<P>Not documented</P>
</TD>
<TD>
<P>Fasted for 2 hours. no bronchodilators pre testing</P>
</TD>
</TR>
<TR>
<TD>
<P>King (1973)</P>
</TD>
<TD>
<P>Treadmill walking at 0.84 (0.18) mph</P>
</TD>
<TD>
<P>1-2 minute practice followed by 5 minute rest</P>
</TD>
<TD>
<P>10minutes between tests</P>
</TD>
<TD>
<P>Not documented</P>
</TD>
<TD>
<P>2 hours after light lunch</P>
</TD>
</TR>
<TR>
<TD>
<P>Eaton (2002)</P>
</TD>
<TD>
<P>6 Minute Walk Test oxygen carried in back pack or shoulder bag</P>
</TD>
<TD>
<P>3 practice tests</P>
</TD>
<TD>
<P>20-30 minutes between tests</P>
</TD>
<TD>
<P>Not documented</P>
</TD>
<TD>
<P>Not documented</P>
</TD>
</TR>
<TR>
<TD>
<P>Bradley (1978)</P>
</TD>
<TD>
<P>Treadmill test- initial speed chosen by patient as one comforatable and unlikely to lead to intolerable dysponea after several mins. Treadmill grade increased by 2% per min starting at zero.</P>
</TD>
<TD>
<P>Demonstration and practice walk on 3 consecutive days prior to test</P>
</TD>
<TD>
<P>10 mins but some needed 1-2 hours (3 tests per day)</P>
</TD>
<TD>
<P>Not documented</P>
</TD>
<TD>
<P>Not documented</P>
</TD>
</TR>
<TR>
<TD>
<P>Stein (1982)</P>
</TD>
<TD>
<P>Incremental treadmill test</P>
</TD>
<TD>
<P>Demonstration and oportunity to walk on treadmill before test</P>
</TD>
<TD>
<P>15 mins</P>
</TD>
<TD>
<P>7 mins prior to exercise</P>
</TD>
<TD>
<P>Breakfast before tests- all tests carried out in the morning</P>
</TD>
</TR>
<TR>
<TD>
<P>Mannix (1992)</P>
</TD>
<TD>
<P>Incremental cycle ergometer 4 min stages (0W and progressed by 12.5W)</P>
</TD>
<TD>
<P>Not documented</P>
</TD>
<TD>
<P>1 day</P>
</TD>
<TD>
<P>Not documented</P>
</TD>
<TD>
<P>same time of day</P>
</TD>
</TR>
<TR>
<TD>
<P>Bye (1985)</P>
</TD>
<TD>
<P>Cycle ergometer test at 80% of previously determined max</P>
</TD>
<TD>
<P>Not documented</P>
</TD>
<TD>
<P>2 days</P>
</TD>
<TD>
<P>10mins pre dosing</P>
</TD>
<TD>
<P>same time of day</P>
</TD>
</TR>
<TR>
<TD>
<P>Light (1989)</P>
</TD>
<TD>
<P>cycle ergometer with 10 to 20 W increases each min</P>
</TD>
<TD>
<P>At least 1 practice test</P>
</TD>
<TD>
<P>45 mins</P>
</TD>
<TD>
<P>10mins pre dosing</P>
</TD>
<TD>
<P>Two inhalations of metaproterenol on arrival unless he had received this within 90 last mins</P>
</TD>
</TR>
<TR>
<TD>
<P>Leach (1992)</P>
</TD>
<TD>
<P>6 Minute Walk Test Endurance test walking as far as possible at a pace as though late for an appointment</P>
</TD>
<TD>
<P>3 practices of each test</P>
</TD>
<TD>
<P>45min</P>
</TD>
<TD>
<P>Not documented</P>
</TD>
<TD>
<P>Fasted for at least 90 ins standardised for time of testing bronchodilator treatment</P>
</TD>
</TR>
<TR>
<TD>
<P>Kurihara (1989)</P>
</TD>
<TD>
<P>6 Minute Walk Test Endurance test</P>
</TD>
<TD>
<P>No documented</P>
</TD>
<TD>
<P>30minutes</P>
</TD>
<TD>
<P>Not documented</P>
</TD>
<TD>
<P>Not documented</P>
</TD>
</TR>
<TR>
<TD>
<P>Ishimine (1995)</P>
</TD>
<TD>
<P>6 Minute Walk Test Endurance test</P>
</TD>
<TD>
<P>1 practice test</P>
</TD>
<TD>
<P>30minutes</P>
</TD>
<TD>
<P>Not documented</P>
</TD>
<TD>
<P>Oral bronchodilator stopped on evening before trial and inhaled bronchodilators stopped on morning of test</P>
</TD>
</TR>
<TR>
<TD>
<P>Fujimoto (2002)</P>
</TD>
<TD>
<P>6 Minute Walk Test Endurance test</P>
</TD>
<TD>
<P>1 practice walk</P>
</TD>
<TD>
<P>20 minutes</P>
</TD>
<TD>
<P>Not ducumented</P>
</TD>
<TD>
<P>Not documented</P>
</TD>
</TR>
<TR>
<TD>
<P>Garrod (1999)</P>
</TD>
<TD>
<P>Shuttle walk test carrying small portable tank</P>
</TD>
<TD>
<P>1 practice walk</P>
</TD>
<TD>
<P>Not documented</P>
</TD>
<TD>
<P>Not documented</P>
</TD>
<TD>
<P>Not documented</P>
</TD>
</TR>
<TR>
<TD>
<P>Swinburn (1984)</P>
</TD>
<TD>
<P>Maximal cycle ergometer test</P>
</TD>
<TD>
<P>Familiar with test</P>
</TD>
<TD>
<P>3 hours</P>
</TD>
<TD>
<P>4 minutes</P>
</TD>
<TD>
<P>salbutamol 1 hour pre test</P>
</TD>
</TR>
<TR>
<TD>
<P>Vyas (1971)</P>
</TD>
<TD>
<P>Maximal cycle ergometry at 60kgm per min work load increased each minute</P>
</TD>
<TD>
<P>Familiar with test</P>
</TD>
<TD>
<P>1 hour</P>
</TD>
<TD>
<P>20 minutes</P>
</TD>
<TD>
<P>Not documented</P>
</TD>
</TR>
<TR>
<TD>
<P>Woodcock 1981</P>
</TD>
<TD>
<P>Maximal Treadmill Test<BR/>6 Minute Walk Test Endurance test</P>
</TD>
<TD>
<P>Practice sessions</P>
</TD>
<TD>
<P>30 minutes</P>
</TD>
<TD>
<P>Not documented</P>
</TD>
<TD>
<P>Not documented</P>
</TD>
</TR>
<TR>
<TD>
<P>Palange 1995</P>
</TD>
<TD>
<P>Submaximal Cycle ergometer</P>
</TD>
<TD>
<P>Not documented</P>
</TD>
<TD>
<P>1 hour</P>
</TD>
<TD>
<P>Not documented</P>
</TD>
<TD>
<P>Not documented</P>
</TD>
</TR>
<TR>
<TD>
<P>Gosselin 2004<BR/>
<BR/>
<BR/>
</P>
</TD>
<TD>
<P>Maximal Cycle ergometer</P>
</TD>
<TD>
<P>Not documented</P>
</TD>
<TD>
<P>1 day</P>
</TD>
<TD>
<P>15 mins</P>
</TD>
<TD>
<P>Light breakfast 2 hours before</P>
</TD>
</TR>
<TR>
<TD>
<P>Knebel 2000</P>
</TD>
<TD>
<P>Submaximal 6 MWT</P>
</TD>
<TD>
<P>3 practice walks</P>
</TD>
<TD>
<P>45 minutes</P>
</TD>
<TD>
<P>Not documented</P>
</TD>
<TD>
<P>2 hours after meals or after waking</P>
</TD>
</TR>
<TR>
<TD>
<P>Maltais 2001</P>
</TD>
<TD>
<P>Maximal cycle ergometer</P>
</TD>
<TD>
<P>Not documented</P>
</TD>
<TD>
<P>2 hours</P>
</TD>
<TD>
<P>Not documented</P>
</TD>
<TD>
<P>Not documented</P>
</TD>
</TR>
<TR>
<TD>
<P>Criner (1987)</P>
</TD>
<TD>
<P>Maximal Symptom limited unloaded leg ergometry</P>
</TD>
<TD>
<P>Not documented</P>
</TD>
<TD>
<P>Not documented</P>
</TD>
<TD>
<P>Not documented</P>
</TD>
<TD>
<P>Not documented</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2008-08-22 16:58:51 +0100" MODIFIED_BY="Toby J Lasserson" NO="2">
<TITLE>Outcome Measures Used (E=Endurance test; M=maximal test; *=Isotime)</TITLE>
<TABLE COLS="10" ROWS="32">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Exercise Distance</P>
</TH>
<TH>
<P>Exercise Time</P>
</TH>
<TH>
<P>VO2</P>
</TH>
<TH>
<P>Number Steps</P>
</TH>
<TH>
<P>Isotime breathless</P>
</TH>
<TH>
<P/>
</TH>
<TH>
<P>Isotime SaO2/PaO2</P>
</TH>
<TH>
<P>Isotime VE</P>
</TH>
<TH>
<P>Watts</P>
</TH>
</TR>
<TR>
<TD>
<P>Bradley 1978</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Bye 1985</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>E</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>E*</P>
</TD>
<TD>
<P>E*</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Davidson 1988</P>
</TD>
<TD>
<P>E6MW , Ewalk</P>
</TD>
<TD>
<P>Ecycle, Ewalk</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Dean 1992</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>E</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>E*</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>E*</P>
</TD>
<TD>
<P>E*</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Eaton 2002</P>
</TD>
<TD>
<P>E</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Garrod 2000</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>--</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Ishimine 1995</P>
</TD>
<TD>
<P>E</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>King 1973</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Kurihara 1989</P>
</TD>
<TD>
<P>E</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Leach 1992</P>
</TD>
<TD>
<P>E</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Legget 1977</P>
</TD>
<TD>
<P>E</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Light 1989</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>M*</P>
</TD>
<TD>
<P>M*</P>
</TD>
<TD>
<P>M</P>
</TD>
</TR>
<TR>
<TD>
<P>Mannix 1992</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>M*</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>McDonald 1995</P>
</TD>
<TD>
<P>E6MW</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>EStep</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>McKeon 1988</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>ODonnell 1997</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>E</P>
</TD>
<TD>
<P>[E*]</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>E*</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>E*</P>
</TD>
<TD>
<P>E*</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>ODonell 2001</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>E</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>E*</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>E*</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Raimondi 1970</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>M E</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Somfay 2001</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>E</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>E*</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>E*</P>
</TD>
<TD>
<P>E*</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Stein 1982</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Wadell</P>
</TD>
<TD>
<P>E</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Fujim oto 2002</P>
</TD>
<TD>
<P>E</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Garrod 1999</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Swinburn 1984</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Vyas 1971</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M [M*]</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>M*</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Woodcock 1981</P>
</TD>
<TD>
<P>M E</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Palange 1995</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>E</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Knebel 2000</P>
</TD>
<TD>
<P>E</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Gosselin 2004</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
</TR>
<TR>
<TD>
<P>Maltais 2001</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Criner 1987</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Oxygen versus placebo (crossover studies)</NAME>
<IV_OUTCOME CHI2="13.50349968697816" CI_END="24.609754096722444" CI_START="13.113713759148933" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_SIZE="18.86173392793569" ESTIMABLE="YES" I2="33.35061125910213" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="1.3911072742078787" LOG_CI_START="1.1177256998292895" LOG_DATA="NO" LOG_EFFECT_SIZE="1.27558161420835" NO="1" P_CHI2="0.14111524888651028" P_Q="1.0" P_Z="1.2636127413545456E-10" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="238" TOTAL_2="238" WEIGHT="100.0" Z="6.431487381599449">
<NAME>Endurance test - exercise distance (Davidson 1988 6MWT)</NAME>
<GROUP_LABEL_1>Oxygen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oxygen</GRAPH_LABEL_2>
<EFFECT_MEASURE>Metres</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="13.50349968697816" CI_END="24.609754096722444" CI_START="13.113713759148933" DF="9.0" EFFECT_SIZE="18.86173392793569" ESTIMABLE="YES" I2="33.35061125910213" ID="CMP-001.01.01" LOG_CI_END="1.3911072742078787" LOG_CI_START="1.1177256998292895" LOG_EFFECT_SIZE="1.27558161420835" NO="1" P_CHI2="0.14111524888651028" P_Z="1.2636127413545456E-10" STUDIES="10" TAU2="0.0" TOTAL_1="238" TOTAL_2="238" WEIGHT="100.0" Z="6.431487381599449">
<NAME>Low dose</NAME>
<IV_DATA CI_END="102.03788052530759" CI_START="1.9621194746924147" EFFECT_SIZE="52.0" ESTIMABLE="YES" ESTIMATE="52.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11781" SE="25.53" STUDY_ID="STD-Davidson-1988" TOTAL_1="17" TOTAL_2="17" WEIGHT="1.3195892077265448"/>
<IV_DATA CI_END="59.14884812895633" CI_START="20.85115187104367" EFFECT_SIZE="40.0" ESTIMABLE="YES" ESTIMATE="40.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11782" SE="9.77" STUDY_ID="STD-Eaton-2002" TOTAL_1="41" TOTAL_2="41" WEIGHT="9.010549092194104"/>
<IV_DATA CI_END="23.054196872805903" CI_START="0.945803127194095" EFFECT_SIZE="12.0" ESTIMABLE="YES" ESTIMATE="12.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11783" SE="5.64" STUDY_ID="STD-Fujimoto-2002a" TOTAL_1="16" TOTAL_2="16" WEIGHT="27.038473965164435"/>
<IV_DATA CI_END="46.813980780046236" CI_START="1.1860192199537671" EFFECT_SIZE="24.0" ESTIMABLE="YES" ESTIMATE="24.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11784" SE="11.64" STUDY_ID="STD-Fujimoto-2002b" TOTAL_1="25" TOTAL_2="25" WEIGHT="6.347963544377533"/>
<IV_DATA CI_END="63.41822267217707" CI_START="0.5817773278229268" EFFECT_SIZE="32.0" ESTIMABLE="YES" ESTIMATE="32.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11785" SE="16.03" STUDY_ID="STD-Fujimoto-2002c" TOTAL_1="34" TOTAL_2="34" WEIGHT="3.3471358539073233"/>
<IV_DATA CI_END="31.07295977688216" CI_START="4.927040223117839" EFFECT_SIZE="18.0" ESTIMABLE="YES" ESTIMATE="18.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11786" SE="6.67" STUDY_ID="STD-Ishimine-1995" TOTAL_1="22" TOTAL_2="22" WEIGHT="19.332531068250606"/>
<IV_DATA CI_END="19.705618779869013" CI_START="-8.725618779869013" EFFECT_SIZE="5.49" ESTIMABLE="YES" ESTIMATE="5.49" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11787" SE="7.253" STUDY_ID="STD-Knebel-2000" TOTAL_1="33" TOTAL_2="33" WEIGHT="16.34952085877289"/>
<IV_DATA CI_END="48.83316205200706" CI_START="1.1668379479929385" EFFECT_SIZE="25.0" ESTIMABLE="YES" ESTIMATE="25.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11788" SE="12.16" STUDY_ID="STD-Kurihara-1989" TOTAL_1="14" TOTAL_2="14" WEIGHT="5.816654052344117"/>
<IV_DATA CI_END="41.481623638443565" CI_START="0.5183763615564345" EFFECT_SIZE="21.0" ESTIMABLE="YES" ESTIMATE="21.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11789" SE="10.45" STUDY_ID="STD-McDonald-1995" TOTAL_1="26" TOTAL_2="26" WEIGHT="7.876038016000499"/>
<IV_DATA CI_END="65.45784031975245" CI_START="4.542159680247558" EFFECT_SIZE="35.0" ESTIMABLE="YES" ESTIMATE="35.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11790" SE="15.54" STUDY_ID="STD-Woodcock-1981" TOTAL_1="10" TOTAL_2="10" WEIGHT="3.561544341261951"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="15.07627878235762" CI_END="24.393843794978878" CI_START="12.82932820436379" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_SIZE="18.611585999671334" ESTIMABLE="YES" I2="40.303571392352666" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="1.3872802385023804" LOG_CI_START="1.1082039155505767" LOG_DATA="NO" LOG_EFFECT_SIZE="1.2697833834239869" NO="2" P_CHI2="0.08886198806953971" P_Q="1.0" P_Z="2.815434991711115E-10" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="238" TOTAL_2="238" WEIGHT="99.99999999999999" Z="6.30861499882081">
<NAME>Endurance test - exercise distance (Davidson 1988 endurance walk)</NAME>
<GROUP_LABEL_1>Oxygen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oxygen</GRAPH_LABEL_2>
<EFFECT_MEASURE>Metres</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="15.07627878235762" CI_END="24.393843794978878" CI_START="12.82932820436379" DF="9.0" EFFECT_SIZE="18.611585999671334" ESTIMABLE="YES" I2="40.303571392352666" ID="CMP-001.02.01" LOG_CI_END="1.3872802385023804" LOG_CI_START="1.1082039155505767" LOG_EFFECT_SIZE="1.2697833834239869" NO="1" P_CHI2="0.08886198806953971" P_Z="2.815434991711115E-10" STUDIES="10" TAU2="0.0" TOTAL_1="238" TOTAL_2="238" WEIGHT="99.99999999999999" Z="6.30861499882081">
<NAME>Low dose</NAME>
<IV_DATA CI_END="327.697447092439" CI_START="6.302552907560965" EFFECT_SIZE="167.0" ESTIMABLE="YES" ESTIMATE="167.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11791" SE="81.99" STUDY_ID="STD-Davidson-1988" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.1294723246391073"/>
<IV_DATA CI_END="59.14884812895633" CI_START="20.85115187104367" EFFECT_SIZE="40.0" ESTIMABLE="YES" ESTIMATE="40.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11792" SE="9.77" STUDY_ID="STD-Eaton-2002" TOTAL_1="41" TOTAL_2="41" WEIGHT="9.118210019896534"/>
<IV_DATA CI_END="23.054196872805903" CI_START="0.945803127194095" EFFECT_SIZE="12.0" ESTIMABLE="YES" ESTIMATE="12.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11793" SE="5.64" STUDY_ID="STD-Fujimoto-2002a" TOTAL_1="16" TOTAL_2="16" WEIGHT="27.3615383157343"/>
<IV_DATA CI_END="46.794381140200834" CI_START="1.2056188597991664" EFFECT_SIZE="24.0" ESTIMABLE="YES" ESTIMATE="24.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11794" SE="11.63" STUDY_ID="STD-Fujimoto-2002b" TOTAL_1="25" TOTAL_2="25" WEIGHT="6.434862762699585"/>
<IV_DATA CI_END="63.41822267217707" CI_START="0.5817773278229268" EFFECT_SIZE="32.0" ESTIMABLE="YES" ESTIMATE="32.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11795" SE="16.03" STUDY_ID="STD-Fujimoto-2002c" TOTAL_1="34" TOTAL_2="34" WEIGHT="3.3871285055749007"/>
<IV_DATA CI_END="31.07295977688216" CI_START="4.927040223117839" EFFECT_SIZE="18.0" ESTIMABLE="YES" ESTIMATE="18.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11796" SE="6.67" STUDY_ID="STD-Ishimine-1995" TOTAL_1="22" TOTAL_2="22" WEIGHT="19.56352234395954"/>
<IV_DATA CI_END="19.705618779869013" CI_START="-8.725618779869013" EFFECT_SIZE="5.49" ESTIMABLE="YES" ESTIMATE="5.49" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11797" SE="7.253" STUDY_ID="STD-Knebel-2000" TOTAL_1="33" TOTAL_2="33" WEIGHT="16.544870172686576"/>
<IV_DATA CI_END="48.83316205200706" CI_START="1.1668379479929385" EFFECT_SIZE="25.0" ESTIMABLE="YES" ESTIMATE="25.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11798" SE="12.16" STUDY_ID="STD-Kurihara-1989" TOTAL_1="14" TOTAL_2="14" WEIGHT="5.8861532987265575"/>
<IV_DATA CI_END="41.481623638443565" CI_START="0.5183763615564345" EFFECT_SIZE="21.0" ESTIMABLE="YES" ESTIMATE="21.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11799" SE="10.45" STUDY_ID="STD-McDonald-1995" TOTAL_1="26" TOTAL_2="26" WEIGHT="7.970143441845945"/>
<IV_DATA CI_END="65.45784031975245" CI_START="4.542159680247558" EFFECT_SIZE="35.0" ESTIMABLE="YES" ESTIMATE="35.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11800" SE="15.54" STUDY_ID="STD-Woodcock-1981" TOTAL_1="10" TOTAL_2="10" WEIGHT="3.6040988142369415"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="5.8794338618659365" CI_END="3.4438892757216606" CI_START="1.9534297370756035" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_SIZE="2.698659506398632" ESTIMABLE="YES" I2="0.0" I2_Q="42.602851693658906" ID="CMP-001.03" LOG_CI_END="0.5370491800301341" LOG_CI_START="0.29079779470125133" LOG_DATA="NO" LOG_EFFECT_SIZE="0.431148092477758" NO="3" P_CHI2="0.43683084969730734" P_Q="0.1868544979816925" P_Z="1.2702498931148397E-12" Q="1.7422468354399454" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="77" TOTAL_2="77" WEIGHT="100.0" Z="7.097509596111238">
<NAME>Endurance test - exercise time (Davidson 1988 low dose cycle data/Somfay 2001 low dose)</NAME>
<GROUP_LABEL_1>O2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oxygen</GRAPH_LABEL_2>
<EFFECT_MEASURE>Minutes</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="2.289576127674267" CI_END="3.2500024466684554" CI_START="1.1774820064470182" DF="2.0" EFFECT_SIZE="2.213742226557737" ESTIMABLE="YES" I2="12.647586781419498" ID="CMP-001.03.01" LOG_CI_END="0.5118836879247849" LOG_CI_START="0.07095427923152595" LOG_EFFECT_SIZE="0.34512704919801485" NO="1" P_CHI2="0.3182917461608247" P_Z="2.8262559096125785E-5" STUDIES="3" TAU2="0.0" TOTAL_1="35" TOTAL_2="35" WEIGHT="51.71812084769024" Z="4.187032321519677">
<NAME>Low dose</NAME>
<IV_DATA CI_END="10.079109241040936" CI_START="0.20089075895906294" EFFECT_SIZE="5.14" ESTIMABLE="YES" ESTIMATE="5.14" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11801" SE="2.52" STUDY_ID="STD-Davidson-1988" TOTAL_1="17" TOTAL_2="17" WEIGHT="2.276581103038187"/>
<IV_DATA CI_END="3.027179471187831" CI_START="0.792820528812169" EFFECT_SIZE="1.91" ESTIMABLE="YES" ESTIMATE="1.91" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11802" SE="0.57" STUDY_ID="STD-Raimondi-1970" TOTAL_1="8" TOTAL_2="8" WEIGHT="44.497385770186845"/>
<IV_DATA CI_END="6.951538413563493" CI_START="0.24846158643650718" EFFECT_SIZE="3.6" ESTIMABLE="YES" ESTIMATE="3.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11803" SE="1.71" STUDY_ID="STD-Somfay-2001" TOTAL_1="10" TOTAL_2="10" WEIGHT="4.9441539744652045"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="1.8476108987517244" CI_END="4.290590558535661" CI_START="2.145586548447646" DF="3.0" EFFECT_SIZE="3.2180885534916537" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.6325170727585516" LOG_CI_START="0.3315460377477954" LOG_EFFECT_SIZE="0.5075979905907413" NO="2" P_CHI2="0.6046296583907007" P_Z="4.079023067194627E-9" STUDIES="4" TAU2="0.0" TOTAL_1="42" TOTAL_2="42" WEIGHT="48.281879152309756" Z="5.880956524314783">
<NAME>High dose</NAME>
<IV_DATA CI_END="5.222766505622251" CI_START="1.5772334943777493" EFFECT_SIZE="3.4" ESTIMABLE="YES" ESTIMATE="3.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11804" SE="0.93" STUDY_ID="STD-Bye-1985" TOTAL_1="8" TOTAL_2="8" WEIGHT="16.715459170694533"/>
<IV_DATA CI_END="7.3887358924812965" CI_START="0.41126410751870335" EFFECT_SIZE="3.9" ESTIMABLE="YES" ESTIMATE="3.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11805" SE="1.78" STUDY_ID="STD-Dean-1992" TOTAL_1="12" TOTAL_2="12" WEIGHT="4.562934173947009"/>
<IV_DATA CI_END="4.1267701071682446" CI_START="0.873229892831755" EFFECT_SIZE="2.5" ESTIMABLE="YES" ESTIMATE="2.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11806" SE="0.83" STUDY_ID="STD-O_x0027_Donnell-1997" TOTAL_1="11" TOTAL_2="11" WEIGHT="20.985920506218182"/>
<IV_DATA CI_END="7.737944176037084" CI_START="1.6620558239629162" EFFECT_SIZE="4.7" ESTIMABLE="YES" ESTIMATE="4.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11807" SE="1.55" STUDY_ID="STD-O_x0027_Donnell-2001" TOTAL_1="11" TOTAL_2="11" WEIGHT="6.017565301450032"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="6.940811508966793" CI_END="3.4604408192969345" CI_START="1.958457813852795" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_SIZE="2.7094493165748648" ESTIMABLE="YES" I2="13.55477681178007" I2_Q="72.13605284341331" ID="CMP-001.04" LOG_CI_END="0.5391314263054114" LOG_CI_START="0.29191422106730747" LOG_DATA="NO" LOG_EFFECT_SIZE="0.4328810314370849" NO="4" P_CHI2="0.326355813342061" P_Q="0.058168056046610905" P_Z="1.5358193442748092E-12" Q="3.588866984208346" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="77" TOTAL_2="77" WEIGHT="100.0" Z="7.071215931438712">
<NAME>Endurance test - exercise time (Davidson 1988 high dose cycle/Somfay 2001 high dose)</NAME>
<GROUP_LABEL_1>Oxygen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oxygen</GRAPH_LABEL_2>
<EFFECT_MEASURE>Minutes</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="3.027179471187831" CI_START="0.792820528812169" DF="0.0" EFFECT_SIZE="1.91" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.4810381695644328" LOG_CI_START="-0.10082511302023676" LOG_EFFECT_SIZE="0.2810333672477275" NO="1" P_CHI2="1.0" P_Z="8.055601837444874E-4" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="8" WEIGHT="45.18810745507242" Z="3.3508771929824563">
<NAME>Low dose</NAME>
<IV_DATA CI_END="3.027179471187831" CI_START="0.792820528812169" EFFECT_SIZE="1.91" ESTIMABLE="YES" ESTIMATE="1.91" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11808" SE="0.57" STUDY_ID="STD-Raimondi-1970" TOTAL_1="8" TOTAL_2="8" WEIGHT="45.18810745507242"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="3.3519445247584474" CI_END="4.382905458882417" CI_START="2.354159723348179" DF="5.0" EFFECT_SIZE="3.3685325911152977" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.6417621028400183" LOG_CI_START="0.3718359252089926" LOG_EFFECT_SIZE="0.5274407535806552" NO="2" P_CHI2="0.6458989490501532" P_Z="7.582688188883509E-11" STUDIES="6" TAU2="0.0" TOTAL_1="69" TOTAL_2="69" WEIGHT="54.811892544927574" Z="6.508654528456016">
<NAME>High dose</NAME>
<IV_DATA CI_END="5.222766505622251" CI_START="1.5772334943777493" EFFECT_SIZE="3.4" ESTIMABLE="YES" ESTIMATE="3.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11809" SE="0.93" STUDY_ID="STD-Bye-1985" TOTAL_1="8" TOTAL_2="8" WEIGHT="16.97492902318537"/>
<IV_DATA CI_END="9.881111041813934" CI_START="0.19888895818606578" EFFECT_SIZE="5.04" ESTIMABLE="YES" ESTIMATE="5.04" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11810" SE="2.47" STUDY_ID="STD-Davidson-1988" TOTAL_1="17" TOTAL_2="17" WEIGHT="2.406467260921016"/>
<IV_DATA CI_END="7.3887358924812965" CI_START="0.41126410751870335" EFFECT_SIZE="3.9" ESTIMABLE="YES" ESTIMATE="3.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11811" SE="1.78" STUDY_ID="STD-Dean-1992" TOTAL_1="12" TOTAL_2="12" WEIGHT="4.63376344910776"/>
<IV_DATA CI_END="4.067971187632043" CI_START="0.9320288123679565" EFFECT_SIZE="2.5" ESTIMABLE="YES" ESTIMATE="2.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11812" SE="0.8" STUDY_ID="STD-O_x0027_Donnell-1997" TOTAL_1="11" TOTAL_2="11" WEIGHT="22.940025175239104"/>
<IV_DATA CI_END="7.737944176037084" CI_START="1.6620558239629162" EFFECT_SIZE="4.7" ESTIMABLE="YES" ESTIMATE="4.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11813" SE="1.55" STUDY_ID="STD-O_x0027_Donnell-2001" TOTAL_1="11" TOTAL_2="11" WEIGHT="6.110974448346733"/>
<IV_DATA CI_END="11.783895555166158" CI_START="0.41610444483384246" EFFECT_SIZE="6.1" ESTIMABLE="YES" ESTIMATE="6.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11814" SE="2.9" STUDY_ID="STD-Somfay-2001" TOTAL_1="10" TOTAL_2="10" WEIGHT="1.7457331881275895"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="4.93299567125016" CI_END="3.3412584189950185" CI_START="1.9131549083241182" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_SIZE="2.6272066636595683" ESTIMABLE="YES" I2="0.0" I2_Q="51.27738855683869" ID="CMP-001.05" LOG_CI_END="0.5239100660611812" LOG_CI_START="0.2817501363140846" LOG_DATA="NO" LOG_EFFECT_SIZE="0.4194942369873483" NO="5" P_CHI2="0.5524353377442524" P_Q="0.1519634100592343" P_Z="5.542646396576967E-13" Q="2.0524351433144696" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="77" TOTAL_2="77" WEIGHT="100.0" Z="7.211284619414405">
<NAME>Endurance test - exercise time (Davidson 1988 low dose end'rnce walk/Somfay 2001 low dose)</NAME>
<GROUP_LABEL_1>Oxygen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oxygen</GRAPH_LABEL_2>
<EFFECT_MEASURE>Minutes</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.9775967796256786" CI_END="3.117326549440654" CI_START="1.1775384117486318" DF="2.0" EFFECT_SIZE="2.147432480594643" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="0.49378229832814535" LOG_CI_START="0.07097508288236168" LOG_EFFECT_SIZE="0.3319195176645588" NO="1" P_CHI2="0.6133630271551643" P_Z="1.4278381322882315E-5" STUDIES="3" TAU2="0.0" TOTAL_1="35" TOTAL_2="35" WEIGHT="54.201433802936165" Z="4.339536096147887">
<NAME>Low dose</NAME>
<IV_DATA CI_END="4.905659794624462" CI_START="0.09434020537553733" EFFECT_SIZE="2.5" ESTIMABLE="YES" ESTIMATE="2.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11815" SE="1.2274" STUDY_ID="STD-Davidson-1988" TOTAL_1="17" TOTAL_2="17" WEIGHT="8.810305384611029"/>
<IV_DATA CI_END="3.027179471187831" CI_START="0.792820528812169" EFFECT_SIZE="1.91" ESTIMABLE="YES" ESTIMATE="1.91" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11816" SE="0.57" STUDY_ID="STD-Raimondi-1970" TOTAL_1="8" TOTAL_2="8" WEIGHT="40.852015576492626"/>
<IV_DATA CI_END="6.951538413563493" CI_START="0.24846158643650718" EFFECT_SIZE="3.6" ESTIMABLE="YES" ESTIMATE="3.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11817" SE="1.71" STUDY_ID="STD-Somfay-2001" TOTAL_1="10" TOTAL_2="10" WEIGHT="4.539112841832514"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="1.9029637483100121" CI_END="4.250131763836168" CI_START="2.1398825563987023" DF="3.0" EFFECT_SIZE="3.1950071601174352" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="0.6284023943844081" LOG_CI_START="0.3303899385325485" LOG_EFFECT_SIZE="0.5044718357639049" NO="2" P_CHI2="0.5927893314474437" P_Z="2.9395680189928293E-9" STUDIES="4" TAU2="0.0" TOTAL_1="42" TOTAL_2="42" WEIGHT="45.798566197063835" Z="5.934937866207764">
<NAME>High dose</NAME>
<IV_DATA CI_END="5.222766505622251" CI_START="1.5772334943777493" EFFECT_SIZE="3.4" ESTIMABLE="YES" ESTIMATE="3.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11818" SE="0.93" STUDY_ID="STD-Bye-1985" TOTAL_1="8" TOTAL_2="8" WEIGHT="15.346074529775063"/>
<IV_DATA CI_END="7.3887358924812965" CI_START="0.41126410751870335" EFFECT_SIZE="3.9" ESTIMABLE="YES" ESTIMATE="3.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11819" SE="1.78" STUDY_ID="STD-Dean-1992" TOTAL_1="12" TOTAL_2="12" WEIGHT="4.189123804065917"/>
<IV_DATA CI_END="4.067971187632043" CI_START="0.9320288123679565" EFFECT_SIZE="2.5" ESTIMABLE="YES" ESTIMATE="2.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11820" SE="0.8" STUDY_ID="STD-O_x0027_Donnell-1997" TOTAL_1="11" TOTAL_2="11" WEIGHT="20.73878103250383"/>
<IV_DATA CI_END="7.737944176037084" CI_START="1.6620558239629162" EFFECT_SIZE="4.7" ESTIMABLE="YES" ESTIMATE="4.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11821" SE="1.55" STUDY_ID="STD-O_x0027_Donnell-2001" TOTAL_1="11" TOTAL_2="11" WEIGHT="5.524586830719023"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.06" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="53" TOTAL_2="34" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Endurance test - exercise time (change from baseline)</NAME>
<GROUP_LABEL_1>Oxygen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours O2</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.06.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="53" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>Low dose</NAME>
<CONT_DATA CI_END="52.64925706540503" CI_START="-64.64925706540504" EFFECT_SIZE="-6.0" ESTIMABLE="YES" MEAN_1="541.0" MEAN_2="547.0" ORDER="11822" SD_1="125.0" SD_2="118.0" SE="29.92364019340298" STUDY_ID="STD-Knebel-2000" TOTAL_1="33" TOTAL_2="33" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="28.6" MEAN_2="0.0" ORDER="11823" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Leach-1992" TOTAL_1="20" TOTAL_2="1" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="NO" LOG_EFFECT_SIZE="-Infinity" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0" Z="0.0">
<NAME>Endurance test - exercise steps</NAME>
<GROUP_LABEL_1>Oxygen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oxygen</GRAPH_LABEL_2>
<EFFECT_MEASURE>Number</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0" Z="0.0">
<NAME>Low dose</NAME>
<IV_DATA CI_END="9.762712482432331" CI_START="0.23728751756766808" EFFECT_SIZE="5.0" ESTIMABLE="YES" ESTIMATE="5.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11824" SE="2.43" STUDY_ID="STD-McDonald-1995" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.07.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>High dose</NAME>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="4.840781176064516" CI_END="43.38413189820732" CI_START="20.608934177447345" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="31.996533037827334" ESTIMABLE="YES" I2="38.026531444270816" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="1.6373309117892034" LOG_CI_START="1.3140555321565832" LOG_DATA="NO" LOG_EFFECT_SIZE="1.5051029231914308" NO="8" P_CHI2="0.18383426247854495" P_Q="1.0" P_Z="3.649009996764735E-8" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="70" TOTAL_2="70" WEIGHT="100.0" Z="5.507047899489755">
<NAME>Maximal test - exercise distance</NAME>
<GROUP_LABEL_1>Oxygen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oxygen</GRAPH_LABEL_2>
<EFFECT_MEASURE>Metres</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="4.840781176064516" CI_END="43.38413189820732" CI_START="20.608934177447345" DF="3.0" EFFECT_SIZE="31.996533037827334" ESTIMABLE="YES" I2="38.026531444270816" ID="CMP-001.08.01" LOG_CI_END="1.6373309117892034" LOG_CI_START="1.3140555321565832" LOG_EFFECT_SIZE="1.5051029231914308" NO="1" P_CHI2="0.18383426247854495" P_Z="3.649009996764735E-8" STUDIES="4" TAU2="0.0" TOTAL_1="70" TOTAL_2="70" WEIGHT="100.0" Z="5.507047899489755">
<NAME>Low dose</NAME>
<IV_DATA CI_END="95.06452876846122" CI_START="-65.06452876846122" EFFECT_SIZE="15.0" ESTIMABLE="YES" ESTIMATE="15.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11825" SE="40.85" STUDY_ID="STD-Garrod-1999" TOTAL_1="14" TOTAL_2="14" WEIGHT="2.022944727487358"/>
<IV_DATA CI_END="39.84376950105635" CI_START="14.756230498943653" EFFECT_SIZE="27.3" ESTIMABLE="YES" ESTIMATE="27.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11826" SE="6.4" STUDY_ID="STD-Garrod-2000" TOTAL_1="25" TOTAL_2="25" WEIGHT="82.415365796253"/>
<IV_DATA CI_END="141.42610801125446" CI_START="22.57389198874555" EFFECT_SIZE="82.0" ESTIMABLE="YES" ESTIMATE="82.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11827" SE="30.32" STUDY_ID="STD-McKeon-1988" TOTAL_1="21" TOTAL_2="21" WEIGHT="3.672059795573821"/>
<IV_DATA CI_END="85.02539313949993" CI_START="18.97460686050008" EFFECT_SIZE="52.0" ESTIMABLE="YES" ESTIMATE="52.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11828" SE="16.85" STUDY_ID="STD-Woodcock-1981" TOTAL_1="10" TOTAL_2="10" WEIGHT="11.88962968068583"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="10.318828005135142" CI_END="1.4565035818355334" CI_START="0.6672031755687862" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_SIZE="1.0618533787021598" ESTIMABLE="YES" I2="51.54488477265286" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.16331155698256322" LOG_CI_START="-0.17574189533087117" LOG_DATA="NO" LOG_EFFECT_SIZE="0.02606455326461754" NO="9" P_CHI2="0.06668934593269604" P_Q="0.4525450537586795" P_Z="1.3383417603964475E-7" Q="0.5642698778535902" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0" Z="5.273516553632829">
<NAME>Maximal test - exercise time</NAME>
<GROUP_LABEL_1>Oxygen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oxygen</GRAPH_LABEL_2>
<EFFECT_MEASURE>Minutes</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="8.349193030214225" CI_END="2.044564641756872" CI_START="0.5607141511203276" DF="3.0" EFFECT_SIZE="1.3026393964385998" ESTIMABLE="YES" I2="64.06838374506926" ID="CMP-001.09.01" LOG_CI_END="0.3106008459319361" LOG_CI_START="-0.2512584831811236" LOG_EFFECT_SIZE="0.11482420864319157" NO="1" P_CHI2="0.0393202116868856" P_Z="5.791023568575021E-4" STUDIES="4" TAU2="0.0" TOTAL_1="33" TOTAL_2="33" WEIGHT="28.294652427846408" Z="3.4412177210217525">
<NAME>Low dose</NAME>
<IV_DATA CI_END="9.12872688861631" CI_START="1.1712731113836905" EFFECT_SIZE="5.15" ESTIMABLE="YES" ESTIMATE="5.15" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11829" SE="2.03" STUDY_ID="STD-Criner-1987" TOTAL_1="6" TOTAL_2="6" WEIGHT="0.9838670213002125"/>
<IV_DATA CI_END="3.724768306395248" CI_START="0.2752316936047523" EFFECT_SIZE="2.0" ESTIMABLE="YES" ESTIMATE="2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11830" SE="0.88" STUDY_ID="STD-Mannix-1992" TOTAL_1="10" TOTAL_2="10" WEIGHT="5.2355599277841485"/>
<IV_DATA CI_END="1.3239765899510354" CI_START="-1.2239765899510353" EFFECT_SIZE="0.05" ESTIMABLE="YES" ESTIMATE="0.05" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11831" SE="0.65" STUDY_ID="STD-Raimondi-1970" TOTAL_1="8" TOTAL_2="8" WEIGHT="9.59625469367111"/>
<IV_DATA CI_END="2.787179471187831" CI_START="0.552820528812169" EFFECT_SIZE="1.67" ESTIMABLE="YES" ESTIMATE="1.67" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11832" SE="0.57" STUDY_ID="STD-Stein-1982" TOTAL_1="9" TOTAL_2="9" WEIGHT="12.478970785090937"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="1.405365097067327" CI_END="1.4328944902771297" CI_START="0.5007858071206391" DF="1.0" EFFECT_SIZE="0.9668401486988845" ESTIMABLE="YES" I2="28.84411302893679" ID="CMP-001.09.02" LOG_CI_END="0.1562142127438713" LOG_CI_START="-0.3003479880574789" LOG_EFFECT_SIZE="-0.014645323514337854" NO="2" P_CHI2="0.23582756317364362" P_Z="4.782917242213011E-5" STUDIES="2" TAU2="0.0" TOTAL_1="17" TOTAL_2="17" WEIGHT="71.70534757215358" Z="4.065989094404819">
<NAME>High dose</NAME>
<IV_DATA CI_END="2.097685953970621" CI_START="0.5689140460293788" EFFECT_SIZE="1.3333" ESTIMABLE="YES" ESTIMATE="1.3333" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11833" SE="0.39" STUDY_ID="STD-Swinburn-1984" TOTAL_1="5" TOTAL_2="5" WEIGHT="26.656263037975307"/>
<IV_DATA CI_END="1.3379891953620162" CI_START="0.16201080463798379" EFFECT_SIZE="0.75" ESTIMABLE="YES" ESTIMATE="0.75" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11834" SE="0.3" STUDY_ID="STD-Vyas-1971" TOTAL_1="12" TOTAL_2="12" WEIGHT="45.04908453417827"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.10" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="63" TOTAL_2="63" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Maximal test - exercise VO2max (SMD)</NAME>
<GROUP_LABEL_1>Oxygen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oxygen</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="2.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.10.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="3" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>Low dose</NAME>
<CONT_DATA CI_END="4.715275273377134" CI_START="1.0889562394218457" EFFECT_SIZE="2.90211575639949" ESTIMABLE="YES" MEAN_1="13.3" MEAN_2="9.6" ORDER="11835" SD_1="0.9" SD_2="1.4" SE="0.9250983851129996" STUDY_ID="STD-Criner-1987" TOTAL_1="6" TOTAL_2="6" WEIGHT="0.0"/>
<CONT_DATA CI_END="1.2809711404843749" CI_START="-0.5847328056190262" EFFECT_SIZE="0.3481191674326743" ESTIMABLE="YES" MEAN_1="22.03" MEAN_2="20.2" ORDER="11836" SD_1="4.2" SD_2="5.7" SE="0.4759536299696922" STUDY_ID="STD-Gosselin-2004" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0"/>
<CONT_DATA CI_END="1.3320691383567895" CI_START="-0.4474684383586743" EFFECT_SIZE="0.4423003499990576" ESTIMABLE="YES" MEAN_1="740.0" MEAN_2="609.0" ORDER="11837" SD_1="335.2" SD_2="220.39" SE="0.4539720093716591" STUDY_ID="STD-Mannix-1992" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="1.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.10.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="38" TOTAL_2="38" WEIGHT="0.0" Z="0.0">
<NAME>High dose</NAME>
<CONT_DATA CI_END="0.7201588101002867" CI_START="-0.36929394081309336" EFFECT_SIZE="0.17543243464359665" ESTIMABLE="YES" MEAN_1="8.7" MEAN_2="8.2" ORDER="11838" SD_1="3.0" SD_2="2.6" SE="0.27792672709979477" STUDY_ID="STD-Bradley-1978" TOTAL_1="26" TOTAL_2="26" WEIGHT="0.0"/>
<CONT_DATA CI_END="2.181615517071964" CI_START="0.39385644796361063" EFFECT_SIZE="1.2877359825177874" ESTIMABLE="YES" MEAN_1="4.14" MEAN_2="2.74" ORDER="11839" SD_1="1.21" SD_2="0.86" SE="0.45606936739908716" STUDY_ID="STD-Vyas-1971" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="1.9941691007863205" CI_END="12.061046834883346" CI_START="5.707496538095377" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_SIZE="8.884271686489361" ESTIMABLE="YES" I2="0.0" I2_Q="42.77777106473565" ID="CMP-001.11" LOG_CI_END="1.0813850038972332" LOG_CI_START="0.7564456567393153" LOG_DATA="NO" LOG_EFFECT_SIZE="0.9486218310717297" NO="11" P_CHI2="0.3689536486275481" P_Q="0.18618229167098455" P_Z="4.2221565668902365E-8" Q="1.7475726105169769" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="5.481298398846746">
<NAME>Maximal test - wattage output</NAME>
<GROUP_LABEL_1>Oxygen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oxygen</GRAPH_LABEL_2>
<EFFECT_MEASURE>Watts</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.24659649026934355" CI_END="11.3502789809359" CI_START="4.187286339810309" DF="1.0" EFFECT_SIZE="7.7687826603731045" ESTIMABLE="YES" I2="0.0" ID="CMP-001.11.01" LOG_CI_END="1.055006536277335" LOG_CI_START="0.6219326603293841" LOG_EFFECT_SIZE="0.8903529717865246" NO="1" P_CHI2="0.6194818864928207" P_Z="2.1239578099068905E-5" STUDIES="2" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="78.67630125656724" Z="4.251444886493101">
<NAME>Low dose</NAME>
<IV_DATA CI_END="15.036689072383368" CI_START="2.9633109276166323" EFFECT_SIZE="9.0" ESTIMABLE="YES" ESTIMATE="9.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11840" SE="3.08" STUDY_ID="STD-Gosselin-2004" TOTAL_1="9" TOTAL_2="9" WEIGHT="27.693340032991014"/>
<IV_DATA CI_END="11.549118244905923" CI_START="2.650881755094076" EFFECT_SIZE="7.1" ESTIMABLE="YES" ESTIMATE="7.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11841" SE="2.27" STUDY_ID="STD-Light-1989" TOTAL_1="17" TOTAL_2="17" WEIGHT="50.982961223576226"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="19.87947358573559" CI_START="6.12052641426441" DF="0.0" EFFECT_SIZE="13.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.11.02" LOG_CI_END="1.2984048799688825" LOG_CI_START="0.7867887765538002" LOG_EFFECT_SIZE="1.1139433523068367" NO="2" P_CHI2="1.0" P_Z="2.1247441490673206E-4" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="14" WEIGHT="21.32369874343276" Z="3.7037037037037037">
<NAME>High dose</NAME>
<IV_DATA CI_END="19.87947358573559" CI_START="6.12052641426441" EFFECT_SIZE="13.0" ESTIMABLE="YES" ESTIMATE="13.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11842" SE="3.51" STUDY_ID="STD-Maltais-2001" TOTAL_1="14" TOTAL_2="14" WEIGHT="21.32369874343276"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="5.003639625408261" CI_END="-0.655595164679206" CI_START="-1.6523295443831942" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="-1.1539623545312" ESTIMABLE="YES" I2="40.043643735529386" I2_Q="12.795574836835087" ID="CMP-001.12" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" NO="12" P_CHI2="0.17153100028949386" P_Q="0.28423459979123356" P_Z="5.671772622137818E-6" Q="1.1467307973522418" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="44" WEIGHT="100.0" Z="4.5382695740220855">
<NAME>Endurance test - isotime breathlessness (Somfay 2001 low dose)</NAME>
<GROUP_LABEL_1>Oxygen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Borg</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="-0.14403961700593992" CI_START="-4.45596038299406" DF="0.0" EFFECT_SIZE="-2.3" ESTIMABLE="YES" I2="0.0" ID="CMP-001.12.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="1.0" P_Z="0.036536214024079285" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="5.343395655592421" Z="2.0909090909090904">
<NAME>Low dose</NAME>
<IV_DATA CI_END="-0.14403961700593992" CI_START="-4.45596038299406" EFFECT_SIZE="-2.3" ESTIMABLE="YES" ESTIMATE="-2.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11843" SE="1.1" STUDY_ID="STD-Somfay-2001" TOTAL_1="10" TOTAL_2="10" WEIGHT="5.343395655592421"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="3.856908828056019" CI_END="-0.5770275800552153" CI_START="-1.601508744153188" DF="2.0" EFFECT_SIZE="-1.0892681621042015" ESTIMABLE="YES" I2="48.145001887222435" ID="CMP-001.12.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="0.14537284886536495" P_Z="3.0752708288130634E-5" STUDIES="3" TAU2="0.0" TOTAL_1="34" TOTAL_2="34" WEIGHT="94.65660434440758" Z="4.167819657494858">
<NAME>High dose</NAME>
<IV_DATA CI_END="-0.804421969430567" CI_START="-3.195578030569433" EFFECT_SIZE="-2.0" ESTIMABLE="YES" ESTIMATE="-2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11844" SE="0.61" STUDY_ID="STD-Dean-1992" TOTAL_1="12" TOTAL_2="12" WEIGHT="17.375728952611748"/>
<IV_DATA CI_END="-0.21201080463798383" CI_START="-1.3879891953620163" EFFECT_SIZE="-0.8" ESTIMABLE="YES" ESTIMATE="-0.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11845" SE="0.3" STUDY_ID="STD-O_x0027_Donnell-1997" TOTAL_1="11" TOTAL_2="11" WEIGHT="71.83898603629812"/>
<IV_DATA CI_END="0.1363607431486593" CI_START="-4.136360743148659" EFFECT_SIZE="-2.0" ESTIMABLE="YES" ESTIMATE="-2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11846" SE="1.09" STUDY_ID="STD-O_x0027_Donnell-2001" TOTAL_1="11" TOTAL_2="11" WEIGHT="5.441889355497711"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="5.377064463686378" CI_END="-0.651846463891926" CI_START="-1.6556176653694177" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="-1.153732064630672" ESTIMABLE="YES" I2="44.20747565404346" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" NO="13" P_CHI2="0.14617930745670782" P_Q="1.0" P_Z="6.619961676483953E-6" Q="0.0" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="44" WEIGHT="100.00000000000001" Z="4.5055552324208845">
<NAME>Endurance test - isotime breathlessness (Somfay 2001 high dose)</NAME>
<GROUP_LABEL_1>Oxygen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oxygen</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<EFFECT_MEASURE>Borg</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.13.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Low dose</NAME>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="5.377064463686378" CI_END="-0.651846463891926" CI_START="-1.6556176653694177" DF="3.0" EFFECT_SIZE="-1.153732064630672" ESTIMABLE="YES" I2="44.20747565404346" ID="CMP-001.13.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="0.14617930745670782" P_Z="6.619961676483953E-6" STUDIES="4" TAU2="0.0" TOTAL_1="44" TOTAL_2="44" WEIGHT="100.00000000000001" Z="4.5055552324208845">
<NAME>High dose</NAME>
<IV_DATA CI_END="-0.804421969430567" CI_START="-3.195578030569433" EFFECT_SIZE="-2.0" ESTIMABLE="YES" ESTIMATE="-2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11847" SE="0.61" STUDY_ID="STD-Dean-1992" TOTAL_1="12" TOTAL_2="12" WEIGHT="17.621935997450098"/>
<IV_DATA CI_END="-0.21201080463798383" CI_START="-1.3879891953620163" EFFECT_SIZE="-0.8" ESTIMABLE="YES" ESTIMATE="-0.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11848" SE="0.3" STUDY_ID="STD-O_x0027_Donnell-1997" TOTAL_1="11" TOTAL_2="11" WEIGHT="72.85691538501312"/>
<IV_DATA CI_END="0.1363607431486593" CI_START="-4.136360743148659" EFFECT_SIZE="-2.0" ESTIMABLE="YES" ESTIMATE="-2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11849" SE="1.09" STUDY_ID="STD-O_x0027_Donnell-2001" TOTAL_1="11" TOTAL_2="11" WEIGHT="5.518998724561215"/>
<IV_DATA CI_END="-0.19124609978873064" CI_START="-5.20875390021127" EFFECT_SIZE="-2.7" ESTIMABLE="YES" ESTIMATE="-2.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11850" SE="1.28" STUDY_ID="STD-Somfay-2001" TOTAL_1="10" TOTAL_2="10" WEIGHT="4.0021498929755746"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="1.752650994429123" CI_END="11.643807902182829" CI_START="5.083849187226804" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_SIZE="8.363828544704816" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="1.066095031899875" LOG_CI_START="0.7061926586941895" LOG_DATA="NO" LOG_EFFECT_SIZE="0.9224051213656476" NO="14" P_CHI2="0.4163102192030744" P_Q="0.6359673908792729" P_Z="5.797691073454375E-7" Q="0.22405507758193943" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="29" TOTAL_2="29" WEIGHT="100.0" Z="4.997837161113714">
<NAME>Endurance test - isotime SaO2 (Somfay 2001 low dose)</NAME>
<GROUP_LABEL_1>Oxygen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oxygen</GRAPH_LABEL_2>
<EFFECT_MEASURE>%</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="13.53059999648746" CI_START="0.46940000351253985" DF="0.0" EFFECT_SIZE="7.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.14.01" LOG_CI_END="1.1313170552366585" LOG_CI_START="-0.32845691148758244" LOG_EFFECT_SIZE="0.8450980400142568" NO="1" P_CHI2="1.0" P_Z="0.03565498431214054" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="25.225283361841505" Z="2.100840336134454">
<NAME>Low dose</NAME>
<IV_DATA CI_END="13.53059999648746" CI_START="0.46940000351253985" EFFECT_SIZE="7.0" ESTIMABLE="YES" ESTIMATE="7.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11851" SE="3.332" STUDY_ID="STD-Somfay-2001" TOTAL_1="10" TOTAL_2="10" WEIGHT="25.225283361841505"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="1.5285959168471837" CI_END="12.617011723120132" CI_START="5.030821678387771" DF="1.0" EFFECT_SIZE="8.823916700753951" ESTIMABLE="YES" I2="34.58048729695961" ID="CMP-001.14.02" LOG_CI_END="1.1009565065852134" LOG_CI_START="0.7016389236734497" LOG_EFFECT_SIZE="0.9456613996391082" NO="2" P_CHI2="0.2163237267771354" P_Z="5.12792786369765E-6" STUDIES="2" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="74.7747166381585" Z="4.55948475692831">
<NAME>High dose</NAME>
<IV_DATA CI_END="33.03292376142222" CI_START="2.967076238577784" EFFECT_SIZE="18.0" ESTIMABLE="YES" ESTIMATE="18.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11852" SE="7.67" STUDY_ID="STD-Bye-1985" TOTAL_1="8" TOTAL_2="8" WEIGHT="4.760530051499135"/>
<IV_DATA CI_END="12.119927969080107" CI_START="4.280072030919891" EFFECT_SIZE="8.2" ESTIMABLE="YES" ESTIMATE="8.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11853" SE="2.0" STUDY_ID="STD-O_x0027_Donnell-1997" TOTAL_1="11" TOTAL_2="11" WEIGHT="70.01418658665936"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="1.5292044363853325" CI_END="12.240381819325272" CI_START="5.3643017231756644" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_SIZE="8.802341771250468" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.15" LOG_CI_END="1.0877949651493908" LOG_CI_START="0.7295131974094282" LOG_DATA="NO" LOG_EFFECT_SIZE="0.9445982270406684" NO="15" P_CHI2="0.4655191931531266" P_Q="1.0" P_Z="5.219733020898122E-7" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="29" TOTAL_2="29" WEIGHT="100.0" Z="5.018054650330256">
<NAME>Endurance test - isotime SaO2 (Somfay 2001 high dose)</NAME>
<GROUP_LABEL_1>Oxygen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oxygen</GRAPH_LABEL_2>
<EFFECT_MEASURE>%</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.15.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Low dose</NAME>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="1.5292044363853325" CI_END="12.240381819325272" CI_START="5.3643017231756644" DF="2.0" EFFECT_SIZE="8.802341771250468" ESTIMABLE="YES" I2="0.0" ID="CMP-001.15.02" LOG_CI_END="1.0877949651493908" LOG_CI_START="0.7295131974094282" LOG_EFFECT_SIZE="0.9445982270406684" NO="2" P_CHI2="0.4655191931531266" P_Z="5.219733020898122E-7" STUDIES="3" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="100.0" Z="5.018054650330256">
<NAME>High dose</NAME>
<IV_DATA CI_END="33.03292376142222" CI_START="2.967076238577784" EFFECT_SIZE="18.0" ESTIMABLE="YES" ESTIMATE="18.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11854" SE="7.67" STUDY_ID="STD-Bye-1985" TOTAL_1="8" TOTAL_2="8" WEIGHT="5.230400594482484"/>
<IV_DATA CI_END="12.122671918658463" CI_START="4.277328081341535" EFFECT_SIZE="8.2" ESTIMABLE="YES" ESTIMATE="8.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11855" SE="2.0014" STUDY_ID="STD-O_x0027_Donnell-1997" TOTAL_1="11" TOTAL_2="11" WEIGHT="76.81709680728005"/>
<IV_DATA CI_END="16.814250895995823" CI_START="0.5857491040041758" EFFECT_SIZE="8.7" ESTIMABLE="YES" ESTIMATE="8.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11856" SE="4.14" STUDY_ID="STD-Somfay-2001" TOTAL_1="10" TOTAL_2="10" WEIGHT="17.95250259823745"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.6934791739887018" CI_END="23.88557438674828" CI_START="6.422610874316213" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="15.154092630532247" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.16" LOG_CI_END="1.3781356894123757" LOG_CI_START="0.8077116102817993" LOG_DATA="NO" LOG_EFFECT_SIZE="1.1805299375792444" NO="16" P_CHI2="0.404983905043347" P_Q="1.0" P_Z="6.697949338373107E-4" Q="0.0" RANDOM="NO" SCALE="1000.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="23" TOTAL_2="23" WEIGHT="100.0" Z="3.4016535341303626">
<NAME>Endurance test - isotime PaO2</NAME>
<GROUP_LABEL_1>Oxygen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oxygen</GRAPH_LABEL_2>
<EFFECT_MEASURE>mmHg</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.16.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Low dose</NAME>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.6934791739887018" CI_END="23.88557438674828" CI_START="6.422610874316213" DF="1.0" EFFECT_SIZE="15.154092630532247" ESTIMABLE="YES" I2="0.0" ID="CMP-001.16.02" LOG_CI_END="1.3781356894123757" LOG_CI_START="0.8077116102817993" LOG_EFFECT_SIZE="1.1805299375792444" NO="2" P_CHI2="0.404983905043347" P_Z="6.697949338373107E-4" STUDIES="2" TAU2="0.0" TOTAL_1="23" TOTAL_2="23" WEIGHT="100.0" Z="3.4016535341303626">
<NAME>High dose</NAME>
<IV_DATA CI_END="23.132631447647455" CI_START="4.787368552352547" EFFECT_SIZE="13.96" ESTIMABLE="YES" ESTIMATE="13.96" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11857" SE="4.68" STUDY_ID="STD-Dean-1992" TOTAL_1="12" TOTAL_2="12" WEIGHT="90.61247931971506"/>
<IV_DATA CI_END="55.17787633521239" CI_START="-1.8178763352123894" EFFECT_SIZE="26.68" ESTIMABLE="YES" ESTIMATE="26.68" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11858" SE="14.54" STUDY_ID="STD-O_x0027_Donnell-2001" TOTAL_1="11" TOTAL_2="11" WEIGHT="9.387520680284938"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="1.100519171061776" CI_END="-2.3142242798990296" CI_START="-4.850594162370026" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="-3.5824092211345278" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.17" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" NO="17" P_CHI2="0.8941898328193248" P_Q="0.7441625243838064" P_Z="3.0845488125780627E-8" Q="0.10650179639960011" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="52" TOTAL_2="52" WEIGHT="100.0" Z="5.536568699883347">
<NAME>Endurance test - isotime ventilation (Somfay low dose)</NAME>
<GROUP_LABEL_1>Oxygen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oxygen</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<EFFECT_MEASURE>L/min</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="-0.28007203091989163" CI_START="-8.11992796908011" DF="0.0" EFFECT_SIZE="-4.2" ESTIMABLE="YES" I2="0.0" ID="CMP-001.17.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="1.0" P_Z="0.035728841126557685" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="10.466681541088837" Z="2.1">
<NAME>Low dose</NAME>
<IV_DATA CI_END="-0.28007203091989163" CI_START="-8.11992796908011" EFFECT_SIZE="-4.2" ESTIMABLE="YES" ESTIMATE="-4.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11859" SE="2.0" STUDY_ID="STD-Somfay-2001" TOTAL_1="10" TOTAL_2="10" WEIGHT="10.466681541088837"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.994017374662176" CI_END="-2.16994753929459" CI_START="-4.850474914612559" DF="3.0" EFFECT_SIZE="-3.5102112269535746" ESTIMABLE="YES" I2="0.0" ID="CMP-001.17.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="0.8026995868783875" P_Z="2.848049358969119E-7" STUDIES="4" TAU2="0.0" TOTAL_1="42" TOTAL_2="42" WEIGHT="89.53331845891117" Z="5.133234337620637">
<NAME>High dose</NAME>
<IV_DATA CI_END="-1.9872424982427357" CI_START="-6.6127575017572635" EFFECT_SIZE="-4.3" ESTIMABLE="YES" ESTIMATE="-4.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11860" SE="1.18" STUDY_ID="STD-Bye-1985" TOTAL_1="8" TOTAL_2="8" WEIGHT="30.06803085633105"/>
<IV_DATA CI_END="-0.31484934118012564" CI_START="-5.685150658819874" EFFECT_SIZE="-3.0" ESTIMABLE="YES" ESTIMATE="-3.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11861" SE="1.37" STUDY_ID="STD-Dean-1992" TOTAL_1="12" TOTAL_2="12" WEIGHT="22.306316886544487"/>
<IV_DATA CI_END="-0.23887095045609286" CI_START="-7.961129049543906" EFFECT_SIZE="-4.1" ESTIMABLE="YES" ESTIMATE="-4.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11862" SE="1.97" STUDY_ID="STD-O_x0027_Donnell-1997" TOTAL_1="11" TOTAL_2="11" WEIGHT="10.78789099547923"/>
<IV_DATA CI_END="-0.33044537947953145" CI_START="-5.269554620520468" EFFECT_SIZE="-2.8" ESTIMABLE="YES" ESTIMATE="-2.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11863" SE="1.26" STUDY_ID="STD-O_x0027_Donnell-2001" TOTAL_1="11" TOTAL_2="11" WEIGHT="26.371079720556402"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="1.188120989218276" CI_END="-2.3252435128525533" CI_START="-4.878581510368999" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="-3.601912511610776" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.18" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" NO="18" P_CHI2="0.8800505353868101" P_Q="1.0" P_Z="3.2074704641265284E-8" Q="0.0" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="52" TOTAL_2="52" WEIGHT="100.0" Z="5.529717417034493">
<NAME>Endurance test - isotime ventilation (Somfay high dose)</NAME>
<GROUP_LABEL_1>Oxygen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oxygen</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<EFFECT_MEASURE>L/min</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.18.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Low dose</NAME>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="1.188120989218276" CI_END="-2.3252435128525533" CI_START="-4.878581510368999" DF="4.0" EFFECT_SIZE="-3.601912511610776" ESTIMABLE="YES" I2="0.0" ID="CMP-001.18.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="0.8800505353868101" P_Z="3.2074704641265284E-8" STUDIES="5" TAU2="0.0" TOTAL_1="52" TOTAL_2="52" WEIGHT="100.0" Z="5.529717417034493">
<NAME>High dose</NAME>
<IV_DATA CI_END="-1.9872424982427357" CI_START="-6.6127575017572635" EFFECT_SIZE="-4.3" ESTIMABLE="YES" ESTIMATE="-4.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11864" SE="1.18" STUDY_ID="STD-Bye-1985" TOTAL_1="8" TOTAL_2="8" WEIGHT="30.471682076052545"/>
<IV_DATA CI_END="-0.31484934118012564" CI_START="-5.685150658819874" EFFECT_SIZE="-3.0" ESTIMABLE="YES" ESTIMATE="-3.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11865" SE="1.37" STUDY_ID="STD-Dean-1992" TOTAL_1="12" TOTAL_2="12" WEIGHT="22.6057702182831"/>
<IV_DATA CI_END="-0.23887095045609286" CI_START="-7.961129049543906" EFFECT_SIZE="-4.1" ESTIMABLE="YES" ESTIMATE="-4.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11866" SE="1.97" STUDY_ID="STD-O_x0027_Donnell-1997" TOTAL_1="11" TOTAL_2="11" WEIGHT="10.932714092786611"/>
<IV_DATA CI_END="-0.33044537947953145" CI_START="-5.269554620520468" EFFECT_SIZE="-2.8" ESTIMABLE="YES" ESTIMATE="-2.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11867" SE="1.26" STUDY_ID="STD-O_x0027_Donnell-2001" TOTAL_1="11" TOTAL_2="11" WEIGHT="26.72510085833683"/>
<IV_DATA CI_END="-0.3056770730842837" CI_START="-8.694322926915717" EFFECT_SIZE="-4.5" ESTIMABLE="YES" ESTIMATE="-4.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11868" SE="2.14" STUDY_ID="STD-Somfay-2001" TOTAL_1="10" TOTAL_2="10" WEIGHT="9.264732754540912"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.38092223277408477" CI_END="10.740176469613521" CI_START="4.89213122269417" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="7.816153846153846" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.19" LOG_CI_END="1.0310114172247795" LOG_CI_START="0.68949809769533" LOG_DATA="NO" LOG_EFFECT_SIZE="0.8929930990574559" NO="19" P_CHI2="0.5371104093140322" P_Q="0.5371104093140322" P_Z="1.6132179416988637E-7" Q="0.38092223277408477" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="2" TOTAL_2="2" WEIGHT="100.0" Z="5.239145522738815">
<NAME>Maximal test - isotime SaO2</NAME>
<GROUP_LABEL_1>Oxygen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oxygen</GRAPH_LABEL_2>
<EFFECT_MEASURE>%</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="10.804331930780702" CI_START="3.395668069219297" DF="0.0" EFFECT_SIZE="7.1" ESTIMABLE="YES" I2="0.0" ID="CMP-001.19.01" LOG_CI_END="1.0335979181192667" LOG_CI_START="0.5309252308204712" LOG_EFFECT_SIZE="0.8512583487190752" NO="1" P_CHI2="1.0" P_Z="1.7222800138694494E-4" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="62.30769230769231" Z="3.7566137566137567">
<NAME>Low dose</NAME>
<IV_DATA CI_END="10.804331930780702" CI_START="3.395668069219297" EFFECT_SIZE="7.1" ESTIMABLE="YES" ESTIMATE="7.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11869" SE="1.89" STUDY_ID="STD-Light-1989" TOTAL_1="1" TOTAL_2="1" WEIGHT="62.30769230769231"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="13.762712482432331" CI_START="4.237287517567668" DF="0.0" EFFECT_SIZE="9.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.19.02" LOG_CI_END="1.1387040371013708" LOG_CI_START="0.6270879336862882" LOG_EFFECT_SIZE="0.9542425094393249" NO="2" P_CHI2="1.0" P_Z="2.1247441490673246E-4" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="37.692307692307686" Z="3.7037037037037033">
<NAME>High dose</NAME>
<IV_DATA CI_END="13.762712482432331" CI_START="4.237287517567668" EFFECT_SIZE="9.0" ESTIMABLE="YES" ESTIMATE="9.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11870" SE="2.43" STUDY_ID="STD-Maltais-2001" TOTAL_1="1" TOTAL_2="1" WEIGHT="37.692307692307686"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="7.937222637377272" CI_END="11.061137362534815" CI_START="4.322035421708695" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="7.691586392121755" ESTIMABLE="YES" I2="87.40113455693069" I2_Q="0.0" ID="CMP-001.20" LOG_CI_END="1.043799785637457" LOG_CI_START="0.6356883218692002" LOG_DATA="NO" LOG_EFFECT_SIZE="0.8860159224139772" NO="20" P_CHI2="0.004842831009094883" P_Q="1.0" P_Z="7.678453289738346E-6" Q="0.0" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="31" TOTAL_2="31" WEIGHT="100.0" Z="4.473958828611814">
<NAME>Maximal test - isotime PaO2</NAME>
<GROUP_LABEL_1>Oxygen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oxygen</GRAPH_LABEL_2>
<EFFECT_MEASURE>kPa</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.20.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Low dose</NAME>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="7.937222637377272" CI_END="11.061137362534815" CI_START="4.322035421708695" DF="1.0" EFFECT_SIZE="7.691586392121755" ESTIMABLE="YES" I2="87.40113455693069" ID="CMP-001.20.02" LOG_CI_END="1.043799785637457" LOG_CI_START="0.6356883218692002" LOG_EFFECT_SIZE="0.8860159224139772" NO="2" P_CHI2="0.004842831009094883" P_Z="7.678453289738346E-6" STUDIES="2" TAU2="0.0" TOTAL_1="31" TOTAL_2="31" WEIGHT="100.0" Z="4.473958828611814">
<NAME>High dose</NAME>
<IV_DATA CI_END="10.079536612790495" CI_START="3.1804633872095045" EFFECT_SIZE="6.63" ESTIMABLE="YES" ESTIMATE="6.63" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11871" SE="1.76" STUDY_ID="STD-Light-1989" TOTAL_1="17" TOTAL_2="17" WEIGHT="95.41629364368845"/>
<IV_DATA CI_END="45.52851079585663" CI_START="14.051489204143365" EFFECT_SIZE="29.79" ESTIMABLE="YES" ESTIMATE="29.79" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11872" SE="8.03" STUDY_ID="STD-Maltais-2001" TOTAL_1="14" TOTAL_2="14" WEIGHT="4.5837063563115485"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="3.876761208582913" CI_END="-2.188076250608132" CI_START="-4.32810571359869" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="-3.258090982103411" ESTIMABLE="YES" I2="22.615816693631196" I2_Q="0.0" ID="CMP-001.21" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" NO="21" P_CHI2="0.27508293426613695" P_Q="0.6157536850221206" P_Z="2.4032648484071973E-9" Q="0.2518810868456258" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="48" TOTAL_2="48" WEIGHT="100.0" Z="5.967900062790485">
<NAME>Maximal test - isotime ventilation</NAME>
<GROUP_LABEL_1>Oxygen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oxygen</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<EFFECT_MEASURE>L/min</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="3.624880121737287" CI_END="-1.988421932578911" CI_START="-5.109509581307888" DF="2.0" EFFECT_SIZE="-3.5489657569433994" ESTIMABLE="YES" I2="44.82576160224948" ID="CMP-001.21.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="0.1632553660286934" P_Z="8.299020829222398E-6" STUDIES="3" TAU2="0.0" TOTAL_1="36" TOTAL_2="36" WEIGHT="47.01404028193723" Z="4.457321196223165">
<NAME>Low dose</NAME>
<IV_DATA CI_END="-2.2960864371038703" CI_START="-11.70391356289613" EFFECT_SIZE="-7.0" ESTIMABLE="YES" ESTIMATE="-7.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11873" SE="2.4" STUDY_ID="STD-Gosselin-2004" TOTAL_1="9" TOTAL_2="9" WEIGHT="5.174410128717067"/>
<IV_DATA CI_END="-1.0556320537593515" CI_START="-4.544367946240648" EFFECT_SIZE="-2.8" ESTIMABLE="YES" ESTIMATE="-2.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11874" SE="0.89" STUDY_ID="STD-Light-1989" TOTAL_1="17" TOTAL_2="17" WEIGHT="37.62732273880862"/>
<IV_DATA CI_END="-0.7864958011234551" CI_START="-11.213504198876546" EFFECT_SIZE="-6.0" ESTIMABLE="YES" ESTIMATE="-6.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11875" SE="2.66" STUDY_ID="STD-Mannix-1992" TOTAL_1="10" TOTAL_2="10" WEIGHT="4.2123074144115416"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="-1.5300270115949592" CI_START="-4.469972988405041" DF="0.0" EFFECT_SIZE="-3.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.21.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="1.0" P_Z="6.334248366713452E-5" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="52.985959718062766" Z="4.0">
<NAME>High dose</NAME>
<IV_DATA CI_END="-1.5300270115949592" CI_START="-4.469972988405041" EFFECT_SIZE="-3.0" ESTIMABLE="YES" ESTIMATE="-3.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11876" SE="0.75" STUDY_ID="STD-Vyas-1971" TOTAL_1="12" TOTAL_2="12" WEIGHT="52.985959718062766"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.22" NO="22" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="9" TOTAL_2="9" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Endurance test VO2</NAME>
<GROUP_LABEL_1>Oxygen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Oxygen</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.22.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Low dose</NAME>
<CONT_DATA CI_END="1468.5807532030572" CI_START="851.419246796943" EFFECT_SIZE="1160.0" ESTIMABLE="YES" MEAN_1="2280.0" MEAN_2="1120.0" ORDER="11877" SD_1="426.0" SD_2="204.0" SE="157.4420528321452" STUDY_ID="STD-Palange-1995" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>SUBGROUP ANALYSES: mean baseline kPa/PaO2 &amp; high dose versus low dose studies)</NAME>
<IV_OUTCOME CHI2="13.50349968697816" CI_END="24.609754096722437" CI_START="13.113713759148926" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_SIZE="18.86173392793568" ESTIMABLE="YES" I2="33.35061125910213" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="1.3911072742078787" LOG_CI_START="1.1177256998292893" LOG_DATA="NO" LOG_EFFECT_SIZE="1.2755816142083498" NO="1" P_CHI2="0.14111524888651028" P_Q="1.0" P_Z="1.2636127413545686E-10" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="238" TOTAL_2="238" WEIGHT="100.0" Z="6.431487381599446">
<NAME>MEAN BASELINE PAO2 &lt;/&gt; 7.3kPa/55mmHG: Endurance test - exercise distance</NAME>
<GROUP_LABEL_1>Oxygen</GROUP_LABEL_1>
<GROUP_LABEL_2>Air</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oxygen</GRAPH_LABEL_2>
<EFFECT_MEASURE>Metres</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Mean baseline PaO2 &lt;/=7.3 kPa/55 mmHg</NAME>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="13.50349968697816" CI_END="24.609754096722437" CI_START="13.113713759148926" DF="9.0" EFFECT_SIZE="18.86173392793568" ESTIMABLE="YES" I2="33.35061125910213" ID="CMP-002.01.02" LOG_CI_END="1.3911072742078787" LOG_CI_START="1.1177256998292893" LOG_EFFECT_SIZE="1.2755816142083498" NO="2" P_CHI2="0.14111524888651028" P_Z="1.2636127413545686E-10" STUDIES="10" TAU2="0.0" TOTAL_1="238" TOTAL_2="238" WEIGHT="100.0" Z="6.431487381599446">
<NAME>Mean baseline PaO2 &gt;7.3 kPa/55 mmHg</NAME>
<IV_DATA CI_END="102.03788052530759" CI_START="1.9621194746924147" EFFECT_SIZE="52.0" ESTIMABLE="YES" ESTIMATE="52.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11878" SE="25.53" STUDY_ID="STD-Davidson-1988" TOTAL_1="17" TOTAL_2="17" WEIGHT="1.3195892077265448"/>
<IV_DATA CI_END="59.14884812895633" CI_START="20.85115187104367" EFFECT_SIZE="40.0" ESTIMABLE="YES" ESTIMATE="40.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11879" SE="9.77" STUDY_ID="STD-Eaton-2002" TOTAL_1="41" TOTAL_2="41" WEIGHT="9.010549092194102"/>
<IV_DATA CI_END="23.054196872805903" CI_START="0.945803127194095" EFFECT_SIZE="12.0" ESTIMABLE="YES" ESTIMATE="12.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11880" SE="5.64" STUDY_ID="STD-Fujimoto-2002a" TOTAL_1="16" TOTAL_2="16" WEIGHT="27.03847396516443"/>
<IV_DATA CI_END="46.813980780046236" CI_START="1.1860192199537671" EFFECT_SIZE="24.0" ESTIMABLE="YES" ESTIMATE="24.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11881" SE="11.64" STUDY_ID="STD-Fujimoto-2002b" TOTAL_1="25" TOTAL_2="25" WEIGHT="6.347963544377532"/>
<IV_DATA CI_END="63.41822267217707" CI_START="0.5817773278229268" EFFECT_SIZE="32.0" ESTIMABLE="YES" ESTIMATE="32.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11882" SE="16.03" STUDY_ID="STD-Fujimoto-2002c" TOTAL_1="34" TOTAL_2="34" WEIGHT="3.347135853907323"/>
<IV_DATA CI_END="31.07295977688216" CI_START="4.927040223117839" EFFECT_SIZE="18.0" ESTIMABLE="YES" ESTIMATE="18.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11883" SE="6.67" STUDY_ID="STD-Ishimine-1995" TOTAL_1="22" TOTAL_2="22" WEIGHT="19.332531068250603"/>
<IV_DATA CI_END="19.705618779869013" CI_START="-8.725618779869013" EFFECT_SIZE="5.49" ESTIMABLE="YES" ESTIMATE="5.49" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11884" SE="7.253" STUDY_ID="STD-Knebel-2000" TOTAL_1="33" TOTAL_2="33" WEIGHT="16.349520858772888"/>
<IV_DATA CI_END="48.83316205200706" CI_START="1.1668379479929385" EFFECT_SIZE="25.0" ESTIMABLE="YES" ESTIMATE="25.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11885" SE="12.16" STUDY_ID="STD-Kurihara-1989" TOTAL_1="14" TOTAL_2="14" WEIGHT="5.816654052344117"/>
<IV_DATA CI_END="41.481623638443565" CI_START="0.5183763615564345" EFFECT_SIZE="21.0" ESTIMABLE="YES" ESTIMATE="21.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11886" SE="10.45" STUDY_ID="STD-McDonald-1995" TOTAL_1="26" TOTAL_2="26" WEIGHT="7.876038016000498"/>
<IV_DATA CI_END="65.45784031975245" CI_START="4.542159680247558" EFFECT_SIZE="35.0" ESTIMABLE="YES" ESTIMATE="35.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11887" SE="15.54" STUDY_ID="STD-Woodcock-1981" TOTAL_1="10" TOTAL_2="10" WEIGHT="3.5615443412619507"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="4.31639588194749" CI_END="3.855321629266001" CI_START="2.1150495941539313" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_SIZE="2.985185611709966" ESTIMABLE="YES" I2="0.0" I2_Q="27.56686348753919" ID="CMP-002.02" LOG_CI_END="0.5860606148094972" LOG_CI_START="0.3253205552641891" LOG_DATA="NO" LOG_EFFECT_SIZE="0.47497133969831584" NO="2" P_CHI2="0.6339427393244654" P_Q="0.25143202280279" P_Z="1.7671635905808045E-11" Q="2.7611671899033894" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="77" TOTAL_2="77" WEIGHT="100.0" Z="6.724070913133904">
<NAME>MEAN BASELINE PAO2 &lt;/&gt; 7.3kPa/55mmHG: Endurance test - exercise time</NAME>
<GROUP_LABEL_1>O2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oxygen</GRAPH_LABEL_2>
<EFFECT_MEASURE>Minutes</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="7.737944176037084" CI_START="1.6620558239629162" DF="0.0" EFFECT_SIZE="4.7" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="0.8886255922595472" LOG_CI_START="0.22064560647089723" LOG_EFFECT_SIZE="0.6720978579357175" NO="1" P_CHI2="1.0" P_Z="0.002427315889322963" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="11" WEIGHT="8.203793369827109" Z="3.032258064516129">
<NAME>Mean baseline PaO2 &lt;/=7.3 kPa/55 mmHg</NAME>
<IV_DATA CI_END="7.737944176037084" CI_START="1.6620558239629162" EFFECT_SIZE="4.7" ESTIMABLE="YES" ESTIMATE="4.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11888" SE="1.55" STUDY_ID="STD-O_x0027_Donnell-2001" TOTAL_1="11" TOTAL_2="11" WEIGHT="8.203793369827109"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="1.5552286920441007" CI_END="4.223842036903077" CI_START="2.105075092336631" DF="4.0" EFFECT_SIZE="3.164458564619854" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="0.6257076680995913" LOG_CI_START="0.32326759262097615" LOG_EFFECT_SIZE="0.5002994134013802" NO="2" P_CHI2="0.8168155610638196" P_Z="4.78272581843307E-9" STUDIES="5" TAU2="0.0" TOTAL_1="58" TOTAL_2="58" WEIGHT="67.46335036966717" Z="5.854560675613489">
<NAME>Mean baseline PaO2 &gt;7.3 kPa/55 mmHg</NAME>
<IV_DATA CI_END="5.222766505622251" CI_START="1.5772334943777493" EFFECT_SIZE="3.4" ESTIMABLE="YES" ESTIMATE="3.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11889" SE="0.93" STUDY_ID="STD-Bye-1985" TOTAL_1="8" TOTAL_2="8" WEIGHT="22.788314916186412"/>
<IV_DATA CI_END="10.079109241040936" CI_START="0.20089075895906294" EFFECT_SIZE="5.14" ESTIMABLE="YES" ESTIMATE="5.14" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11890" SE="2.52" STUDY_ID="STD-Davidson-1988" TOTAL_1="17" TOTAL_2="17" WEIGHT="3.1036806454726675"/>
<IV_DATA CI_END="7.3887358924812965" CI_START="0.41126410751870335" EFFECT_SIZE="3.9" ESTIMABLE="YES" ESTIMATE="3.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11891" SE="1.78" STUDY_ID="STD-Dean-1992" TOTAL_1="12" TOTAL_2="12" WEIGHT="6.220683490408291"/>
<IV_DATA CI_END="4.1267701071682446" CI_START="0.873229892831755" EFFECT_SIZE="2.5" ESTIMABLE="YES" ESTIMATE="2.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11892" SE="0.83" STUDY_ID="STD-O_x0027_Donnell-1997" TOTAL_1="11" TOTAL_2="11" WEIGHT="28.61026792133783"/>
<IV_DATA CI_END="6.951538413563493" CI_START="0.24846158643650718" EFFECT_SIZE="3.6" ESTIMABLE="YES" ESTIMATE="3.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11893" SE="1.71" STUDY_ID="STD-Somfay-2001" TOTAL_1="10" TOTAL_2="10" WEIGHT="6.740403396261971"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="3.673967586086049" CI_START="0.14603241391395105" DF="0.0" EFFECT_SIZE="1.91" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.03" LOG_CI_END="0.5651353203840344" LOG_CI_START="-0.8355507358488685" LOG_EFFECT_SIZE="0.2810333672477275" NO="3" P_CHI2="1.0" P_Z="0.03381908128016954" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="8" WEIGHT="24.332856260505714" Z="2.1222222222222222">
<NAME>Unclear O2 status</NAME>
<IV_DATA CI_END="3.673967586086049" CI_START="0.14603241391395105" EFFECT_SIZE="1.91" ESTIMABLE="YES" ESTIMATE="1.91" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11894" SE="0.9" STUDY_ID="STD-Raimondi-1970" TOTAL_1="8" TOTAL_2="8" WEIGHT="24.332856260505714"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="4.840781176064515" CI_END="43.38413189820732" CI_START="20.608934177447345" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="31.996533037827334" ESTIMABLE="YES" I2="38.02653144427081" I2_Q="67.34583950036615" ID="CMP-002.03" LOG_CI_END="1.6373309117892034" LOG_CI_START="1.3140555321565832" LOG_DATA="NO" LOG_EFFECT_SIZE="1.5051029231914308" NO="3" P_CHI2="0.18383426247854495" P_Q="0.0801236381287237" P_Z="3.649009996764735E-8" Q="3.0623969034855856" RANDOM="NO" SCALE="1000.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="70" TOTAL_2="70" WEIGHT="100.0" Z="5.507047899489755">
<NAME>MEAN BASELINE PAO2 &lt;/&gt; 7.3kPa/55mmHG: Maximal test - exercise distance</NAME>
<GROUP_LABEL_1>Oxygen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oxygen</GRAPH_LABEL_2>
<EFFECT_MEASURE>Metres</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="39.84376950105635" CI_START="14.756230498943653" DF="0.0" EFFECT_SIZE="27.3" ESTIMABLE="YES" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="1.6003604190103589" LOG_CI_START="1.1689754304824882" LOG_EFFECT_SIZE="1.436162647040756" NO="1" P_CHI2="1.0" P_Z="1.993433660611968E-5" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="82.415365796253" Z="4.265625">
<NAME>Mean baseline PaO2 &lt;/=7.3 kPa/55 mmHg</NAME>
<IV_DATA CI_END="39.84376950105635" CI_START="14.756230498943653" EFFECT_SIZE="27.3" ESTIMABLE="YES" ESTIMATE="27.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11895" SE="6.4" STUDY_ID="STD-Garrod-2000" TOTAL_1="25" TOTAL_2="25" WEIGHT="82.415365796253"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="1.778384272578929" CI_END="81.16414522474176" CI_START="26.85218386587506" DF="2.0" EFFECT_SIZE="54.00816454530841" ESTIMABLE="YES" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="1.9093642192664286" LOG_CI_START="1.4289796122824927" LOG_EFFECT_SIZE="1.732459418136789" NO="2" P_CHI2="0.41098767872472475" P_Z="9.698975750430894E-5" STUDIES="3" TAU2="0.0" TOTAL_1="45" TOTAL_2="45" WEIGHT="17.584634203747008" Z="3.898001645732735">
<NAME>Mean baseline PaO2 &gt;7.3 kPa/55 mmHg</NAME>
<IV_DATA CI_END="95.06452876846122" CI_START="-65.06452876846122" EFFECT_SIZE="15.0" ESTIMABLE="YES" ESTIMATE="15.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11896" SE="40.85" STUDY_ID="STD-Garrod-1999" TOTAL_1="14" TOTAL_2="14" WEIGHT="2.022944727487358"/>
<IV_DATA CI_END="141.42610801125446" CI_START="22.57389198874555" EFFECT_SIZE="82.0" ESTIMABLE="YES" ESTIMATE="82.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11897" SE="30.32" STUDY_ID="STD-McKeon-1988" TOTAL_1="21" TOTAL_2="21" WEIGHT="3.6720597955738206"/>
<IV_DATA CI_END="85.02539313949993" CI_START="18.97460686050008" EFFECT_SIZE="52.0" ESTIMABLE="YES" ESTIMATE="52.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11898" SE="16.85" STUDY_ID="STD-Woodcock-1981" TOTAL_1="10" TOTAL_2="10" WEIGHT="11.889629680685829"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="10.318828005135142" CI_END="1.4565035818355334" CI_START="0.6672031755687862" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_SIZE="1.0618533787021598" ESTIMABLE="YES" I2="51.54488477265286" I2_Q="44.85040492396827" ID="CMP-002.04" LOG_CI_END="0.16331155698256322" LOG_CI_START="-0.17574189533087117" LOG_DATA="NO" LOG_EFFECT_SIZE="0.02606455326461754" NO="4" P_CHI2="0.06668934593269604" P_Q="0.16312320273270986" P_Z="1.3383417603964475E-7" Q="3.6264998813549028" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0" Z="5.273516553632829">
<NAME>MEAN BASELINE PAO2 &lt;/&gt; 7.3kPa/55mmHG: Maximal test - exercise time</NAME>
<GROUP_LABEL_1>Oxygen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oxygen</GRAPH_LABEL_2>
<EFFECT_MEASURE>Minutes</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="3.724768306395248" CI_START="0.2752316936047523" DF="0.0" EFFECT_SIZE="2.0" ESTIMABLE="YES" I2="0.0" ID="CMP-002.04.01" LOG_CI_END="0.5710992632900753" LOG_CI_START="-0.5603015574818557" LOG_EFFECT_SIZE="0.3010299956639812" NO="1" P_CHI2="1.0" P_Z="0.023042620087592877" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="5.2355599277841485" Z="2.272727272727273">
<NAME>Mean baseline PaO2 &lt;/=7.3 kPa/55 mmHg</NAME>
<IV_DATA CI_END="3.724768306395248" CI_START="0.2752316936047523" EFFECT_SIZE="2.0" ESTIMABLE="YES" ESTIMATE="2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11899" SE="0.88" STUDY_ID="STD-Mannix-1992" TOTAL_1="10" TOTAL_2="10" WEIGHT="5.2355599277841485"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="6.692328123780239" CI_END="1.5458276397928992" CI_START="0.6905568706126788" DF="3.0" EFFECT_SIZE="1.118192255202789" ESTIMABLE="YES" I2="55.172550650349535" ID="CMP-002.04.02" LOG_CI_END="0.189161068327539" LOG_CI_START="-0.16080054941522948" LOG_EFFECT_SIZE="0.0485164799327235" NO="2" P_CHI2="0.08237850423580961" P_Z="2.975923977261171E-7" STUDIES="4" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="85.16818537854473" Z="5.124965395671733">
<NAME>Mean baseline PaO2 &gt;7.3 kPa/55 mmHg</NAME>
<IV_DATA CI_END="9.12872688861631" CI_START="1.1712731113836905" EFFECT_SIZE="5.15" ESTIMABLE="YES" ESTIMATE="5.15" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11900" SE="2.03" STUDY_ID="STD-Criner-1987" TOTAL_1="6" TOTAL_2="6" WEIGHT="0.9838670213002125"/>
<IV_DATA CI_END="2.787179471187831" CI_START="0.552820528812169" EFFECT_SIZE="1.67" ESTIMABLE="YES" ESTIMATE="1.67" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11901" SE="0.57" STUDY_ID="STD-Stein-1982" TOTAL_1="9" TOTAL_2="9" WEIGHT="12.478970785090937"/>
<IV_DATA CI_END="2.097685953970621" CI_START="0.5689140460293788" EFFECT_SIZE="1.3333" ESTIMABLE="YES" ESTIMATE="1.3333" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11902" SE="0.39" STUDY_ID="STD-Swinburn-1984" TOTAL_1="5" TOTAL_2="5" WEIGHT="26.656263037975307"/>
<IV_DATA CI_END="1.3379891953620162" CI_START="0.16201080463798379" EFFECT_SIZE="0.75" ESTIMABLE="YES" ESTIMATE="0.75" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11903" SE="0.3" STUDY_ID="STD-Vyas-1971" TOTAL_1="12" TOTAL_2="12" WEIGHT="45.04908453417827"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="1.3239765899510354" CI_START="-1.2239765899510353" DF="0.0" EFFECT_SIZE="0.05" ESTIMABLE="YES" I2="0.0" ID="CMP-002.04.03" LOG_CI_END="0.1218803061422241" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.3010299956639813" NO="3" P_CHI2="1.0" P_Z="0.9386847392079931" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="8" WEIGHT="9.59625469367111" Z="0.07692307692307693">
<NAME>Unclear O2 status</NAME>
<IV_DATA CI_END="1.3239765899510354" CI_START="-1.2239765899510353" EFFECT_SIZE="0.05" ESTIMABLE="YES" ESTIMATE="0.05" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11904" SE="0.65" STUDY_ID="STD-Raimondi-1970" TOTAL_1="8" TOTAL_2="8" WEIGHT="9.59625469367111"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.05" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="63" TOTAL_2="63" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>MEAN BASELINE PAO2 &lt;/&gt; 7.3kPa/55mmHG: Maximal test - exercise VO2max (SMD)</NAME>
<GROUP_LABEL_1>Oxygen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oxygen</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.05.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Mean baseline PaO2 &lt;/=7.3 kPa/55 mmHg</NAME>
<CONT_DATA CI_END="1.3320691383567895" CI_START="-0.4474684383586743" EFFECT_SIZE="0.4423003499990576" ESTIMABLE="YES" MEAN_1="740.0" MEAN_2="609.0" ORDER="11905" SD_1="335.2" SD_2="220.39" SE="0.4539720093716591" STUDY_ID="STD-Mannix-1992" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="3.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.05.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="4" TAU2="0.0" TOTAL_1="53" TOTAL_2="53" WEIGHT="0.0" Z="0.0">
<NAME>Mean baseline PaO2 &gt;7.3 kPa/55 mmHg</NAME>
<CONT_DATA CI_END="0.7201588101002867" CI_START="-0.36929394081309336" EFFECT_SIZE="0.17543243464359665" ESTIMABLE="YES" MEAN_1="8.7" MEAN_2="8.2" ORDER="11906" SD_1="3.0" SD_2="2.6" SE="0.27792672709979477" STUDY_ID="STD-Bradley-1978" TOTAL_1="26" TOTAL_2="26" WEIGHT="0.0"/>
<CONT_DATA CI_END="4.715275273377134" CI_START="1.0889562394218457" EFFECT_SIZE="2.90211575639949" ESTIMABLE="YES" MEAN_1="13.3" MEAN_2="9.6" ORDER="11907" SD_1="0.9" SD_2="1.4" SE="0.9250983851129996" STUDY_ID="STD-Criner-1987" TOTAL_1="6" TOTAL_2="6" WEIGHT="0.0"/>
<CONT_DATA CI_END="1.2809711404843749" CI_START="-0.5847328056190262" EFFECT_SIZE="0.3481191674326743" ESTIMABLE="YES" MEAN_1="22.03" MEAN_2="20.2" ORDER="11908" SD_1="4.2" SD_2="5.7" SE="0.4759536299696922" STUDY_ID="STD-Gosselin-2004" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0"/>
<CONT_DATA CI_END="2.181615517071964" CI_START="0.39385644796361063" EFFECT_SIZE="1.2877359825177874" ESTIMABLE="YES" MEAN_1="4.14" MEAN_2="2.74" ORDER="11909" SD_1="1.21" SD_2="0.86" SE="0.45606936739908716" STUDY_ID="STD-Vyas-1971" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="5.003639625408262" CI_END="-0.6555951646792058" CI_START="-1.652329544383194" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="-1.1539623545311999" ESTIMABLE="YES" I2="40.04364373552939" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" NO="6" P_CHI2="0.17153100028949342" P_Q="0.42475246559903723" P_Z="5.67177262213784E-6" Q="0.6371293238710471" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="44" WEIGHT="100.0" Z="4.538269574022085">
<NAME>MEAN BASELINE PAO2 &lt;/&gt; 7.3kPa/55mmHG: Endurance test - isotime breathlessness</NAME>
<GROUP_LABEL_1>Oxygen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Borg</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.1363607431486593" CI_START="-4.136360743148659" DF="0.0" EFFECT_SIZE="-2.0" ESTIMABLE="YES" I2="0.0" ID="CMP-002.06.01" LOG_CI_END="-0.8653106405871585" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="1.0" P_Z="0.06652608221990326" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="11" WEIGHT="5.441889355497711" Z="1.8348623853211008">
<NAME>Mean baseline PaO2 &lt;/= 7.3kPa/55mmHg</NAME>
<IV_DATA CI_END="0.1363607431486593" CI_START="-4.136360743148659" EFFECT_SIZE="-2.0" ESTIMABLE="YES" ESTIMATE="-2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11910" SE="1.09" STUDY_ID="STD-O_x0027_Donnell-2001" TOTAL_1="11" TOTAL_2="11" WEIGHT="5.441889355497711"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="4.366510301537215" CI_END="-0.5927649680882392" CI_START="-1.6177795537888175" DF="2.0" EFFECT_SIZE="-1.1052722609385284" ESTIMABLE="YES" I2="54.19683312562192" ID="CMP-002.06.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="0.11267424607865151" P_Z="2.3698065602543982E-5" STUDIES="3" TAU2="0.0" TOTAL_1="33" TOTAL_2="33" WEIGHT="94.55811064450229" Z="4.226854631673462">
<NAME>Mean baseline PaO2 &gt;7.3 kPa/55 mmHg</NAME>
<IV_DATA CI_END="-0.804421969430567" CI_START="-3.195578030569433" EFFECT_SIZE="-2.0" ESTIMABLE="YES" ESTIMATE="-2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11911" SE="0.61" STUDY_ID="STD-Dean-1992" TOTAL_1="12" TOTAL_2="12" WEIGHT="17.375728952611748"/>
<IV_DATA CI_END="-0.21201080463798383" CI_START="-1.3879891953620163" EFFECT_SIZE="-0.8" ESTIMABLE="YES" ESTIMATE="-0.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11912" SE="0.3" STUDY_ID="STD-O_x0027_Donnell-1997" TOTAL_1="11" TOTAL_2="11" WEIGHT="71.83898603629812"/>
<IV_DATA CI_END="-0.14403961700593992" CI_START="-4.45596038299406" EFFECT_SIZE="-2.3" ESTIMABLE="YES" ESTIMATE="-2.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11913" SE="1.1" STUDY_ID="STD-Somfay-2001" TOTAL_1="10" TOTAL_2="10" WEIGHT="5.343395655592421"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="3.876761208582913" CI_END="-2.188076250608132" CI_START="-4.328105713598691" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="-3.2580909821034116" ESTIMABLE="YES" I2="22.615816693631196" I2_Q="9.849756282876786" ID="CMP-002.07" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" NO="7" P_CHI2="0.27508293426613695" P_Q="0.2922430419571389" P_Z="2.4032648484071803E-9" Q="1.1092593417027659" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="48" TOTAL_2="48" WEIGHT="100.00000000000001" Z="5.967900062790486">
<NAME>MEAN BASELINE PAO2 &lt;/&gt; 7.3kPa/55mmHG: Maximal test - isotime ventilation</NAME>
<GROUP_LABEL_1>Oxygen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oxygen</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<EFFECT_MEASURE>L/min</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="-0.7864958011234551" CI_START="-11.213504198876546" DF="0.0" EFFECT_SIZE="-6.0" ESTIMABLE="YES" I2="0.0" ID="CMP-002.07.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="1.0" P_Z="0.02409324254785743" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="4.212307414411542" Z="2.255639097744361">
<NAME>Mean baseline PaO2 &lt;/= 7.3kPa/55mmHg</NAME>
<IV_DATA CI_END="-0.7864958011234551" CI_START="-11.213504198876546" EFFECT_SIZE="-6.0" ESTIMABLE="YES" ESTIMATE="-6.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11914" SE="2.66" STUDY_ID="STD-Mannix-1992" TOTAL_1="10" TOTAL_2="10" WEIGHT="4.212307414411542"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="2.767501866880147" CI_END="-2.044225479121008" CI_START="-4.230803088987299" DF="2.0" EFFECT_SIZE="-3.1375142840541534" ESTIMABLE="YES" I2="27.732659409020204" ID="CMP-002.07.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="0.2506369186925863" P_Z="1.8583708359124796E-8" STUDIES="3" TAU2="0.0" TOTAL_1="38" TOTAL_2="38" WEIGHT="95.78769258558847" Z="5.624694014956232">
<NAME>Mean baseline PaO2 &gt;7.3 kPa/55 mmHg</NAME>
<IV_DATA CI_END="-2.2960864371038703" CI_START="-11.70391356289613" EFFECT_SIZE="-7.0" ESTIMABLE="YES" ESTIMATE="-7.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11915" SE="2.4" STUDY_ID="STD-Gosselin-2004" TOTAL_1="9" TOTAL_2="9" WEIGHT="5.174410128717068"/>
<IV_DATA CI_END="-1.0556320537593515" CI_START="-4.544367946240648" EFFECT_SIZE="-2.8" ESTIMABLE="YES" ESTIMATE="-2.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11916" SE="0.89" STUDY_ID="STD-Light-1989" TOTAL_1="17" TOTAL_2="17" WEIGHT="37.62732273880862"/>
<IV_DATA CI_END="-1.5300270115949592" CI_START="-4.469972988405041" EFFECT_SIZE="-3.0" ESTIMABLE="YES" ESTIMATE="-3.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11917" SE="0.75" STUDY_ID="STD-Vyas-1971" TOTAL_1="12" TOTAL_2="12" WEIGHT="52.98595971806277"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="1.2061026711241842" CI_END="3.859246828160594" CI_START="-0.1602880009302987" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="1.8494794136151478" ESTIMABLE="YES" I2="17.088318934911243" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="0.5865025558919585" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="0.26704950158647545" NO="8" P_CHI2="0.27210542023989215" P_Q="1.0" P_Z="0.07128650127387108" Q="0.0" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0" Z="1.803648031408551">
<NAME>HIGH DOSE VERSUS LOW DOSE: Endurance test - exercise time (Davidson imputed SEM)</NAME>
<GROUP_LABEL_1>High dose oxygen</GROUP_LABEL_1>
<GROUP_LABEL_2>Low dose oxygen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Low dose better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>High dose better</GRAPH_LABEL_2>
<EFFECT_MEASURE>Minutes</EFFECT_MEASURE>
<IV_DATA CI_END="3.9179261683071105" CI_START="-4.11792616830711" EFFECT_SIZE="-0.1" ESTIMABLE="YES" ESTIMATE="-0.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11918" SE="2.05" STUDY_ID="STD-Davidson-1988" TOTAL_1="17" TOTAL_2="17" WEIGHT="25.020022553263544"/>
<IV_DATA CI_END="4.820989350492332" CI_START="0.17901064950766798" EFFECT_SIZE="2.5" ESTIMABLE="YES" ESTIMATE="2.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11919" SE="1.1842" STUDY_ID="STD-Somfay-2001" TOTAL_1="10" TOTAL_2="10" WEIGHT="74.97997744673646"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="NO" LOG_EFFECT_SIZE="-Infinity" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>HIGH DOSE VERSUS LOW DOSE: Endurance test - isotime breathlessness</NAME>
<GROUP_LABEL_1>High dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Borg</EFFECT_MEASURE>
<IV_DATA CI_END="2.1087539002112696" CI_START="-2.9087539002112694" EFFECT_SIZE="-0.4" ESTIMABLE="YES" ESTIMATE="-0.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11920" SE="1.28" STUDY_ID="STD-Somfay-2001" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="NO" LOG_EFFECT_SIZE="-Infinity" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>HIGH DOSE VERSUS LOW DOSE: Endurance test - isotime SaO2</NAME>
<GROUP_LABEL_1>High dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>%</EFFECT_MEASURE>
<IV_DATA CI_END="3.287570827477444" CI_START="0.11242917252255591" EFFECT_SIZE="1.7" ESTIMABLE="YES" ESTIMATE="1.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11921" SE="0.81" STUDY_ID="STD-Somfay-2001" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="NO" LOG_EFFECT_SIZE="-Infinity" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>HIGH DOSE VERSUS LOW DOSE: Endurance test - isotime ventilation</NAME>
<GROUP_LABEL_1>High dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>L/min</EFFECT_MEASURE>
<IV_DATA CI_END="4.494322926915716" CI_START="-3.8943229269157165" EFFECT_SIZE="0.3" ESTIMABLE="YES" ESTIMATE="0.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11922" SE="2.14" STUDY_ID="STD-Somfay-2001" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.12" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="NO" LOG_EFFECT_SIZE="-Infinity" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>HIGH DOSE VERSUS LOW DOSE: Maximal test - isotimeSaO2</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>SaO2</EFFECT_MEASURE>
</IV_OUTCOME>
<IV_OUTCOME CHI2="1.9941691007863205" CI_END="12.061046834883346" CI_START="5.707496538095377" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_SIZE="8.884271686489361" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.13" LOG_CI_END="1.0813850038972332" LOG_CI_START="0.7564456567393153" LOG_DATA="NO" LOG_EFFECT_SIZE="0.9486218310717297" NO="13" P_CHI2="0.3689536486275481" P_Q="1.0" P_Z="4.2221565668902365E-8" Q="0.0" RANDOM="NO" SCALE="1000.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="5.481298398846746">
<NAME>MEAN BASELINE PA02&lt;/&gt; 7.3kPa/55mmHg: Maximal test- wattage</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Wattage</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.13.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Mean baseline PaO2 &lt;/=7.3 kPa/55 mmHg</NAME>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="1.9941691007863205" CI_END="12.061046834883346" CI_START="5.707496538095377" DF="2.0" EFFECT_SIZE="8.884271686489361" ESTIMABLE="YES" I2="0.0" ID="CMP-002.13.02" LOG_CI_END="1.0813850038972332" LOG_CI_START="0.7564456567393153" LOG_EFFECT_SIZE="0.9486218310717297" NO="2" P_CHI2="0.3689536486275481" P_Z="4.2221565668902365E-8" STUDIES="3" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="5.481298398846746">
<NAME>Mean baseline PaO2 &gt;7.3 kPa/55 mmHg</NAME>
<IV_DATA CI_END="15.036689072383368" CI_START="2.9633109276166323" EFFECT_SIZE="9.0" ESTIMABLE="YES" ESTIMATE="9.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11923" SE="3.08" STUDY_ID="STD-Gosselin-2004" TOTAL_1="9" TOTAL_2="9" WEIGHT="27.693340032991014"/>
<IV_DATA CI_END="11.549118244905923" CI_START="2.650881755094076" EFFECT_SIZE="7.1" ESTIMABLE="YES" ESTIMATE="7.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11924" SE="2.27" STUDY_ID="STD-Light-1989" TOTAL_1="17" TOTAL_2="17" WEIGHT="50.982961223576226"/>
<IV_DATA CI_END="19.87947358573559" CI_START="6.12052641426441" EFFECT_SIZE="13.0" ESTIMABLE="YES" ESTIMATE="13.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11925" SE="3.51" STUDY_ID="STD-Maltais-2001" TOTAL_1="14" TOTAL_2="14" WEIGHT="21.32369874343276"/>
</IV_SUBGROUP>
</IV_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2008-08-22 16:58:51 +0100" MODIFIED_BY="Toby J Lasserson">
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2008-08-22 16:58:51 +0100" MODIFIED_BY="Toby J Lasserson" NO="1" REF_ID="CMP-001.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Oxygen versus placebo (crossover studies), outcome: 1.1 Endurance test - exercise distance (Davidson 1988 6MWT).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAFgCAMAAABdZ4f0AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2008-08-22 16:58:51 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" REF_ID="CMP-001.02" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Oxygen versus placebo (crossover studies), outcome: 1.2 Endurance test - exercise distance (Davidson 1988 endurance walk).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAmMAAAFgCAMAAADAao58AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2008-08-22 16:58:51 +0100" MODIFIED_BY="Toby J Lasserson" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Funnel plot of exercise distance (Comparison 01; outcome 01). The blue dots represent the mean differences of individual trial estimates. The distribution of these dots to the right of the dotted line suggests that there may be the equivalent number of 'negative' trials that have not been included in this analysis.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAIAAAD9V4nPAAALzUlEQVR42u3d0XLbKhRAUX16/pw+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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2008-08-22 16:58:51 +0100" MODIFIED_BY="Toby J Lasserson" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Funnel plot of exercise distance (Comparison 01; outcome 03). The blue dots represent the mean differences of individual trials. The distribution of these dots to the right of the dotted line suggests that there may be the equivalent number of 'negative' trials that have not been included in this analysis.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAmMAAAGQCAIAAABtRPAAAAAK00lEQVR42u3d3XbaOhCAUT963ly9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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>